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ABSTRACT  
Title: Adverse drug reactions causing admission in children     Author: R Gallagher      
Children are vulnerable to adverse drug reactions (ADRs) but have been under-
represented in studies which have addressed their incidence and prevention. The aim of 
my thesis was to undertake a prospective study of ADR-related hospital admissions.  
The first step involved the development of the methodology by undertaking a 
prospective observational pilot study assessing all unplanned admissions over a 2 week 
period. There were 19 admissions to the main hospital wards related to an ADR, giving 
an estimated ADR incidence of 4%. Among the methodological considerations 
assessed in the study was the definition of what constitutes an admission (whether to 
include patients admitted to the Accident & Emergency observation ward), the 
feasibility of the data collection methods, and an assessment of the feasibility of 
managing the workload between three investigators.  
ADR causality assessment in the pilot study was undertaken using the validated 
Naranjo tool.  However, this was found to be lacking in sensitivity, with 
underestimation of the likelihood of an ADR.  A causality assessment tool (CAT) that 
would overcome some of these issues, while at the same time making it as easy, or 
easier, to use than the Naranjo tool was formulated by an expert focus group. We 
undertook a comparison of the new Liverpool CAT with the Naranjo tool using seven 
assessors. This showed that the Liverpool CAT assigned the full range of causality 
categories and showed better inter-rater reliability than Naranjo.  
ADRs causing paediatric hospital admission were subsequently studied over a one year 
period. There were 247 ADRs in 240/8345 patients admitted acutely to the hospital, 
giving an estimated ADR admission incidence of 2.9% (95% CI 2.5, 3.3). There were 
no deaths attributable to an ADR. 120/249 (48.2%) ADRs resulted from treatment for 
malignancies. The origin of prescription for causative drugs was assessed; 
prescriptions originating in the community accounted for 44/249 (17.7%) of ADRs 
with the remainder from hospital. Assessment of the avoidability of the ADR cases 
using the Liverpool CAT showed that 22.1% (95% CI 17%, 28%) of the reactions 
were either ‘definitely’ or ‘possibly’ avoidable. Few studies in the literature have 
reported specific avoidability outcomes, which is important to prioritise interventional 
strategies to reduce the burden of ADRs.  
ADRs in children are an important public health problem. Most of those serious 
enough to require hospital admission are due to hospital-based prescribing, of which 
just over a fifth may be avoidable.  Strategies to reduce the burden of ill-health from 
these ADRs are needed. 
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CHAPTER 1  INTRODUCTION 
“Do not rashly use every new product of which the peripatetic siren sings. 
Consider what surprising reactions may occur in the laboratory from the 
careless mixing of unknown substances. Be as considerate of your patient 
and yourself as you are of the test tube.” Sir William Osler (1849 – 1919) 
1.1 BACKGROUND 
Adverse drug reactions (ADRs) are a common problem and have been recognised for 
many years (Laughlin & Jackson 1986). More ADR literature concerns adults rather 
than children. However, children have been affected by ADRs, and serious 
occurrences of reactions, for several decades (McKenzie et al. 1976). In fact, episodes 
of ADRs in children have shaped the nature of drug regulation and adverse event 
monitoring internationally (Neubert 2012). Perhaps the most well-known of these 
episodes was the thalidomide disaster of the 1960s (Botting 2002). In the 1950s and 
early 1960s the drug thalidomide was used as a hypnotic/sedative agent. It was used 
widely in pregnancy to alleviate morning sickness. In 1961, a link was shown between 
maternal ingestion of thalidomide and the occurrence of limb defects, specifically 
phocomelia, in their offspring. The effect of this was seen in many countries across the 
world (Laughlin & Jackson 1986) and had a major, lasting, impact on governments 
and national legislation regarding drug regulation and safety. These events lead to the 
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United Kingdom (UK) government setting up the Committee on the Safety of 
Medicines (CSM) to regulate the use of medicines in Britain. In January 2010, 50 
years after the description of the link between Thalidomide and phocomelia, the UK 
government issued an apology, and a new £20m compensation package, to 
‘thalidomiders’ (a self-styled name for sufferers from the disaster in the UK). 
The United States (US) Food and Drug Administration (FDA) has a longer history 
than the CSM. Its origins lie in the mid 1800’s. However, the nature of US legislation 
regarding drug regulation, and the duties of the FDA, were shaped by a tragedy of 
different proportions, but not necessarily of less impact, than that of the thalidomide 
episode (Wax 1995). In 1937, a previously much used tablet and powder-based drug 
for the treatment of streptococcal throat infections, sulfanilamide, was re-formulated 
after a reported demand from the public for a new product in liquid form. The drug 
was dissolved in diethylene glycol by the manufacturing chemists to make an elixir. 
This new formulation was not tested for toxic effects since testing for safety was not a 
legal requirement at that time in the US. After shipments were sent all over the 
country, it was found that there were deaths occurring after exposure to the new 
medicine. In all, more than one hundred people, mostly children, died in the incident. 
The drug was re-called after intervention from the FDA. In the next year, the US 
government instituted new legislation which made it illegal to introduce new medicinal 
products without testing for toxicity (1938 Federal Food, Drug, and Cosmetic Act 
(Hamrell 1985)). It was probably this tragedy, leading to the new legislative powers of 
the FDA, that prevented thalidomide, a drug with little or no evidence of safety in 
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pregnant women, from gaining a licence in the US, thereby sparing the US public from 
the international disaster that occurred in many other countries around the world (Bren 
2001).  
Formulation of two of the world’s oldest medicines regulatory bodies, the UK 
Medicines and Healthcare Products Regulatory Agency (MHRA, previously CSM, the 
UK government agency responsible for ensuring that medicines and medical devices 
work, and are acceptably safe) and the US FDA, were largely brought about by 
paediatric medicine tragedies. These government bodies have formal processes to 
assess pharmaceutical manufacturers’ evidence of the efficacy and safety of drugs. The 
regulators also decide, based on this information, whether to grant a licence for the 
drugs to be used in their respective countries. It would seem, at face value, that the 
disasters described above could not be repeated, especially in children, in these 
countries. However, there are other complicating factors that may mean serious ADRs 
can still occur in children.  
The two ADR examples highlighted are very serious and both occurred before major 
legislative change allowed regulatory bodies to control the licensing of drugs based on 
evidence of their efficacy and safety. The safety profile of a medicine, when suitability 
for a licence is being assessed by a regulatory body, is derived primarily from adverse 
event data in clinical trials. This is supplemented by “pre-clinical” studies in animals. 
Human safety data is derived from early phase clinical studies and randomised 
controlled trials (RCTs). RCTs are usually designed to enable an analysis of efficacy 
of a drug and when compared to clinical use are often of relatively short duration and 
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include relatively small numbers of patients (Sammons & Choonara 2005). RCTs are 
useful for identifying common ADRs that will occur with exposure to a drug and they 
may also elucidate some serious ADRs. However, RCTs are less likely to be able to 
elucidate serious uncommon ADRs (Stricker & Psaty 2004). Ioannidis and Lau 
reported that the quantity and quality of safety reporting in RCTs is largely inadequate 
(Ioannidis & Lau 2001). Several types of ADR may not be identified during RCTs 
including: 
Rare ADRs 
Rare ADRs may not be picked up with the relatively small sample size of RCTs. 
However rare ADRs, for example Stevens-Johnson Syndrome, may be severe and 
difficult to relate to the drug.  
Delayed ADRs that occur on prolonged use  
Some ADRs, for example cough associated with Angiotensin Converting Enzyme 
inhibitors, may only appear after many months of use in the majority of patients. 
Whilst some of these ADRs may not be severe they may nonetheless cause discomfort 
or embarrassment to the patient. 
Delayed ADRs that occur after drug cessation  
Although this is likely to be rare in general medical patients, these reactions may be 
severe for certain subgroups of patients. For example, patients exposed to cytotoxic 
chemotherapy may present with neutropenia days after the drugs have been 
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administered once only. Alternatively, patients who have received prolonged 
chemotherapy or immunosuppressant therapy may be at an increased risk of 
malignancy later in life. 
ADRs in special populations that are not routinely included in drug development 
Traditionally, the young and the old were not included in clinical studies during drug 
development. In Europe, the situation has changed with respect to children since the 
introduction of the European Union Regulation about Medicines for Children in 2007. 
However, many medicines used in children were developed before children were 
routinely involved in clinical studies of new medicines. Much medicines use in 
children continues to be off-label (prescribing medication for an unapproved indication 
or in an unapproved age group, unapproved dose or unapproved form of 
administration). This means that routine surveillance for ADRs in children is 
important.  
ADRs to excipients 
Excipients are an important factor in medicine production, formulation and 
preservation. ADRs may occur due to excipients and not the active drug. These ADRs 
may be difficult to identify (Mori et al. 2012). 
 
 
6 
 
For these reasons, RCTs alone are not enough to establish the full safety profile of a 
drug. Evaluation of drug safety requires careful examination of data from 
heterogeneous sources (Singh & Loke 2012). Post-licensing safety data, which will be 
discussed later in this chapter, must be collected to further understand the adverse 
reactions associated with a drug and build up a true profile of its safety. Studies of 
adverse reactions associated with specific drugs, or groups of drugs, can also be 
helpful to negotiate the complex issue of benefit versus risk.  With accumulating 
knowledge about a drug’s adverse reaction profile over time, it may be that a drug 
previously thought to be safe and effective could be deemed too risky to the population 
exposed to it. Knowledge about the risks of a particular medication can be 
accumulated in several ways. Observational studies of ADRs are one important source 
of information.  
Thus there is a need to gather information about adverse events associated with 
medicines, particularly medicines given to children. This thesis describes a range of 
studies that gather information about ADRs. The purpose of this work was to define 
opportunities to reduce the impact of ADRs on children. The studies explore the 
methodological challenges of gathering information about ADRs in children and 
provide novel data about this topic. This introductory chapter sets the scene by 
introducing the terminology and conceptual frameworks used to describe the data 
gained from observational studies.  
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1.2 PHARMACOVIGILANCE 
Pharmacovigilance, as described by the World Health Organisation (WHO), is the 
science and activities relating to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related problems (WHO-UMC 2002). 
The practice of pharmacovigilance aims to enhance patient care and safety in relation 
to the use of medicines, especially with regard to the prevention of unintended harm, to 
improve public health and safety in relation to the use of medicines by the provision of 
reliable, balanced information resulting in more rational use of medicines; and to 
contribute to the assessment of the risk-benefit profile of medicines, thus encouraging 
safer and more effective use of medicines. 
One important aspect of pharmacovigilance is data collection and analysis of adverse 
effects associated with a drug after a license has been granted. The reason for 
collecting this data is because of the likely limited safety data gained from RCTs, as 
described earlier in this chapter. There are now many countries with good 
pharmacovigilance practice. Many of these are individual regulatory bodies within 
countries and many are part of larger bodies such as the WHO monitoring centre.  
In the UK, the MHRA is the government body that regulates the licensing of medicinal 
products. The Yellow Card scheme is the spontaneous reporting system in the UK 
which collects information about ADRs after a drug has been granted a license and has 
been authorised for use in the UK population (MHRA). The scheme works by 
collecting spontaneous reports of drug reactions. At first, the Yellow Card scheme 
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allowed only physicians to report possible ADRs. In 1997, the scheme was extended to 
include pharmacists. After this, other health care practitioners, including nurses, were 
invited to report possible ADRs. Patients/carers were finally invited to report their 
adverse experiences of medication in 2008. Reports can be submitted in one of three 
ways: by completing a ‘yellow card’ in writing, which can be found at the back of the 
British National Formulary (BNF), a medical pharmaceutical reference book 
commonly used in hospitals, general practice surgeries and pharmacies; by completing 
an electronic yellow card on the MHRA website; or by phoning the yellow card hotline 
number (available on the MHRA website).  
The information from Yellow Card reports is entered onto a specific database. The 
data is analysed on a weekly basis by the MHRA and the reports can be used in the 
following ways:  
 Requesting additional information from the reporter to understand better the 
suspected reaction.  
 Noting the patient perspective of a suspected adverse effect, to understand 
better the impact of these effects on the people who use medicines.  
 Requesting further information from other sources, including from the 
manufacturer/s of the medicine.  
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 Highlighting the report as a possible safety issue on the MHRA database and 
keeping a close watch on the safety of the medicine by monitoring similar 
reports.  
 Conducting a specific analysis of similar Yellow Card reports to identify 
potential safety signals.  
 Discussing the suspected adverse effect with other medicines regulatory 
agencies, within and outside the European Union.  
Any or all of these actions can result in a number of different outcomes with regard to 
a medication. The regulators may make no changes or may add additional information 
to the product literature, alter the license (dose, indication or some other aspect) or, 
rarely, withdraw the product from the market.  
1.3 DEFINITIONS OF ADVERSE DRUG REACTIONS 
There are many definitions of what constitutes an ADR. The WHO, more than thirty 
years ago, defined an ADR as “a response to a drug that is noxious and unintended and 
occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of 
disease, or for modification of physiological function.” The WHO definition would 
seem to comprehensively describe ADRs but it has come under scrutiny from 
pharmacologists. Although comprehensive, the definition, by using the word noxious, 
encompasses all adverse reactions no matter how minor. This definition, if used by 
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those reporting ADRs to regulatory bodies, may lead to the submission of large 
numbers of common minor ADRs. Pharmacologists would argue that this is not very 
helpful in signal detection of new, or more clinically relevant, ADRs. 
Edwards and Aronson (Edwards & Aronson 2000) suggest a definition of an ADR as 
“an appreciably harmful or unpleasant reaction, resulting from an intervention related 
to the use of a medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of the dosage regimen, or 
withdrawal of the product.” Edwards and Aronson argue that their definition is more 
specific to ADRs that cause harm and do not include adverse events/overdose (OD). 
This definition is more acceptable to pharmacologists who are interested in studying 
clinically relevant ADRs. The definition by Edwards and Aronson has been used in 
several studies since its publication and will be used in the studies in this thesis.  
1.4 TYPES OF ADVERSE DRUG REACTION 
In describing ADRs in differing contexts (studies, case reports, post-marketing 
surveillance reports), it can be useful to classify the type of ADR/s being described. 
Definitions of these types of ADRs have evolved with time. In the first instance, ADRs 
were classified as one of two types (Rawlins 1977).  
A. Type A reactions (Augmented) are dose-related, and, therefore, predictable 
from the known pharmacology. They are more common than type B.  
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B. Type B reactions (Bizarre) are not dose related, unpredictable from the known 
pharmacology and are rarer than type A. Type B reactions may also be more 
likely to be severe.  
To some extent, these classifications can be helpful when determining why an ADR 
occurred and whether or not it may have been avoidable. Avoidability (preventability) 
will be discussed later in this chapter. This early classification of the type of ADR was 
expanded subsequently to include four more categories. These are as follows: 
Type C reactions (Chronic) occur after some time of prolonged administration and are 
usually dose and time-related. They usually refer to ADRs which are due to cumulative 
dose. The drugs that cause these types of ADRs may also need gradual decrease in 
dose for withdrawal. 
Type D reactions (Delayed) occur some time after use of the drug. They are usually 
uncommon and may be dose-related. 
Type E reactions (End of treatment) occur sometime after withdrawal of the drug. They 
are uncommon and usually occur shortly after drug cessation/withdrawal.  
Type F reactions (Failure) occur as a result of unexpected failure of therapy. 
Unfortunately, this is common. However, it may not lead to ADRs as described by 
Edwards and Aronson as no appreciable event will have taken place.  
The definitions of types C-F may provide more in depth description of the ADRs that 
have occurred. However, it is likely that all ADRs can still be described by types A/B. 
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The ADRs described in the studies in this thesis will be classified as either Type A or 
B. This will allow for comparison with other studies that have used these 
classifications.  
1.5 CAUSALITY ASSESSMENT OF ADRS 
It is not always possible to absolutely relate a reaction to a drug. In fact, this may be 
rarely possible and is due, in part, to the nature of illness in patients and the interaction 
of drugs with illness. Patients rarely take medication unless they are unwell or have 
chronic problems. This is especially true in children. A lot of the difficulty in assessing 
the causal relationship (causality) between drug and adverse effect is that 
disease/illness may have an unexpected course and the symptoms of illness may 
overlap with symptoms of ADRs. For example, children can often develop a rash 
during viral infections and a similar rash may be precipitated by many drugs. In reality, 
the viral illness may even make a patient more susceptible to developing a rash. This 
makes it extremely difficult to decide whether the rash is due to drug or disease. This is 
a common situation in clinical practice with many different symptoms imitated by drug 
reactions caused by many different drugs. Even something seemingly as minor as a 
drug eruption can provoke anxiety in the parents of a baby or young child and may 
make management decisions for clinicians more difficult than had the rash not been 
present.  
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Causality assessment is not a new idea in medicine. In 1965, Sir Austin Bradford Hill 
wrote an article describing a set of criteria that investigators should consider when 
assessing whether a causal link can be established between an environmental factor 
and the onset of a particular disease process (Hill 1965). His paper is regarded as 
seminal and attempted to describe the process of making the leap from a clear 
association between two variables to stating likely causation of one based upon 
exposure to the other. This thinking, underpinned by appropriately robust research 
methodology and studies, has aided researchers’ advancement of knowledge of risk 
factors for disease e.g. smoking and lung cancer. The features to be assessed between 
the two variables in question, according to Hill, were as follows: 
1) Strength. The effect of one variable on another must be assessed to gain an 
understanding of the magnitude of the association. The stronger the association, 
as long as other factors are assessed cautiously, the more likely the relationship 
will be causative.    
2) Consistency. Has the association been observed repeatedly by different 
persons, in different places, circumstances and times? 
3) Specificity. Hill states that one must be cautious in interpreting specificity. “If 
other causes of death are raised 10, 20 or even 50% in smokers whereas cancer 
of the lung is raised 900-1,000% we have specificity - a specificity in the 
magnitude of the association.” In this example, if the magnitude of association 
is not specific to lung cancer one must be cautious in interpreting the results – it 
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may be that there is another underlying factor which could explain any or all of 
these increases in death rates. 
4) Temporality. The temporal relationship of an association is important when 
assessing for possible causation. It might be particularly relevant to assess this 
carefully with diseases of slow development.  
5) Biological gradient. If the association is one which has a biological gradient, or 
positive dose-response, this evidence should be assessed.  
6) Plausibility. It is helpful to persuade others of causation if there is a 
biologically plausible mechanism. However, Hill states that plausibility is a 
feature which cannot be demanded, saying “What is biologically plausible 
depends upon the biological knowledge of the day......the association we 
observe may be one new to science or medicine and we must not dismiss it too 
light-heartedly as just too odd.” 
7) Coherence. The cause-and-effect interpretation of data should not seriously 
conflict with the generally known facts of the natural history of a disease.  
8) Experiment. It can be important, if possible, to use experimentation. This can 
also be important if an intervention is undertaken. Did the intervention have 
any effect on the frequency of the associated events? 
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9) Analogy. In some circumstances it can be fair and appropriate to judge by 
analogy. Similar evidence from a similar situation can add weight to the 
possible causation regarding a similar new exposure-adverse event pairing.  
Although Hill’s criteria relate to environmental exposure and occurrence of disease, 
there is no doubt that applying similar logic to possible ADR cases will aid in causality 
assessment. When assessing a possible ADR it can be useful to describe the certainty 
with which the assessor relates the drug to the reaction. There are several ways of 
trying to achieve this including; assessor opinion/structured guidance, structured 
algorithms, and Bayesian statistical methods. One of the aims of using structured 
guidance or an algorithm to assess possible ADRs is to reduce the between rater 
variability of assessments. Each of these methods will be discussed in turn. 
1.5.1 Assessor Opinion  
The use of assessor opinion relies on expert assessor judgement of how likely a drug 
caused a reaction, using knowledge of the drug and their clinical experience, without 
using a structured causality assessment tool (CAT) or any guidance. In studies of 
ADRs these are usually clinicians, pharmacologists and possibly pharmacists. These 
assessments can be made by one clinician, or by a group of more than one who then 
seek to provide a consensus causality assessment about each case.   
In one study, five experts assessed 30 cases of reported ADRs (15 sampled from cases 
spontaneously reported to the Regional Pharmacovigilance Centre of Bordeaux and 15 
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sampled from ADR cases collected during a nationwide incidence study conducted the 
same year (Pouyanne et al. 2000)) using a visual analogue scale showing poor 
agreement between raters (kappa 0.2) (Arimone et al. 2005). The agreement between 
raters was lower for intermediate levels of causality (unlikely, doubtful, 
unassessable/unclassifiable, and plausible) than for cases assessed at the extremes of 
the analogue scale (excluded, likely, and certain). This is unsurprising as it is probably 
easier to assess cases which are ‘clear cut.’ This result may also demonstrate that it is 
easier to agree about cases where there is more evidence of causality, or more evidence 
against any causality. This study showed that experts, even those involved in assessing 
ADRs for regulatory authorities, can struggle to reach agreement about causality in the 
absence of a structured assessment tool. 
1.5.2 Structured Guidance  
Methods of assessing causality that provide structured guidance usually make use of 
several headings or categories which describe the likelihood of relationship between 
drug and reaction (e.g. ‘possible’, ‘probable’, ‘definite’). Each category is linked to a 
description of the criteria of the components needed to assign that level of causality. 
The information regarding the reaction in the case being assessed is then cross-
referenced, by the assessor, with the descriptions in the guidance so that the causality 
category which fits best can be chosen. Each category increase in causality is 
accompanied by a description which requires more evidence of the likelihood of drug-
ADR relationship. These structured guidelines can be viewed as being in the same 
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category as expert opinion, as they are generally devised by experts based on their 
clinical experience. However, they aim to give non-experts, and experts alike, a 
framework for assessing ADRs in a more systematic fashion.  
The WHO, with the Uppsala Monitoring Centre (WHO-UMC) in Sweden, reviewed 
the limitations of causality assessment and produced their own structured guidance on 
assessing causality (WHO-UMC 2011). Causality is grouped into six categories with 
corresponding criteria to be filled to reach that level of causality. These categories are; 
Certain, Probable/Likely, Possible, Unlikely, Conditional/Unclassified, and 
Unassessable/ Unclassifiable. The last two categories allow for classification of ADR 
reports in which the evidence may still be under scrutiny or not available. The use of 
this method, using assessor opinion, is often called ‘global introspection’. This 
structured assessment guidance has been used in many studies of ADRs. 
1.5.3 Structured Algorithms  
There has been criticism of the use of expert judgement in assessing ADR causality. 
This has led to many authors proposing structured assessment tools in the form of 
algorithms to aid assessment of ADR causality. An algorithm is a method for solving a 
problem using a finite sequence of instructions. Structured assessment systems of this 
type can be used to aid assessors in estimating the likely relationship between drug and 
reaction. They involve answering individual questions about the reaction in a stepwise 
order which leads to a final causality assessment being assigned.  
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CATs can take the form of a group of structured questions or a flowchart (algorithm). 
CATs which use structured questions usually have an individual score for each 
question/answer. The sum of the scores for each question/answer pair provides a total 
score. The causality categories are each represented by a range of total score and the 
assessor matches their score with the appropriate category.  
Flowcharts, or algorithms, use a series of decision boxes which contain questions. 
Each decision box is linked to one or more boxes by arrows, which represent answers, 
which lead the user to the next appropriate box, depending on the answer selected at 
the previous decision box. The user starts with a question in the first decision box. 
He/she chooses one of the available answers that they think is the most appropriate or 
correct. The answer, which is represented by an arrow from the decision box, leads the 
user to a new decision box with a new question. This process is repeated until the 
flowchart eventually leads to a solution, from which there are no more arrows, answers 
or questions. This provides the user with the final assigned causality category. 
Some of these methods, both structured questions and flowcharts, are more than 30 
years old and all were published following Hill’s causality paper. Irey, in 1976, was 
the first to publish an ADR causality algorithm (Irey 1976). This algorithm relies 
heavily on time-relationships, and pathological evidence, of drug and event. Karch and 
Lasagna, in 1977, published an algorithm using three decision-tables which lead the 
user to assess potential drug reactions, assess the certainty of the link between the drug 
and event, and evaluate the underlying causes of the identified untoward events (Karch 
& Lasagna 1977). The tool requires previous bibliographical evidence of the ADR and, 
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therefore, is not appropriate for assessing/identifying new ADRs. Kramer expanded 
upon the work of Karch and Lasagna by publishing a new six decision-table algorithm 
with a new scoring system of minus and positive scores for answers given to questions 
within the tables (Kramer 1979). This algorithm was tested among four practicing 
clinicians and four interns. It had an impressive effect on inter-observer agreements 
between the senior clinicians (33% without algorithm to 77% with, weighted kappa 
0.27–0.67) but did not significantly affect agreement levels between interns. It is likely 
that a degree of experience is needed to use the tool effectively.  
Another algorithmic tool, published in 1981by Naranjo et al (Naranjo, Busto & Sellers 
1981), consists of ten questions regarding the details of the reaction. Each question has 
a corresponding answer of ‘yes’, ‘no’ or ‘don’t know’ with each answer having a 
weighting ranging from -1 to +2. The values assigned to each question answered are 
totalled, and the final score corresponds to causality categories of ‘definite’, 
‘probable’, ‘possible’ or ‘doubtful’. The Naranjo ADR Probability Scale is easily the 
most widely used algorithm in the ADR literature (this literature does not include 
algorithms or causality methods used for ADR case reports submitted to national 
regulatory authorities in post-marketing surveillance). In developing this scale, two 
physicians and four pharmacists independently assessed 63 randomly selected alleged 
ADRs with agreement ranging from 38% to 63% (kappa varied from 0.21 to 0.40). Six 
weeks later the same observers independently reanalyzed the 63 cases using the ADR 
probability scale. The between-raters reliability (range: percent agreement = 83% to 
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92%; kappa = 0.69 to 0.86) improved on use of the scale. The between-raters reliability 
was maintained on retesting at 22 weeks.  
Although the results are impressive, the cases used in the internal validation of the 
Naranjo algorithm were published case reports of ADRs. Published ADR case reports 
usually contain more information than other types of ADR reports and usually only get 
published if there is enough evidence of more than an association. It is not surprising to 
see that there may be a high degree of agreement between raters when using a 
structured tool in assessing cases with strong evidence of causality. This tool may not 
be as useful for assessing ADR cases in clinical practice or in other situations such as 
reports from clinical trials, observational studies and post-marketing surveillance. 
1.5.4 Bayesian Statistical Method 
Bayesian statistics can be used to calculate the odds of an adverse reaction having 
occurred (posterior odds) by using detailed knowledge of the details of the case and 
prior knowledge of the chance of the event occurring (epidemiological and clinical trial 
information) (Agbabiaka, Savovic & Ernst 2008). There is no limit to the amount of 
factors that can be incorporated into the method and it can be used to quantify the odds 
of more than one factor having caused the event. It is regarded as possibly the most 
accurate and logical method for estimating causality of an ADR as there is no limit to 
the information that can be used to make an assessment of causality, unlike the 
algorithmic methods which ask for the answer to defined questions. Also, the method 
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is demonstrably reproducible i.e. an investigator can show exactly how they came to 
their conclusions.  
The Bayesian Adverse Reaction Diagnostic Instrument (BARDI) is the probabilistic 
instrument most often evaluated in ADR causality literature (Lane et al. 1987). The 
output of a Bayesian probability method ranges from 0% (not a drug-induced event) to 
100% (definitely a drug-induced event). This method may be the most appropriate for 
assessing causality in individual cases when certainty of causality may be very 
important, such as the first report of a severe reaction. However, Bayesian methods are 
limited by complexity, the need for expertise, time to complete and the statistical 
information needed, which may not be available (Lanctot & Naranjo 1995).  
1.5.5 Comparison of causality assessment methods 
A recent systematic review of causality assessment tools, published in 2008, identified 
34 different published causality assessment methods (Agbabiaka, Savovic & Ernst 
2008). These tools consisted of four expert opinion/global introspection, 26 algorithms 
and four Bayesian methods. The use of assessor opinion for the assessment of causality 
of ADR reports, whilst common, has been shown to produce poor reliability among 
clinicians. It seems logical that a structured scoring system may lead to better 
reliability between raters. Many structured scoring/algorithmic systems have been 
formulated. In some, the authors have found good reliability between internal assessors 
after formulation of the assessment tool. Authors have attempted to compare the inter-
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rater reliability between different causality tools in an attempt to find the ‘best’ 
assessment system. A summary of these assessments is tabulated below (Table 1.1). 
Table 1.1 Summary of published causality method comparisons 
Authors Comparison Number of 
raters/reports 
Results 
Frick, 
1997 
Kramer vs Karch 
& Lasagna 
Single rater assessed 
200 published ADR 
reports 
41% agreement between methods. 
Kramer more likely to assign category of 
possible, Karch more likely to assign 
category of unlikely.  
Busto, 
1982 
Naranjo against 
Kramer 
2 raters assessed 63 
possible ADR case 
reports 
Highly correlated score between raters for 
each method and between methods. 
Naranjo took less time to complete. 
Michel, 
1986 
Kramer, Naranjo 
and Jones methods 
compared against 
each other 
Raters assessed 28 
hospital 
pharmacovigilance 
system ADR case 
reports 
Kramer vs Naranjo; 67% agreement, 
kappa 0.43 (moderate). 
Kramer vs Jones; 67% agreement, kappa 
0.48 (moderate).  
Naranjo vs Jones; 64% agreement, kappa 
0.28 (fair). 
Naranjo compared more favourably with 
Kramer than Jones. 
Lanctot 
and 
Naranjo, 
1995 
Naranjo method 
vs BARDI 
(Bayesian method) 
2 raters assessed 
106 cases (91 clinic 
reports and 15 
pharmaceutical 
company reports) 
Kappa 0.48 (moderate) between the two 
methods. BARDI more likely to result in 
category of highly probable or highly 
improbable, Naranjo more likely to result 
in possible or probable causality. 
Macedo, 
2005 
15 different 
algorithms rated 
against WHO 
global 
introspection 
5 clinicians/ 
pharmacists rated 
200 possible ADR 
reports from post-
marketing 
surveillance 
Agreement of between 21% and 56%, 
with an average of 47%. Kappa of 0.26 
(fair) for average agreement between all 
algorithms and global introspection. 
Rehan, 
2007 
Global 
introspection 
against Naranjo 
2 raters assessed 
100 possible ADR 
cases from 
spontaneous reports 
69% agreement, kappa 0.21 (fair). 
Naranjo more likely to produce lower 
probability category. Naranjo took longer 
to complete. 
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Frick et al used a single rater to assess 200 published adverse drug events (132 case 
reports and 68 letters to editors) using the Kramer algorithm compared to the Karch 
and Lasagna algorithm (Frick, Cohen & Rovers 1997). The algorithms agreed in 41% 
of the cases. The methods did not differ in the proportion of events rated definite 
(p=0.52) or probable (p=0.3). There was an obvious discrepancy between the 
assessment methods for those cases which had less evidence of causality within the 
report, with Kramer more likely to lead to a classification of ‘possible’ and Karch to 
‘unlikely’ (p<0.01). 
Plenty of interest was shown in the use of less complex algorithms for assessing 
causality after publication of the Naranjo scale. There have been several published 
comparisons of Naranjo to other methods with a few of these undertaken by Naranjo 
himself. A high between-rater reliability was shown when using the Naranjo method 
compared to the more complex Kramer method (Busto, Naranjo & Sellers 1982). The 
authors showed that the Naranjo method took less time to complete assessments than 
the Kramer algorithm. They concluded that the Naranjo method was preferable, for 
future use in their hospital-based pharmacovigilance practice, due to its applicability 
and similar results obtained in comparison with the more detailed Kramer algorithm.  
Lanctot and Naranjo compared a Bayesian method for assessing causality, BARDI, 
with the Naranjo ADR probability scale (Lanctot & Naranjo 1995). The investigators 
had previously used BARDI to assess the same cases between one and five years 
previously (the method is complex and time-consuming). The investigators then 
individually assessed the same cases with the Naranjo scale. The correlation between 
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the two raters was high for the Naranjo scale. Therefore, the mean Naranjo score for 
each case was compared to the probability generated by the BARDI method. The 
reliability between the two methods was moderate, with weighted kappa 0.48, when 
considering a diagnostic cut-off for cases assigned above 50% (posterior probability 
0.5) probability for the BARDI method and above a score of 5 (‘probable’ causality) 
for the Naranjo scale. Despite this agreement a difference between the tools still 
remained. Use of BARDI was more likely to result in a causality assessment of highly 
probable (probability 0.76-1) or highly improbable (probability 0-0.25), whilst use of 
Naranjo was more likely to result in possible or probable causality. This is due to the 
Naranjo scale being more uncertain for idiosyncratic reactions (of which there were 
many in the case series analysed) than for dose-related reactions. Also, the answer 
weightings and causality category score ranges are arbitrary for Naranjo, whereas the 
BARDI method can use prior odds and other extra information to input extra variable 
data into the statistical equation. Therefore, for idiosyncratic reactions with prior 
epidemiological evidence, BARDI is more likely to be able to assign a higher causality 
rating. 
Similar conclusions were drawn by Michel at al (Michel & Knodel 1986) when 
comparing the methods Kramer, Naranjo and an ADR causality assessment flowchart 
by Jones. The initial standard for assessing causality of ADR reports was made by 
using the Kramer algorithm as this seemed to be more comprehensive. The methods of 
Naranjo and Jones were then compared to Kramer. The results of all three methods 
were translated into categories of suspicion (A = definite or probable; B = probable; C 
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= possible; and D = unlikely, doubtful, or remote), due to the differences in outputs 
between the three methods. Comparisons were then made using % agreement and 
kappa analysis (Table 1.1). The simpler and less time-consuming Naranjo algorithm 
compared favourably with the Kramer method, both in causality categorisation and 
total numerical score.   
In comparing 200 possible ADR reports from post-marketing surveillance, Macedo et 
al assessed used 15 different algorithmic assessment methods against the opinion of a 
panel of experts (two hospital clinicians, two pharmacists and one general practitioner 
(GP)) using the WHO global introspection assessment method (Macedo et al. 2005). 
The average level of agreement between all the algorithms and global introspection 
was fair, with kappa of 0.26.  
Rehan et al compared the two most frequently used assessment methods, namely 
global introspection and the Naranjo scale, in 100 spontaneously reported adverse drug 
events (Rehan, Chopra & Kakkar 2007). Agreement on causality was found in 69% of 
cases, showing fair reliability with a kappa of 0.21. The Naranjo scale was more likely 
to produce a lower probability category than global introspection. Global introspection 
took significantly less time to complete than Naranjo. Both of these results may be due 
in part to more information needed from the case report to complete all questions 
within the Naranjo scale.  
The above summary of published comparisons of causality assessment methods is not 
systematic but is comprehensive and characterises what many investigators think about 
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these methods. Namely, 1) there is evidence that assessor opinion and global 
introspection provide poor inter-rater reliability; 2) algorithms are of varying 
complexity, and are limited by the information that is required to complete 
assessments, but they can improve inter-rater reliability between assessors; 3) Bayesian 
methods are likely to produce the most realistic assessment of causality, with the most 
comprehensive and adaptable assessment process, but are complex, extremely time-
consuming, and require expertise to complete. The most studied and widely used 
method is the Naranjo ADR probability scale, as it is quick to complete and has 
moderate reliability when compared to more comprehensive and detailed methods. The 
Naranjo method was chosen to assess ADR cases when commencing planning for the 
studies in this thesis. 
1.6 SEVERITY ASSESSMENT 
Assessment of severity of ADRs is important. For regulatory authorities, assessment of 
severity can aid decisions of how best to investigate spontaneous reports of ADRs. 
New reports of a severe ADR may need urgent action to elucidate the potential 
problem and may require intervention as described earlier in this chapter. In studies of 
ADRs, severity assessment can aid in the analysis of ADR importance and highlight 
the burden to patients, burden to the setting (e.g. hospital/primary care) and areas for 
potential intervention.  
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Severity assessment can be undertaken in one of two ways; assessor opinion or use of 
structured guidance in the form of descriptions. Generally, in publications, authors 
describe how they assessed severity for their own study without use of structured 
guidance (assessor opinion), use structured guidance which has been previously 
published or propose a new schema. Dormann et al suggested a severity scale 
consisting of questions and weighted answers, much like the Naranjo probability scale 
for causality, which they used in a study comparing a computer-based ADR 
monitoring system with spontaneous reporting in a hospital setting (Dormann et al. 
2000). A disadvantage of this system is the user must answer each question in turn and 
is limited to using the information asked for in the individual questions. Also, some of 
the questions ask for opinion regarding future outcomes such as, “Did the adverse drug 
reaction lead to permanent inability to work?”, which may require follow-up of the 
patient.  
The WHO defines reactions by seriousness, in the following categories: 
 requires inpatient hospitalisation  
 prolongation of existing hospitalisation  
 results in persistent or significant disability/incapacity 
 is life-threatening or results in death.  
 
The WHO state clearly that they use the term serious, or not serious, to describe ADRs 
as this relates to patient/event outcomes, whereas the definition of ‘severe’ implies a 
description of the intensity of an event e.g. a ‘severe’ headache may affect a patient but 
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unless it causes admission to hospital, or some other measure of poor outcome, it is not 
a ‘serious’ headache.  
The UK MHRA defines ‘serious’ reactions as those that are:  
 Fatal or life-threatening 
 disabling or incapacitating 
 the cause of admission to hospital 
 cause of prolonged hospital stay 
 cause congenital abnormalities 
 are medically significant.  
 
They state “by contrast with serious reactions, a severe reaction refers to the degree of 
harm, disability or effect on quality of life.” They use a similar example of severe 
headache as the WHO above to highlight this difference. However, the UK regulatory 
authority does state that they “are interested to receive reports of any suspected adverse 
reaction, irrespective of severity, for all black triangle drugs and vaccines.” Medicines 
that are being monitored particularly closely by regulatory authorities in the European 
Union (EU) are described as being under 'additional monitoring' and have an inverted 
Black Triangle displayed in their patient information leaflet and summary of product 
characteristics (SPC). 
However, regarding children specifically, the MHRA also comment that all suspected 
ADRs should be reported “even if they occurred with an established drug and 
regardless of whether or not the medicine is licensed for use in children. This is 
because the nature and course of illness and ADRs may differ between adults and 
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children. In general, children are not exposed to medicines in clinical trials, therefore 
very little is known about the safe use of medicines in this group. Furthermore, many 
drugs which are routinely used to treat children are not actually licensed for their use, 
so it is particularly important to focus on their safety in children.” (MHRA 2009, 2012) 
Hartwig et al described the severity assessment they used in assessing ADRs reported 
by pharmacists in a hospital-based pharmacovigilance program (Hartwig, Siegel & 
Schneider 1992). This schema for severity assessment is a seven step increasing scale 
from level one, ‘an ADR occurred but required no change in treatment with the 
suspected drug,’ to level seven, ‘the adverse reaction either directly or indirectly led to 
the death of the patient’; level 4 includes ‘the ADR was the reason for admission.’ One 
advantage of this scale is that it describes potential outcomes in more detail, for 
hospital settings, than the WHO/MHRA criteria. The Hartwig severity scale has been 
used, sometimes having been altered for a particular setting, in many hospital-based 
ADR studies. 
1.7 AVOIDABILITY ASSESSMENT 
Retrospective review of adverse events is undertaken in many settings, not just 
healthcare organisations. A review of an adverse event aims to determine the impact 
on the subjects/organisation involved, define the steps that led to the occurrence of the 
event and, usually, to look at avoidability/preventability to ensure that interventions, if 
necessary, can be put in place to reduce the risk of re-occurrence. A comprehensive 
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review is usually prompted by a spontaneous report of a potentially serious event 
(sometimes called a near miss) or as a result of actual harm. Davies et al showed that, 
in the case of ADRs occurring in hospital, similar risk assessments can be applied to 
ADRs as to other non-ADR events, such as prescription and administration errors 
(Davies et al. 2010). 
There are several methods for assessing avoidability. As with other types of 
assessments of ADRs, many clinicians and researchers use assessor opinion to decide 
whether or not the event in question could have been avoided. This has the advantage 
that assessments can be completed in a timely manner but the disadvantage that it 
relies on the experience and knowledge of the investigator.  
Hallas et al suggested a quick schema to aid in assessor rating of avoidability of ADRs 
(Hallas et al. 1990). The schema consists of three categories, with a description of each 
to aid the assessor in determining which category is appropriate to assign, as follows: 
 Unavoidable.                                                                                                       
The ADR could not have been avoided by any reasonable means. 
 Possibly avoidable.                                                                                                         
The ADR could have been avoided by an effort exceeding the obligatory 
demands of present day knowledge of good medical practice.  
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 Definitely avoidable.                                                                                                      
The ADR was due to a drug treatment procedure inconsistent with present day 
knowledge of good medical practice.  
The definitions for each of the three categories is quite broad and the assessor will rely 
on their experience and knowledge to determine which is best suited to describe the 
avoidability of the reaction in question. This method still encompasses assessor 
opinion, with the advantage that it is quick to use, but provides some simple structure 
for the assessor. Another disadvantage is the description used in the ‘possibly 
avoidable’ category; according to the definition, “an effort exceeding the obligatory 
demands of present day knowledge of good medical practice” is necessary to deem a 
reaction to be possibly avoidable. The difficulty with this definition is that the assessor 
must have obtained the knowledge of what constitutes good medical practice, which 
may vary in differing health care settings, populations or medical specialties. Also, the 
use of ‘obligatory’ is difficult to decipher; does this mean that all clinicians should be 
aware of the good medical practice necessary to avoid the ADR? If the answer to this 
question is yes, it is difficult to see that any ADRs could be labelled as ‘possibly 
avoidable.’ However, the assessor opinion involved in this method may allow this 
category to be used, as individuals will have their own opinions of what obligatory 
good medical practice entails.  
Schumock and Thornton attempted to devise an avoidability assessment tool that was 
more clinically focussed (Schumock & Thornton 1992). Their tool consists of seven 
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questions to which the answers are either yes or no. If any of the questions are 
answered with ‘yes’, the reaction is deemed to be avoidable. The questions are:  
1. Was the drug involved in the adverse drug reaction not considered appropriate 
for the patient’s clinical condition? 
2. Was the dose, route, and frequency of administration not appropriate for the 
patient’s age, weight and disease state? 
3. Was required therapeutic drug monitoring or other necessary laboratory testing 
not performed? 
4. Was there a history of allergy or previous reactions to the drug? 
5. Was a drug interaction involved in the reaction? 
6. Was a toxic serum drug level documented? 
7. Was poor compliance involved in the reaction? 
The tool, whilst attempting to structure assessment of causality more formally, was not 
entirely satisfactory and was modified by other investigators to include previous ADRs 
to classes of drugs, and not just individual drugs. Dormann et al modified the tool 
further to say that if there were no other form of treatment (e.g. cytotoxic therapy for 
cancer), or a positive benefit-risk ratio could be assigned for the causative ADR drug, 
then the ADR was judged to be ‘tolerable.’ This category, in essence, is not avoidable. 
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However, care should be taken in assessing ADRs to be in this category as they may 
be amenable to prevention by using prophylactic treatment.  
Ferner and Aronson (Ferner & Aronson 2010b) conducted a systematic review aiming 
to identify and analyse the approaches used to define ‘preventability’ in relation to 
ADRs. The authors identified eight general methods for attributing avoidability of 
drug-related harm; analysis without explicit criteria, assessment by consensus, 
preventability linked to error, preventability linked to standards of care, preventability 
linked to medication-related factors, preventability linked to information technology, 
categorization of harmful treatments in explicit lists, and a combination of more than 
one approach. The method by Hallas is included in the methods of preventability 
linked to standards of care and the method of Schumock and Thornton belongs to 
methods of preventability linked to medication-related factors. The authors of the 
review importantly state that there is no compelling evidence for the use of any one 
tool used to assess avoidability over another.  
Ferner and Aronson state that the methods identified in the review generally rely on 
two principles; the judgement of one or more investigators or the use of pre-defined 
explicit criteria. They conclude that neither method is satisfactory and suggest a novel 
approach based on analysis of the mechanisms of adverse reactions and their clinical 
features could be preferable. They propose such a method, based on previous 
publications of new classifications of types of ADRs (Aronson & Ferner 2010). These 
classifications are the EIDOS and DOTS methods. EIDOS is based on the mechanism 
of action of the drug and includes assessment of the Extrinsic species (drug), the 
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Intrinsic species (subject or organ), the Distribution of the drug and target together, the 
resulting Outcome (adverse effect), and the Sequelae (adverse reaction) (Ferner & 
Aronson 2010a). The DOTS ADR classification considers classifying ADRs by Dose-
relationship between drug and event, Time relationship between drug and reaction, and 
Susceptibility of individuals (Aronson & Ferner 2003).   
This new classification system is comprehensive in comparison to the methods in the 
systematic review. However, it is also more complex than other methods and, although 
its use has not yet been investigated by other authors, it is likely to be more time 
consuming. The main strength of the new method is that it not only assigns whether an 
ADR was preventable but also gives an indication as to how the ADR could have been 
prevented. This could allow health care workers to assess cases and potentially 
implement interventions to prevent recurrence. Due to the structure of the method, and 
its apparent complexity, it is probably best used for assessing individual clinically 
important cases, or small series’ of cases, of possible ADRs. In this thesis, avoidability 
will be assessed using the definitions derived by Hallas. This will allow timely 
assessment of possible ADR cases, which may be an important factor in assessing 
large numbers of cases from an observational study, and comparison with other 
observational and retrospective studies which have used this method. 
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1.8 OBSERVATIONAL STUDIES OF ADRS CAUSING ADMISSION IN 
CHILDREN 
There have been previous observational studies of ADRs causing admission in 
children. These studies have been incorporated into four systematic reviews.  
1.8.1 Impicciatore et al 
The first systematic review included non-selected studies, from 1966 to May 2000, 
investigating ADRs in hospitalized children, in outpatient children, and ADRs causing 
paediatric hospital admissions (Impicciatore et al. 2001). The review aimed to explore 
the usefulness of data derived from observational studies in defining and preventing 
the risk of pharmacological interventions in children. Five studies investigating ADRs 
as a cause of admission of children to hospital were included. A summary of these 
studies is provided (Table 1.2). Some of the works regarding more accurate formal 
methods of ADR assessment were borne by some of these important early 
observational studies of ADRs.  
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Table 1.2 Summary of studies of paediatric ADR admissions included in the Impicciatore review 
Author (year) 
Setting 
No. ADR 
admission 
Methodology Causative drugs (most frequent) Assessments undertaken Assessments not 
undertaken 
McKenzie (1976)  
Paediatric teaching 
hospital, US 
72/3556 
(2%) 
All admitted patients using chart 
review and clinical rounds for three 
years. Review by pharmacologist. 
Cytotoxics (38%), corticosteroids 
(15%), anti-convulsants (13&), 
antibiotics (13%) 
96% definite causality (self-defined).  
40% ADRs severe. Four deaths. 
Increase risk in age>6 years. 
No formal method for 
causality (pre-dates). 
No avoidability assessment. 
Yosselson-
Superstine (1982)  
AED University 
hospital, Israel 
29/906 
(3.2%) 
Pharmacist participating in physician 
rounds, interviewing patients and/or 
their guardians and reviewing 
medical charts over seven months 
Cytotoxic drugs, corticosteroids, 
anticonvulsants, antibiotics  
41% ADRs severe. One death.  
Causality undertaken 
(McKenzie/Whyte). 
ADRs more common in girls. 
No avoidability assessment. 
No risk factor assessment.  
Mitchell (1988) 
Four teaching 
hospitals/three 
community 
hospitals, US 
288/7271 
(4%) 
Derived from The Pediatric Drug 
Surveillance Program (over 11 
years). Trained nurses on selected 
wards collected data about a sample 
of patients admitted for more than 24 
hours. Ward nurses and house staff 
(clinicians) were consulted.  
Cytotoxic drugs, phenobarbital, 
aspirin, phenytoin, ampicillin or 
amoxicillin, theophylline, co-
trimoxazole, diphtheria-pertussis-
tetanus vaccine. 
51% definite causality (self-defined) 
ADRs increased in age from infancy 
to 5 years. 
Two deaths. 
No formal causality method.  
No avoidability assessment. 
Martinez-Mir 
(1996) 
Children’s 
hospital, Spain 
21/517 
(4.3%) 
Paediatrician collected data on 512 
consecutive admissions under the 
age of 25 months during two periods 
(105 days in summer, 99 days in 
winter) 
Respiratory drugs (35%),  
anti-infective agents (25%),  
drugs active on the central nervous 
system (15%), 
drugs used in dermatology (10%). 
38% severe ADRs. 
Causality (Meyboom 1992). 
No deaths. 
ADRs more common in girls (no 
statistical difference, small sample) 
No avoidability.  
Easton (1998) 
Children’s 
hospital, Australia 
10/1682 
(0.6%) 
Ward pharmacists assessed all 
admissions over a 56 day period 
Anti-epileptic drugs Nine cases possible causality 
(Naranjo). 
 
No avoidability reported.  
No risk factor assessment. 
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The first study assessing ADRs as a cause of admission, included in the review, was a 
prospective observational study by McKenzie et al, published in 1976 (McKenzie et al. 
1976). 72/3556 admissions (2%), in 64 patients, were judged to have resulted from 
ADRs. Cytotoxic drugs were the most frequent drug class causing admission (38%) 
during the study. In four admissions the ADR was thought to have contributed to death 
(bone marrow aplasia and pneumonia following cytotoxic chemotherapy; bone marrow 
depression and pseudomonas bacteraemia following cytotoxic chemotherapy; digitalis 
toxicity and cardiac arrhythmia; thrombocytopenia and bleeding from epistaxis 
following cytotoxic chemotherapy). The authors assigned only three of the ADRs as 
having less than probable causality. This may be due to over-attribution of causality by 
the authors because of lack of use of a causality assessment method or because the data 
collection methodology was not sensitive to picking up less well-defined ADRs.  
There was no reported assessment of whether or not the reactions were avoidable.  
Cytotoxic drugs were also the leading cause of ADR admissions to a university 
hospital in Israel (Yosselson-Superstine & Weiss 1982 ). One admission, occurring as 
a result of cytotoxic therapy, was fatal. In this study, 29/906 (3.2%) admissions were 
attributed to ADRs. Avoidability of the reactions was not assessed.  
In a large US study, trained nurses assessed admissions caused by ADRs over an 11 
year period (Mitchell et al. 1988). Trained nurses were stationed on selected wards 
where they collected information, including a drug history of the three months prior to 
admission, about a sample of patients admitted for more than 24 hours. Only one 
admission per patient was studied over the period. The study nurses also elicited the 
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judgement of ward nurses and house staff (clinicians). The study assessed ADRs 
causing admission in three separate groups: neonates, children with cancer and ‘other 
children’. In babies admitted to three neonatal intensive care units the study team 
found 6/3,026 admissions resulted from ADRs, all of which occurred in referrals from 
another hospital.  
In the same study, in children with cancer, ADRs caused 157/725 (22%) admissions. 
Cytotoxic therapy accounted for the majority of admissions (94%). The study included 
radiotherapy as an ADR, occurring in 10% of admissions, and three admissions were 
prompted by other non-cytotoxic drugs. There were three deaths due to medication; 
two due to immunosuppression and one to cardiotoxicity (attributed to doxorubicin 
given two months prior to admission). In the ‘other children’ studied in two teaching 
hospitals and three community hospitals, 131/6,546 (2%) admissions were related to 
an ADR. There was no difference regarding gender and the occurrence of an ADR. 
There were two deaths due to ADR. A child with congenital myopathy, treated with 
erythromycin and theophylline for a respiratory illness, developed arrhythmia and 
cardiopulmonary arrest. Interestingly, this death was attributed to theophylline toxicity, 
however the case occurred before the interaction of erythromycin and theophylline had 
been described. A second child died after transfer to hospital from a dental facility with 
hypernatraemia and cardiac arrest, where she had been given halothane and nitrous 
oxide. The death was attributed to complications of general anaesthetic. Avoidability 
was not assessed formally for the ADRs in the study.  
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Martinez-Mir et al investigated ADRs causing admission of children, aged 2 years and 
under, to a hospital in Spain (Martinez-Mir et al. 1997). Of the 517 admissions, 21 
(4.3%) were thought to be due to an ADR. The most common ADRs causing 
admission were convulsions (4), dizziness (4), vomiting (3), tremor (2), fever (2), 
itching (2) or apnoea (2). The drugs most commonly implicated as causative agents 
were respiratory drugs (35%), anti-infective agents (25%), drugs active on the central 
nervous system (15%) and drugs used in dermatology (10%). There was no difference 
in the mean number of drugs taken during the month before admission between the 
ADR (n=5.8) and non-ADR (n=4.6) admissions. Eight cases (38%) were judged to be 
severe, defined as directly life-threatening. There were no significant differences in age 
(<1 or >1 year) or gender (14 female, 7 male) for the ADR admissions, although ADRs 
were more common in girls (14/263, 5.3%) compared to boys (7/249, 2.8%). The 
incidence of ADR admissions reported in this study is higher than the other studies 
included in the systematic review but caution should be used when interpreting the 
results. This is a smaller study in an age-limited population and the results may be 
influenced by drug utilisation or the population studied.  
The last study included in the systematic review by Impicciatore was published in 
1998. Easton et al assessed all admissions to an Australian children’s hospital, over a 
56 day period, for the occurrence of drug related problems, of which ADR was one 
category (Easton et al. 1998). There were 58 admissions due to drug related problems. 
10/1682 (0.6%) admissions, in nine patients, were due to an ADR. Anti-epileptic 
medication was implicated in causing 3 admissions. The Naranjo scale was used to 
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assess causality, with nine cases classified as ‘possible’ and one ‘probable.’ Using an 
adapted schema, derived from Schumock and Thornton, the authors assessed 
preventability of all drug related problems citing that 2/3 of cases were preventable. 
However, no detail of preventability was given for the ADR subgroup.  
For these five studies included in the systematic review, the meta-analytic weighted 
average gave an incidence of 2.09% (95%CI, 1.02, 3.77) for ADRs causing paediatric 
admission. Of the ADRs causing admission, 39.3% (95%CI, 30.7, 47.9) were life 
threatening. Although the incidence for admissions caused by ADR was low in 
comparison to the frequency of ADRs occurring in hospital (9.53%; 95%CI 8.43, 
16.17), the high proportion of severe reactions signifies that this aspect of ADRs in the 
paediatric population is a significant public health issue. The review found that poly-
pharmacy was a potential risk factor for development of an ADR. The ADR studies 
included were undertaken in different countries, different healthcare settings and by 
different types of investigators (nurses, pharmacists, paediatricians and 
pharmacologists). Variables such as patient age and prescription patterns were not 
reported consistently. This heterogeneity between studies does not lend itself to 
accurately identifying risk factors for ADRs.  
1.8.2 Clavenna and Bonati 
A second systematic review, published in 2009 by Clavenna and Bonati, aimed to 
assess the incidence of ADRs in the paediatric population since 2001 (Clavenna & 
Bonati 2009). The review included eight studies, of which four collected data 
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regarding ADRs as a cause of admission to hospital. The meta-analytic weighted 
average for the incidence of ADRs causing hospital admission due to ADRs was 1.8% 
(95% CI 0.4, 3.2).  
The first included study was conducted over a period of five months by Buajordet et al 
in the paediatric department of a university hospital in Norway, assessing children up 
to the age of 16 years for the occurrence of adverse drug events (Buajordet et al. 2002). 
Parents and staff were asked to report adverse drug events occurring before and after 
admission. In addition, an investigator (a pharmacist) visited clinical areas daily to 
enquire about possible events and screen medical records. There were 919 admissions 
in 665 patients in the study period with 579 patients having been exposed to 
medication. Although the study was designed to assess adverse drug events, the 
authors state that 5% of admissions were due to ADRs according the WHO definition. 
ADR admissions were most frequently due to cytotoxic therapy (22) and vaccinations 
(9). Most of the cases (81%) were identified by screening of patient records, with the 
remainder identified from cases reported by physicians or parents. Of all the drug 
events/ADR cases identified in the study, a significant proportion occurred in children 
undergoing treatment for cancer.  
Over the course of one week, all children admitted to a regional children’s hospital in 
France were assessed for ADRs (Jonville-Bera et al. 2002) by an investigator who 
collected information daily. Four admissions (4/260 admissions, 1.5%) were due to 
ADRs: convulsion with an antiepileptic drug, myoclonia with an analgesic, melaena 
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with acetyl salicylic acid, and neonatal withdrawal syndrome with methadone). No 
formal assessments were undertaken on these cases.  
During a prospective observational study of ADRs in a Sri Lankan hospital, over an 11 
month period, investigators found 63/39625 (0.16%) admissions occurred as a result of 
ADRs (Lamabadusuriya & Sathiadas 2003). The commonest drugs implicated in 
causing ADR related admissions were antibiotics (32), metoclopramide (7), nalidixic 
acid (6) and Japanese encephalitis vaccine (6). The most common reactions occurred in 
skin (52%) and central nervous system (27%). There were no deaths although 11 
reactions were serious (life threatening). ADRs were more common in girls at a ratio 
of 1.4:1. It is likely, given the very low incidence of ADR admissions in this study, that 
there were issues with prospective collection of data or identification of ADRs. No 
assessment of avoidability was made for the ADR cases. 
A study in a Nigerian hospital found 17/3821 (0.4%) children were admitted to the 
children's ward because of ADRs (Oshikoya et al. 2007). The study used data pooled 
from two studies; a retrospective medical record review of 3139 paediatric admissions, 
from January 2004 to June 2006, and a six month long observational study of 682 
admissions, undertaken by a multi-disciplinary team, from July to December 2006. 
The incidence for the prospective aspect of the study was 0.6%. Antibiotics were the 
group of drugs most likely to be associated with an ADR. Skin reactions were the most 
frequent ADR. 22 children had severe ADRs and two children died as a result of 
ADRs (one death from hepatic failure after ingestion of a herbal medicine and one 
death from Steven’s Johnson syndrome after antibiotic use). 43 ADRs were judged to 
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be preventable, although no detail regarding these cases was reported. The incidence of 
ADRs reported in this study is low and is likely to be due to the mixed methodology 
used, with retrospective case-note review being less likely to give an accurate estimate 
of the frequency of ADRs.  
1.8.3 Aagaard et al 
Aagaard et al. published a third systematic review in 2010 which included 19 studies, 
six of which investigated ADRs as a cause of hospital admission. The review 
concentrated on the quality of the studies and compared methods and reported 
outcomes between them, including; type and occurrence of ADR (incidence and 
prevalence), type of reporter, seriousness, and patient demographics. The average 
incidence rate for inpatients hospitalized due to ADRs was 9% and the prevalence 4%. 
Five of the six ADR admission studies were included in the first systematic review by 
Impicciatore et al. With respect to ADR admission studies, Aagaard did not include 
any of the studies in the review by Clavenna et al, indicating a less than comprehensive 
search strategy.  
 
The sixth study included in the Aagaard review (but not the first systematic review by 
Impicciatore) was published in 2005 by Haffner (Haffner et al. 2005), who 
investigated ADRs in two general paediatric wards and a paediatric intensive care unit 
(PICU). Patients on the paediatric oncology ward were excluded. Haffner et al 
compared intensified ADR surveillance with computerised signal detection, in 
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admissions and inpatients, concluding that intensified surveillance discovered a higher 
frequency of ADRs, and ADRs that were more severe, but required higher personnel 
resources. The incidence of ADR admissions, combining both intensified and 
computerised surveillance, over a 51 day prospective data collection period was 2.7%.  
1.8.4 Smyth et al 
A fourth systematic review was undertaken as part of the Adverse Drug Reactions in 
Children (ADRIC) research programme (Smyth et al. 2012) aiming to investigate 
ADRs reported in observational studies in three settings: causing admission to hospital, 
occurring during hospital stay and occurring in the community. The authors aimed to 
describe the methods used for detecting and assessing ADRs within the studies and to 
better understand how ADRs may be avoided. 102 studies were included in the review, 
of which 72 assessed causality, 34 assessed severity and only 19 studies reported 
avoidability assessments. Of the 19 studies reporting avoidability, only three had 
reported the case-specific rationale for potentially avoidable ADRs.  
There were 42 studies investigating ADRs as a cause of admission. Less than half 
(n=20) of these studies investigated admissions solely, with the remainder 
investigating ADRs occurring in multiple settings. 12 studies did not report rates of 
ADR occurrence. A pooled estimate of 30 studies investigating ADRs causing 
admission showed an incidence rate of 2.9% (95% CI 2.6, 3.1). Individual studies, not 
included in the other reviews, are not described in more detail here. The review 
included both retrospective and prospective studies. Some of the study data revealed 
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very low incidence rates for occurrence of ADRs causing admission (mainly 
retrospective studies). Both prospective observational studies described in this thesis, 
in chapters 2 and 4, are included in the review. 
1.9 PREVENTION OF ADRS 
There are many ways of attempting to prevent ADRs. The majority of these methods 
relate to good clinical practice, such as prescribing for an appropriate indication, 
appropriate dosing of medication, good allergy reporting and monitoring of therapy. 
However, even when information from drug manufacturers advises monitoring to 
prevent ADRs, the evidence of when to do this, how frequently, how long for and how 
to interpret the monitoring findings (often investigations) may not be available 
(Pirmohamed & Ferner 2003).  
Various attempts have been made to reduce the burden of harm from drugs by other 
means. Raschke et al, in an adult medical setting, used an integrated computer system 
to alert physicians of possible drug related problems in 37 drug-adverse event pairings 
(Raschke et al. 1998). The system issued 1116 alerts over a six-month period when 
physicians were prescribing medication to patients. 596/1116 (53%) alerts were true 
positives, with 265/596 (44%) alerts going unrecognised by clinicians prior to alert 
notification by the system. Although an integrated prescribing system can aid decision 
making regarding prescription of drugs, and potentially lower the rate of drug-related 
harm, it is time and cost-expensive and needs to be fully integrated with lab and 
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clinical data to have an impact on routine patient care. It may also only make cost-
savings, for example in length of stay, in environments where there is a high rate of 
drug-related harm or a significant rate of serious harm which creates a cost-burden for 
the institution involved.  
The advent of stratified medicine (the ability to classify individuals into 
subpopulations that differ in their susceptibility to a particular disease or their response 
to a particular treatment) has been hailed as a potential step forward in aiding drug 
safety and assessment of likely drug efficacy (Trusheim, Berndt & Douglas 2007). 
Pharmacogenetics is the study of genetic variability in drug response between 
individuals or, more commonly, groups of individuals. The study of this variation 
holds promise in identifying at risk groups for ADRs from particular drugs, or classes 
of drugs. This could potentially swing the benefit-risk ratio positively in favour of 
certain subgroups of patients. An example of this is the identification of an association 
between human leukocyte antigen (HLA)-B*1502 in Chinese patients and an increased 
risk of Carbamazepine induced Stevens-Johnson syndrome. This allele has not been 
found in a caucasian population in the UK (Alfirevic et al. 2006). This knowledge 
allows for genetic testing prior to commencement of treatment with Carbamazepine to 
reduce the risk of a potentially serious reaction within the high risk group.  
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1.10 COST OF ADRS 
There is little doubt that ADRs increase the cost of patient care. However, the cost of 
ADRs is difficult to calculate accurately. There have been studies assessing the direct 
costs of ADRs. One such study calculated that each ADR during admission increased 
the cost of admission by almost 2000 Euro (Evans et al. 1994). Pirmohamed et al, in a 
large observational study of ADRs causing admission to two hospitals in an adult 
population, estimated the cost of ADR admissions to the National Health Service 
(NHS) to be £466m (€706m, $847m) a year (Pirmohamed et al. 2004). There are few 
estimates of the costs of ADRs in paediatric populations and these are usually in 
relation to inpatient ADRs. There is difficulty in attributing direct costs as a result of 
ADRs due to the heterogeneity of healthcare settings and populations studied. 
However, direct costs are not the whole story when considering costs. There are major 
methodological problems when assessing total costs of the burden of ADRs due to the 
indirect costs such as absence from work (Gautier et al. 2003).  
1.11 CONCLUSIONS 
ADRs are likely to be an important source of avoidable harm to children. A systematic 
approach to reducing this harm is required. The ADRIC project was funded by the 
NIHR to provide this systematic approach. The project set out to describe risk factors 
for ADRs with a view to modifying practice to address those risk factors. 
48 
 
Thus the studies described in this thesis aim to address elements of a systematic 
approach to minimising the harms of ADRs in children. The focus of this thesis is 
ADRs that result in hospital admission (the ADRIC1 study). A companion study 
(ADRIC 2) examined ADRs among children who were hospital inpatients. 
The first element covered in this thesis is a description of the problem. There have 
been several studies aiming to assess the impact of ADRs that cause children to be 
admitted to hospital. A recent comprehensive systematic review of these studies 
estimated the incidence of ADRs causing admission to be 2.9% (95% CI 2.6%, 3.1%) 
and showed that severe ADRs are likely to be common (Smyth et al. 2012). The 
majority of studies have been undertaken prospectively in an aim to maximise the 
accuracy of the estimate of frequency of ADR admissions. However, some of the 
studies were small and undertaken over a short period of time. These studies are 
unlikely to provide information that can be generalised to other healthcare settings or 
countries. There were several larger studies, which are described earlier in this chapter, 
which give more reliable data on the burden of ADRs causing admission of children to 
hospital. Some of these studies were undertaken some time ago and patterns of drug 
usage are likely to have changed since their publication. Mitchel et al reported, in 
1988, that the top three drugs causing ADRs were Phenobarbital, Aspirin and 
Phenytoin. These three drugs are used less in children now, for varying reasons, than 
they were in 1988. It is likely that the frequency and characteristics of ADRs causing 
admission will have changed as a result. None of the studies undertaken addresses the 
problem of ADRs causing admission of children to UK hospitals and none of them 
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examine the risk factors for ADRs. The first step in addressing these issues is to 
undertake a prospective study to assess the frequency of the problem, the types of 
ADRs occurring and the drugs/drug classes implicated. 
Moreover, very few of the studies describe the case-specific rationale for assessment of 
avoidability of the reactions identified; that is, the investigators give no indication as to 
how the ADRs might have been prevented. Although assessments of avoidability can 
be subjective, and difficult to undertake, they may identify patterns of drug use, or 
areas of clinical practice, where interventions might be fruitful in decreasing the 
frequency, or severity, of ADRs. Thus, the second step is to examine the extent to 
which the problems are avoidable.  
There is a paucity of information regarding costs of ADRs in the paediatric population. 
The lack of direct cost estimates for ADRs causing paediatric admissions reduces the 
stimulus for change or intervention. The third step is to estimate the direct costs that 
can be attributed to ADR admissions in children. These steps require some work to 
develop appropriate methods. 
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1.12 AIMS OF THIS THESIS 
The aims of this thesis are to describe ADRs causing admission of children to a UK 
hospital with respect to epidemiology and avoidability. In particular: 
1. To undertake a pilot study to determine the methodology to be used for a larger 
study of ADRs causing admission to a UK paediatric hospital  
2. To develop a causality tool (since existing tools were found to be inadequate 
during the pilot study) 
3. To undertake a one year prospective observational study of acute admissions to 
a UK paediatric hospital, and assess the following: 
a. The incidence of ADRs causing admission. 
b. The type of ADRs causing admission. 
c. The drugs and drug classes most frequently causing ADR admissions. 
d. The severity and causality of ADRs. 
e. The avoidability of the ADR admissions as well as the types of 
interventions that could reduce the burden of avoidable ADRs. 
f. Potential risk factors for occurrence of an ADR causing admission. 
g. The cost of ADRs to the study hospital. 
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CHAPTER 2  ADVERSE DRUG REACTIONS 
CAUSING ADMISSION TO A PAEDIATRIC 
HOSPITAL: A PILOT STUDY  
2.1 INTRODUCTION 
Children are vulnerable to adverse drug reactions. A systematic review of ADRs in 
children, published in 2001, included 5 prospective studies (Easton et al. 1998; 
Martinez-Mir et al. 1997; McKenzie et al. 1976; Mitchell et al. 1988; Yosselson-
Superstine & Weiss 1982 ) and estimated the incidence of ADRs causing hospital 
admission in children to be 2.09% (95%CI 1.02, 3.77) (Impicciatore et al. 2001). A 
second systematic review of studies (Clavenna & Bonati 2009) published in 2009 
included a further four prospective studies (Buajordet et al. 2002; Jonville-Bera et al. 
2002; Lamabadusuriya & Sathiadas 2003; Oshikoya et al. 2007), published between 
2001 and 2007, researching ADRs causing admission to hospital in children. The 
calculated incidence of ADRs in children causing admission to hospital was 1.8% 
(95% CI 0.4, 3.2) using a meta-analytic estimated average, adjusted and weighted by 
sample size of the included studies. These studies were conducted in a wide range of 
healthcare settings and in different countries. Few of the prospective studies included 
analysis of risk factors for developing an ADR or detail about avoidability of the 
reactions. 
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Spontaneous reporting systems, such as the UK Yellow Card Scheme (MHRA), under 
report ADRs (Hazell & Shakir 2006). To obtain reliable information about the 
incidence of ADRs prospective studies are needed. A large prospective study in an 
adult population showed as many as 6.5% of admissions were caused by ADRs 
(Pirmohamed et al. 2004). There are no recent large studies of the incidence and nature 
of ADRs causing admission of children to hospital in the UK. 
The National Institute for Health Research (NIHR) Programme Grants for Applied 
Research were established in 2006 to produce independent research findings that will 
have practical application for the benefit of patients and the UK NHS. In 2007, the 
NIHR funded the ADRIC research programme. The aim of the programme was to 
develop clinical tools to identify, prevent and manage ADRs in children. There was 
little study data regarding the extent of ADRs in a UK paediatric population. 
Therefore, the first step in this process was to investigate the epidemiology of ADRs in 
children which may contribute to acute hospital admissions in the UK. A one-year 
observational study of ADRs causing acute admissions to a UK children’s hospital was 
planned. The aim of this first study of the ADRIC programme is the prospective 
identification of ADRs in children causing admission to hospital to quantify the burden 
and identify key features.  
The setting for the study was Alder Hey Children’s Hospital NHS Foundation Trust, a 
large specialist children’s hospital in the north of England which accepts referrals from 
primary and secondary care. The hospital serves a catchment area of 7.6 million and 
treats approximately 200,000 children and young people, with 30,000 inpatients 
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annually. Approximately 60,000 children attend the Accident and Emergency 
department (AED) each year. 
A similar approach to Pirmohamed et al (Pirmohamed et al. 2004) was planned for our 
study: 2 research pharmacists, as part of a multi-disciplinary investigating team, 
studied 18,820 acute admissions across 2 hospital sites demonstrating an ADR 
incidence of 6.5% (95% CI, 6.2, 6.9) (Pirmohamed et al. 2004). Our study would 
likely have significant differences from an adult study due to the study population age, 
and differences between adult and paediatric medical practice, among other factors. 
We aimed to conduct a pilot study, in the first instance, to develop the methodology to 
enable successful completion of a larger observational study.  
The definition of a pilot study varies depending on the source. Use of the terms ‘pilot 
study’ and ‘feasibility study’ inter-changeably is widespread. The NIHR Evaluation, 
Trials and Studies Coordinating Centre define a pilot study as “a version of the main 
study that is run in miniature to test whether the components of the main study can all 
work together” and a feasibility study as “a piece of research done before a main study 
in order to answer the question “Can this study be done?” but which does not evaluate 
the outcome of interest (that is left to the main study).” Thabane et al., in 2010, 
reviewed several sources of definitions in their commentary and stated that “a pilot 
study is synonymous with a feasibility study intended to guide the planning of a large-
scale investigation.”(Thabane et al. 2010)  
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Lancaster et al., in a review published in 2004, state that “a well-conducted pilot study, 
giving a clear list of aims and objectives within a formal framework, will encourage 
methodological rigour, ensure that the work is scientifically valid and publishable, and 
will lead to higher quality RCTs.” (Lancaster, Dodd & Williamson 2004) The authors 
provided recommendations for the methodology and reporting of pilot studies for 
RCTs some of which are relevant to undertaking pilots of observational studies, such 
as: 
 
 Pilot studies should have a well-defined set of aims and objectives.  
 Participants should not later be included in the main study. 
 The analysis of a pilot study should be mainly descriptive. 
 
The aim of this pilot study was to address questions such as what constitutes an 
admission (which would allow comparison with other UK hospitals providing 
paediatric healthcare), whether to include patients admitted to the AED observation 
ward, and to assess feasibility of improving medication histories by use of a specific 
proforma. This pilot study aims to provide an evaluation of the feasibility of the 
methods required to conduct a larger definitive study and a preliminary assessment of 
the proportion of acute admissions that were associated with ADRs. 
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2.2 METHODS 
2.2.1 Preparation 
Before the pilot study began, a comprehensive educational program was undertaken to 
raise awareness about ADRs within the hospital amongst clinicians of all grades. The 
study team held meetings with clinical teams, and attended educational meetings of 
clinical trainees, to highlight the study, ADRs in children and the importance of taking 
detailed medication histories in relation to patient symptoms. Prior to the study, 
hospital admission documentation was altered with the introduction of a separate 
medication history proforma to highlight the elucidation of recently taken medication 
(in the preceding 2 weeks) as being an important part of general history-taking 
(APPENDIX A). The medication history proforma was presented at a weekly hospital 
grand round presentation, as well as to the clinical teams in the meetings mentioned, to 
ensure as comprehensive co-operation as possible be obtained. The documentation was 
developed by the study team and one of the lead investigators, with a 2-week 
medication history being chosen as the time in which most important reactions causing 
admission were likely to have occurred after exposure to a drug. The proforma was 
double-sided to provide ample room for more extensive medication histories.  
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2.2.2 Categories Of Admissions 
There are many types of admission to the study hospital. Many admissions are planned 
including those for: elective surgical procedures; elective medical admissions for 
investigation or management; day case admissions for treatment or investigations; 
some inter-hospital transfers for investigation or management. These were not included 
in the study. There are many children who return regularly to wards for ongoing 
treatment such as intravenous immunoglobulin infusions or dialysis. These were 
classed as planned admissions and also not included. Other exclusions were patients 
admitted because of accidental or intentional OD.  
All unplanned admissions to the main hospital and the AED observation ward were 
included. These included emergency attendances to AED, primary care referrals, inter-
hospital transfers and self-referrals (defined as patients with chronic conditions with 
clinician-agreed direct access to a hospital ward) who were then admitted to a main 
hospital ward or the observation ward. The intention was to include unplanned 
admissions to main hospital wards in the larger study. However, we were initially 
uncertain whether to include in the larger study patients admitted to the observation 
ward who were discharged without admission to the main hospital. The observation 
ward is an area within the AED department where patients can have treatment, 
investigation, or active observation, within a four hour time limit and are either 
admitted to a main hospital ward or discharged home. These patients mainly include 
those with acute illness who either attend voluntarily or are referred by a GP. 
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2.2.3 Assessment of Admissions 
The study was deemed to be audit after written communication with the National 
Research Ethics Service. All unplanned admissions to a large tertiary paediatric 
hospital were prospectively screened daily for ADRs over a 2 week period including 
weekend days and a bank holiday. The definition of ADR used was that of Edwards 
and Aronson (Edwards & Aronson 2000) which is "an appreciably harmful or 
unpleasant reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, or withdrawal of the product." 
This definition does not include accidental or intentional OD and, therefore, these 
patients were not included. All unplanned admissions in the previous 24 hours were 
identified on a daily basis from hospital computer systems. Members of the study team 
then collected information from the case notes on each patient identified as having an 
unplanned admission including age, sex, presenting complaint, summary of clinical 
history, diagnosis (if available at the time of admission), and medications taken in the 2 
weeks prior to admission. If information on medication history for the preceding 2 
weeks was not available from the case notes, or if clinical information needed to be 
clarified, the study team members interviewed the child/parents/carers as appropriate 
to confirm the history i.e. medication history, symptoms, and timing of events. To 
identify possible ADRs, one investigator screened the main hospital ward admissions, 
and a second investigator screened the case notes of patients admitted to the 
observation ward but subsequently discharged without admission to a main hospital 
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ward. The AED case notes are routinely electronically scanned from paper notes and 
stored on a password protected database. Therefore, there were very few problems 
with retrieval of these notes on a daily basis. 
Presenting symptoms/signs were cross-referenced against the medication history for 
each patient using the ADR profile for relevant drugs from the SPC (Datapharm 1999) 
or, if not available, the British National Formulary (BNF) (British National Formulary  
2008). The study team members identified possible ADRs using this information 
combined with the clinical history and temporal relationships of the medication(s) 
taken. All possible ADRs were reported to the responsible clinicians. Assessment of 
causality was performed for all cases using the method of Naranjo et al. (Naranjo, 
Busto & Sellers 1981). In addition, we determined the ADR type (according to the 
classification of Rawlins and Thompson) (Rawlins 1977), severity using the Hartwig 
scale (Hartwig, Siegel & Schneider 1992) and avoidability using the definitions 
developed by Hallas et al (Hallas et al. 1990). One of the lead investigators, a 
pharmacologist, had the final decision regarding assessments of ADR cases. These 
final decisions regarding assessments of ADRs took place at a meeting between 
investigators at the end of the study period. 
2.2.4 Assessment Of Methodological Issues 
The following were assessed during the pilot study:  
 Whether to include patients admitted to the AED observation ward.  
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The organization of acute paediatric services varies considerably in different 
UK hospitals. One feature of our service is the AED observation ward. Patients 
can stay on the observation ward for up to 4 hours for observation and 
treatment and are then either discharged or admitted to a main hospital ward. 
We therefore needed to define what constitutes an admission, so that it would 
be applicable in a variety of settings. During this pilot study, our intention was 
to identify ADRs occurring during emergency admissions to both the main 
hospital wards and in the AED observation ward in patients who were not 
subsequently admitted to a main hospital ward. This would enable us to make a 
decision about whether it was worthwhile and feasible to include children 
admitted to the observation ward without subsequent admission to a main 
hospital ward in our definitive study. 
 The feasibility of asking clinicians to complete a medication proforma detailing 
the medicines taken by each patient in the 2 weeks prior to their admission and 
assess the adequacy of clinical information recorded on observation ward given 
the relatively short stay of some cases. 
 The workload, shared between 3 investigators, was assessed to identify whether 
it was achievable to screen prospectively both main ward and observation ward 
patients on a daily basis including weekends. The feasibility of collecting data 
from main wards and the AED observation ward at weekends and during 
holiday periods was assessed over a public holiday weekend during the pilot 
study.  
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2.2.5 Analysis 
Analyses of the rates of ADRs were expressed as Number per 100 admissions with 
95% confidence intervals. Other results were stated as raw numbers or tabulated.  
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2.3 RESULTS 
2.3.1 Preliminary Estimates of Incidence of ADRs 
Over the 2 week pilot, 28
th
 April to 12
th
 May 2008, 847 records were identified by the 
hospital computer system for assessment (Figure 2.1). 22 of these were elective 
admissions wrongly coded and three were due to adverse drug events (one accidental 
OD, two accidental poisoning). Therefore, there were 822 acute admissions, in 794 
patients, to the main hospital and observation wards. Twenty-six patients had two 
admissions and one had three admissions during the study period. 462/794 patients 
(58.2%) were boys and 332/794 (41.8%) were girls. There were 473 admissions 
(57.5%), in 462 patients, to the main hospital wards; 274 (59.3%) boys and 188 
(40.7%) girls. Nine patients had two admissions, and one had three, to the main wards. 
There were 349 (42.5%) admissions, in 344 patients, to the observation ward 
subsequently discharged home; 197 (57.3%) boys and 147 (42.7%) girls. One patient 
had two admissions to the observation ward in the study period. The discrepancy 
between the numbers of patients in each admission group occurs because 16 patients 
with two admissions in the study period had one each to the observation ward and 
main wards. 
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Figure 2.1 Flowchart of admissions during the pilot study 
  
Admissions assessed for eligibility 
(n=847) 
Excluded 
- Planned admissions (n=22) 
- Accidental/intentional OD (n=3)  
 
Acute admissions assessed by 
study team (n=822) 
Acute admissions to main 
hospital wards (n=473) 
Acute admissions to the 
observation ward (n=349) 
19 ADR admissions 8 ADR admissions 
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There were 27 admissions identified as being complicated by an ADR. The 27 
admissions occurred in 25 patients, with two patients (one boy and one girl) in the 
main hospital ward group admitted twice with an ADR during the study period. 13/25 
(52%) patients with an ADR were boys and 12/25 (48%) were girls. There were 19 
admissions in 17 main hospital ward patients and eight admissions in 8 AED 
observation ward patients. This gives an incidence of 4 ADRs / 100 admissions (95% 
CI 2.2–5.8) in the main hospital wards and 2.3 ADRs / 100 admissions (95% CI 0.7–
3.9) in the observation ward. Twenty of the 27 (74%) admissions were deemed to have 
been directly caused by ADRs. In six cases (22%), an ADR was deemed to be a co-
factor for the admission. In one case (4%), the ADR was deemed to be incidental. 
Twenty-two (81%) of the ADR admissions were classified as being due to type A 
reactions (predictable from the known pharmacology) with five (19%) being type B 
reactions (not predictable). The five reactions judged to be Type B were: a 
maculopapular rash to the trunk, one day after starting a course of amoxicillin; a 
delayed onset of erythema multiforme, 1 day after finishing a course of cefaclor; a 
child with an oncological problem, who was admitted overnight, developed an altered 
conscious level after receiving PEG-asparaginase earlier in the day as an outpatient 
day-case; a child treated with cefaclor for an upper respiratory tract infection 
developed vomiting 2 days after starting therapy; and an infant who developed tongue 
and facial swelling, needing treatment with intramuscular adrenaline, five minutes after 
taking a first dose of mefloquine for prophylaxis against malaria. 
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The main cause of ADR-related admissions (n=10; 37%) were anti-neoplastic drugs. 
All of the affected children were admitted to the oncology ward. Immunosuppressants, 
antibiotics and analgesics were the next most commonly implicated drug groups in 
causing ADR-related hospital admissions to the main wards. 428/822 (52.1%) 
admissions had been exposed to a medication two weeks prior to admission to either 
the observation ward or main wards. In the 27 admissions associated with an ADR, 
children had been exposed to a total of 169 courses of medication (mean of 6.3 
medicines per admission). The median number of medicines taken by patients in the 
ADR admissions group was four with an inter-quartile range 2-10 (4; 2, 10). There 
were 401 admissions of children, exposed to medication, who did not experience an 
ADR. The total number of courses of medicines in the non-ADR admissions, for 
children who had been exposed to a medicinal product, was 1065 (mean of 2.7 
medicines per admission). The median number of medicines of patients in the non-
ADR group was two (2; 1, 3). There were 25 ADRs identified in the 19 ADR cases 
(Table 2.1).  
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Table 2.1 ADRs and drugs taken for main ward admissions 
ADR Occurrences Drugs identified 
Neutropenia 6 etoposide, carboplatin, vincristine,    
cytarabine, daunorubicin 
Vomiting 5 tacrolimus, prednisolone, etoposide, 
carboplatin, vincristine, 
Diarrhoea 4 cefaclor, mycophenylate mofetil 
Immunosuppression 2 tacrolimus 
Thrombocytopenia 2 etoposide 
Constipation 2 buscopan, ondansetron, tramadol 
Altered conscious 
level 
1 peg-asparaginase 
Anaemia 1 cyclophosphamide, doxorubicin 
Rash 1 amoxicillin 
Haematemesis 1 diclofenac 
Impaired renal 
function 
1 cyclosporin 
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Assessment of causality using the Naranjo algorithm showed the majority of cases to 
be in the ‘possible’ classification (17/27, 63%). Some were classified probable (10/27, 
37%) but none definite. All investigators reported that the Naranjo scale was difficult 
to use accurately in this population due to the nature of some of the questions and their 
relevance to current paediatric practice.  
All of the ADRs were classified as grade 3 (‘required treatment, or drug administration 
discontinued’) according to an adapted Hartwig severity scale. We defined anyone 
requiring admission to hospital as ‘needing treatment.’ No ADRs contributed to a 
death. Investigators reported that the severity tool was easy to use. However, it may 
need modifying for a paediatric population as not all children admitted with an ADR 
needed active treatment or drug withdrawal. In two instances, active observation was 
undertaken until symptoms abated. There were no children admitted to PICU (or any 
other higher level of care) and there were no deaths during the two week period.   
We determined avoidability of admissions related to an ADR by the method of Hallas 
et al. Eighteen (67%) of the ADRs were assessed as unavoidable, while 9 (33%) were 
classified as “possibly avoidable.” None were classified as definitely avoidable. 
Investigators reported that the Hallas system was easy to use but is likely to be user-
dependent given its broad classification terms. The possibly avoidable ADR 
admissions are detailed in Table 2.2 . 
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Table 2.2 Possibly avoidable ADRs 
ADR Drugs Description of reaction 
Nausea codeine 
phosphate 
Infected pin site. Took codeine for headache and 
developed nausea. 
Haematemesis diclofenac Coffee ground vomit after three days taking 
diclofenac post-operatively for bilateral hip surgery. 
Infection 
(cellulitis) 
hydrocortisone 
cream 0.5% 
Secondarily infected eczema. Regular use of 
hydrocortisone.   
Impaired renal 
function 
ciclosporin On ciclosporin for one month for graft versus host 
disease. Admitted with diarrhoea and renal failure. 
Had adenovirus in stool. Ciclosporin dose reduced 
and renal function improved. 
Vomiting carboplatin, 
etoposide 
Re-admitted after cytotoxic chemotherapy with 
vomiting. 
Rash paracetamol Rash after strawberry flavoured paracetamol. 
Previous similar rash after strawberry flavoured 
yoghurt. 
Nausea/vomiting vincristine, 
carboplatin, 
etoposide 
Admitted with nausea and vomiting, post-cytotoxic 
therapy, due to reduced oral intake. 
Constipation buscopan, 
tramadol, 
ondansetron 
Admitted with possible pseudo-obstruction. Previous 
admissions with pseudo-obstruction/constipation. 
Diarrhoea mycophenolate Persistent diarrhoea after liver transplant. Admitted 
with fever, possible infection and dehydration. 
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2.3.2 Methodological Issues 
We found that the majority of main hospital ward admissions (n=473) came from AED 
(n=363, 77%). This included clinical areas within AED and all GP acute referrals (all 
of whom are seen in AED before admission). Hospital transfers and acute self-referrals 
of children with known chronic disease accounted for the remainder of main hospital 
admissions (n=110, 23%). Observation ward admissions (n=349; 42.5%), i.e. where 
there was no admission to the main hospital wards, included self-referrals and acute 
GP referrals. The proportion of admissions to the observation ward that yielded an 
ADR was 2.3%. There were 9 ADRs identified in 8 observation ward cases (Table 
2.3). 
 
Table 2.3 ADRs and drugs taken for AED observation ward admissions 
ADR Occurrences Drugs identified 
Rash 3 paracetamol, cefaclor, MMR vaccine, pneumococcal vaccine 
Irritability 2 DTaP/IPV/HIB vaccine, pneumococcal vaccine 
Anaphylaxis 1 mefloquine 
Fever 1 MMR vaccine, pneumococcal vaccine 
Vomiting 1 cefaclor 
Infection (cellulitis) 1 hydrocortisone (cream) 
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Of the 473 admissions to the main hospital wards, the separate medication history 
proforma was only used in 57 (12%). The use of the proforma was slightly higher in 
the observation ward (60/349; 17%). All of the proformas were completed in AED as 
this is the main route of admission, with none used during the study period when 
clinicians admitted children from other sources. Feedback from clinicians revealed that 
the separate proforma was difficult to use. Clinicians commented that a medication 
history proforma would be more usable if embedded into existing documentation, e.g. 
care pathways.  
The study team encountered difficulties in obtaining a completely accurate two week 
medication history from the time prior to admission in many cases. Many parents 
could not recollect accurately the timings or doses of medication given, especially for 
anti-pyretic/analgesic over-the-counter medications. This was to be expected and is a 
common finding in routine clinical practice. The study team pragmatically captured as 
much information from the recorded history and parental history, as was feasible, to 
allow for assessment of whether an ADR had occurred. Also, many patients had been 
in hospital within the preceding two weeks and had been exposed to medications of 
which parents could not possibly have known the details including cytotoxic drugs and 
general anaesthetic agents. This necessitated comprehensive detailed medical record 
review.  
There was an average of 34 unplanned admissions to main wards to review daily 
during the two week pilot study. The morning was used to collect data and the 
afternoon was used to input the data onto a password protected database on a secure 
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hospital server. The investigator would also have to return to patients whose notes 
were missing or who had left the ward temporarily for investigations elsewhere. 
Follow-up of patients was necessary to look at investigations and follow the 
progression of their clinical history and treatment to complete the assessment of a 
possible ADR. In some cases, several days to weeks were required for follow up.  
The patients from the observation ward, because of short duration of admission, were 
not available for interview. Their case notes were the only source of information about 
symptoms, signs and medication history. There were 349 admissions, of 344 patients, 
to the observation ward during the two weeks with 5 patients being admitted twice. 
Therefore, there were approximately 25 reviews of electronic notes each day. Whilst 
the number of patients in this group was less than on the main ward, the process of 
recording information from one scanned electronic record to our database was time 
consuming, often taking half of the working day. 
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2.4 DISCUSSION 
This pilot study demonstrated that the incidence of ADRs causing admission to the 
main hospital wards was 4% (95% CI 2.2, 5.8). This figure is higher than that seen in 
other studies including two meta-analyses of ADRs causing admission in children. 
McKenzie et al (McKenzie et al. 1976), in 1976, studying 3556 children over a 3 year 
period in the US, found that 2% of admissions were caused by ADRs, with anti-
neoplastic drugs being the most frequently occurring. Easton et al (Easton et al. 1998), 
in Australia, investigated 2933 paediatric admissions over 22 weeks showing that 4.3% 
(95% CI 3.6,5.0) of admissions were due to a drug related problem, with less than a 
quarter of these being ADRs (29/2933, 1%). A study by Martinez-Mir et al in 512 
consecutive admissions over 204 days in Spain found the incidence (4.3%) to be 
similar to our study, but was different in that only children under 2 years old were 
studied.  
The analysis of data from this pilot study was rudimentary and did not include risk 
factor analysis due to sample size. Due to the time-frame studied, there were only a 
small number of patients admitted on multiple occasions. This is likely to be a more 
prominent feature of the admission data in the larger planned study as there will likely 
be some patients with multiple admissions, including multiple ADR admissions (in 
particular, oncology patients). These multiple admissions occurring in the same 
patients may not be independent from each other. The larger study will, therefore, 
include more detailed analysis at first-admission level. 
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Clearly, ours is a pilot study, with limited study duration and sample, designed to 
assess the feasibility of the methodology used, and as such the reported estimate of 
incidence of ADRs should be interpreted with caution. Caution should be exercised in 
assessing the generalizability of the findings of this pilot study both to the larger study 
and to other settings due to the study sample size, methodology and characteristics of 
the settings which may be different from other tertiary children’s hospitals. The 
methodology to be used in the larger study was informed by the pilot study and was 
altered to take account of local hospital difficulties which may not be shared with other 
settings.   
Amongst the methodological questions we wanted to address was the definition of an 
admission. We found that there were possible ADRs that occurred in patients admitted 
solely to the AED observation ward who were then discharged home without 
admission to a main hospital ward. The adequacy of clinical information in some 
cases, the lack of information about progression of clinical history and the short 
duration of stay made it difficult to assess for the occurrence of an ADR in these 
patients. The methodology used to retrieve information, with retrospective note review 
only, in this group of patients was very different to the main hospital group where 
prospective note review and, if needed, interview of parent/carer/child was used to 
assess the possibility of an ADR. The workload for the 3 investigators was also 
significantly increased with inclusion of the observation ward patients. This was 
particularly evident at weekends when only one investigator could be available. 
Therefore, for the above reasons, taken together with the fact that (a) the incidence of 
ADRs was lower in observation ward patients than those admitted to the main ward; 
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(b) an ADR causing admission to a main ward is intuitively more severe than one that 
leads to discharge within 4 hours; and (c) many paediatric departments may not have 
observation wards which would make generalizability of our findings difficult, we 
have elected not to include observation ward admissions in our main admissions study. 
Amongst the unexpected methodological problems encountered was the definition of 
an acute admission. Hospital information systems were used to identify unplanned 
admissions which were coded as such by nursing staff on hospital wards routinely 
when each patient was admitted. However, it became apparent during the pilot study 
that not all the admissions were truly emergency or unplanned and did not meet the 
inclusion criteria for investigation (Figure 2.1). The study team collecting this data 
checked each case excluded, with the other members, in the first instance and with a 
senior investigator at the end of the pilot study. All the cases (planned 
admissions/transfers and poisoning/OD) were agreed to be correctly excluded. It was, 
therefore, decided to capture this information in the larger study, and exclude cases as 
per inclusion criteria, rather than address the problem with hospital staff coding the 
admissions data, as this would have been a significant undertaking with an unknown 
chance of improvement. 
Capturing information about the drug history is crucial in studies such as this. We 
therefore designed a medication proforma for clinicians, with education about its use, 
to record the medication history over a 2 week period before admission. This was a 
separate sheet to be collated with existing case note pathways and clinical history 
recording. We however found that the use of this proforma was inadequate during the 
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pilot study leading to many parent/carer interviews for the investigators. We therefore 
plan to embed a more user friendly proforma within existing admission documentation 
with collaboration from clinicians and the hospital Care Pathways Co-ordinator 
(APPENDIX B, APPENDIX C). 
Identification of ADRs posed an interesting problem for the study team. If in trying to 
identify ADRs a literal approach is taken, and children with signs or symptoms which 
correspond to the known adverse reaction profile of medication they were exposed to 
are identified (and this is the only information used), then the number fo cases needing 
further assessment would be significantly increased. This would be a common 
occurrence because children often present to healthcare settings with generic 
symptoms and signs such as diarrhoea, rash, and vomiting. Therefore, a pragmatic 
approach, as is the case when assessing children clinically for cause of symptoms, 
must be taken.  
The elucidation of possible ADR occurrence encompassed use of clinical knowledge 
and experience of disease processes and drug reactions. To strengthen this approach, 
the study team was made up of multi-disciplinary professionals. To improve ADR 
identification by study team members, during the pilot study, cases were often 
discussed between the investigators. Some cases were relatively straight-forward (as is 
the case for oncology ADRs, for example) whereas others needed multi-disciplinary 
input, with study team members holding discussions with senior investigators 
including paediatricians, a senior pharmacist and a clinical pharmacologist. It was 
decided to have regular meetings, during the larger study, between study team 
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members and a senior investigator to discuss challenging cases. It was helpful that the 
clinical pharmacologist had undertaken very large observational studies of ADRs in 
adults.   
The majority of the ADRs that were seen during our pilot study were oncology related. 
These were mainly children admitted with a febrile illness who were neutropenic 1-2 
weeks after intravenous chemotherapy. This group of patients are often exposed to 
medications which cause ADRs, for example nausea, vomiting, diarrhoea, infection 
with neutropenia, anaemia and bleeding from thrombocytopenia, all of which may 
require admission for treatment. These ADRs can be expected and, for the most part, 
may be unavoidable given the nature of the underlying illness and the treatment 
required. However there may be more unusual or serious ADRs which occur and 
which may be important to capture. We found that although these patients are often 
exposed to many medications in the preceding two weeks, making their data collection 
more time consuming than other groups, it was possible to capture accurately their 
medications and clinical problems and identify ADRs that had occurred.  
Data collection from the main hospital ward patients was challenging. Ideally, if data 
could be collected by electronic means it would undoubtedly make a study like this 
less complex. However, this could not be achieved as a laptop (even with encryption) 
was not deemed safe enough to carry between wards, ward computers were for clinical 
use and there were not enough of them on each ward to allow study team members to 
use them as and when required, and there was little WiFi cover on hospital wards to 
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allow for a secure wireless approach to data collection. Therefore, data collection was 
done on paper and transferred to a secure electronic database (Microsoft Access).  
Assessment of causality using the Naranjo algorithm showed the majority of cases to 
be in the ‘possible’ classification. All investigators reported that the Naranjo scale was 
difficult to use accurately in this population due to the nature of some of the questions. 
Causality assessments were easier to apply to the oncology ADRs because of the 
hospital-intensive nature of their treatment, for example with continuous re-challenge 
to chemotherapy, and detailed clinical records of their recent drug history and clinical 
problems. Causality assessment using the Naranjo tool, and the reported difficulties in 
using Naranjo in our studies, will be discussed in more detail in Chapter 3. 
Risk factor analysis was not undertaken due to the limitations in size of the study 
population. This is something that is planned for the larger study. One aspect of the 
data from this pilot study is that drug exposure was difficult to assess. Information 
such as start date, stop date, dose and frequency of administration of drugs was sought 
but was not always available or felt to be wholly accurate. This was especially true of 
over-the-counter drugs given when required, such as anti-pyretics. Parents could not 
always remember the dose given or timings of administration accurately. These are 
common findings in clinical practice. The definition of ADR used by the investigators 
incorporates drugs being used at a therapeutic dose and, wherever possible, the study 
team made every effort to elucidate that this was the case for patients exposed to 
medication. An assumption was made that, in general, parents and carers would likely 
follow dosage instructions prescribed by clinicians or stated on medicines information. 
77 
 
Therefore, data was included even if parents could not remember a specific dose, using 
the assumption above.   
In summary, this pilot study was used to inform a much larger study to research ADRs 
that cause admission to hospital in the paediatric population. We anticipated that the 
larger study will have ~12000 admissions which will allow a more precise estimate of 
the incidence of ADRs among paediatric admissions and allow more detailed 
description of the ADRs themselves. Given the problems encountered of capturing 
ADRs in children in the observation area, i.e. those that stayed within hospital 
premises for less than 4 hours, this area will not be included in our larger study. 
However, this should not be taken to mean that we feel that this aspect of hospital 
attendance is unimportant with respect to ADRs. On the contrary, further investigation 
of ADRs is required in those attending AED and being discharged within 4 hours, but 
the methodology would have to be altered to achieve this. 
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CHAPTER 3  CAUSALITY ASSESSMENT OF 
ADVERSE DRUG REACTIONS 
3.1 INTRODUCTION 
Causality assessment of ADRs is a method used for estimating the strength of 
relationship between drug(s) exposure and occurrence of adverse reaction(s). Causality 
assessment of ADRs may be undertaken by clinicians, academics, pharmaceutical 
industry and regulators and in different settings, including clinical trials (Agbabiaka, 
Savovic & Ernst 2008; Arimone et al. 2010; Laine et al. 2009; Turner 1984). At an 
individual level, health care providers assess causality informally when dealing with 
ADRs in patients to make decisions regarding future therapy. This is often undertaken 
without using a formal assessment method, with many clinicians not having had 
teaching or experience of assessing causality. Many regulatory authorities assess 
spontaneous ADR reports (Arimone et al. 2010; Turner 1984) where causality 
assessment can help in signal detection and aid in risk-benefit decisions regarding 
medicines (Kling 2004; Macedo et al. 2005). Many regulatory authorities use formal 
assessment tools to aid in this process. 
An early paper by Sir Austin Bradford Hill (Hill 1965), describing minimum criteria 
for establishing causality of adverse events, pre-dates the earliest attempts to formulate 
ADR causality assessment tools. Bradford Hill set out criteria for establishing causality 
which included assessment of; strength of the association, consistency of the 
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association, specificity, temporal relationship, biological gradient (dose response), 
biological plausibility, coherence, experimental evidence, and reasoning by analogy. 
These criteria are described in more detail in the introduction to this thesis. These 
elements of assessing strength of relationship between exposure (drugs) and outcome 
(adverse reaction) are used widely in ADR causality tools. Attempts to formalise 
causality assessment of ADRs into structured assessment tools have been ongoing for 
more than 30 years (Irey 1976; Naranjo, Busto & Sellers 1981). It is known that 
assessing ADR likelihood without a structure can lead to wide disagreements between 
assessors (Arimone et al. 2005). Disagreements may mean that opportunities to avoid 
or ameliorate harm are missed during clinical care or that cases are misclassified in 
epidemiological studies. These disagreements may be the result of differing clinical 
backgrounds, specialties and experience between assessors. A large number of 
causality tools have been developed ranging from the simple to the complex. These 
tools aim to limit disagreement between assessors of ADR cases as to the likelihood 
that a reaction is related to a particular medication taken by the patient. None has 
gained universal acceptance (Jones 2005). 
One of the most widely used CATs is the Naranjo ADR probability scale (Naranjo, 
Busto & Sellers 1981). This is a simple 10-item questionnaire that classifies the 
likelihood that a reaction is related to a drug using concepts such as timing, 
plausibility/evidence, de-challenge and re-challenge/previous exposure. Each element 
of the questionnaire is weighted and the total score used to categorise the event into 
unlikely, possible, probable and definite. The tool was developed 30 years ago by adult 
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pharmacologists/physicians and psychiatrists. Published case reports were used to 
validate the reliability of the tool in assessing causality. It has been widely used, 
including recently by investigators in two large prospective observational studies of 
ADRs causing hospital admission and occurring in hospital inpatients (Davies et al. 
2009; Pirmohamed et al. 2004). However, the reliability and validity of the Naranjo 
scale has been questioned by a number of investigators (Agbabiaka, Savovic & Ernst 
2008; Avner et al. 2007; Garcia-Cortes et al. 2008; Kane-Gill 2005; Macedo et al. 
2005).  
While undertaking a prospective observational pilot study of ADRs in children, 
described in Chapter 2 of this thesis, we found several difficulties with using the 
Naranjo scale. The study detailed in this chapter aims to address these difficulties. Our 
original aim was to use the Naranjo ADR Probability Scale for the larger observational 
study described in Chapter 4. In the observational study we planned to assess the 
causality of the ADRs prospectively rather than at the end of the study period. When 
beginning to assess this heterogeneous mix of potential ADR cases during the pilot 
study (Chapter 2) with the Naranjo scale, the investigators found some questions were 
not appropriate in this clinical context. This led to many elements of the Naranjo scale 
being categorised as “unknown”. In particular, question six (“Did the reaction reappear 
when a placebo was given?”) and question seven (“Was the drug detected in the blood 
(or other fluids) in concentrations known to be toxic?”) were very often answered as 
‘unknown’. Administration of a placebo and assessment of drug concentrations are not 
part of practice when assessing potential causality of ADRs in this clinical setting. An 
answer assigned as “unknown” gives a zero score for that element in the Naranjo scale. 
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This will lower the total achievable score on an individual case basis. This meant that 
the thresholds for recognizing ADRs were not achieved, which in turn underestimated 
the likelihood of an ADR. This led to a lack of sensitivity for many of the early cases 
assessed in our study, as the overall score obtained for each causality assessment was 
artificially lowered. The investigators encountered several cases which were 
unanimously thought to be definite ADRs (e.g. repeated episodes of febrile 
neutropenia during oncological chemotherapy) but which did not reach the threshold 
for ‘definite’ causality using the published Naranjo scale. Accordingly, the Naranjo 
score did not have face validity when applied to our patient population. Moreover, the 
weighting for each question and the ADR classification scoring boundaries used in the 
Naranjo scale were not justified in the original publication or subsequently. Therefore, 
we developed a CAT that would overcome some of these issues, while at the same 
time (a) making it as easy, or easier, to use than the Naranjo scale (a feature which 
holds a distinct advantage for large observational studies of ADRs among other 
situations); and (b) ensuring that the basic principles of assessing causality, as 
described above, were maintained.  
The specific aim of this study was to develop a CAT with good face validity and 
acceptable inter-rater reproducibility. 
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3.2 METHODS 
The pilot study team (RG, JM, KB) noted concerns with using the Naranjo scale. This 
triggered a process in which each of seven investigators (RG, JM, KB, MP, TN, RS, 
MT) independently assessed the first 40 consecutive case reports from an observational 
study of suspected ADRs causing hospital admission (ADRIC Study 1 – described in 
Chapter 4 - available at http://www.ADRIC.org.uk/) using the Naranjo scale. The 
results of these assessments are detailed in the results section of this chapter. In 
summary, there were eight cases where problems with assessments were found. There 
was one case where major discrepancies occurred between at least two of seven raters, 
that is, where the range of causality probability differed by more than one category 
(e.g. possible and definite), and seven cases where close to half of the raters differed 
from the others by one causality category. The questions within the Naranjo scale 
which caused the discrepancies in these cases were identified and reviewed. This 
exercise led to the recognition that a new assessment tool was required. 
The team made several choices at the start of the development of the new assessment 
tool. In order to relate to the existing literature it was agreed that the output of the new 
tool would take the same form as the Naranjo scale. That is, categorical scores from 
both the Naranjo scale and the new tool would take the same four point ordinal scale 
(unlikely, possible, probable and definite). In order to fit with clinicians’ experiences 
the format of the new tool was an algorithm, or flowchart, with dichotomous responses 
to each decision followed by routing to further, specific questions, rather than the 
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weighted responses used in the Naranjo scale. The study team decided to develop the 
new tool in two stages. Firstly, use the extensive clinical and pharmacovigilance 
expertise in the group to develop a tool that had face validity to the team. Secondly, 
iteratively assess the tool to optimise inter-observer agreement within the study team.  
In the first step of the process, each question in the Naranjo scale was reviewed by 
the investigators at a consensus meeting to assess whether it was appropriate to 
incorporate, discard or integrate with other questions into a new, more appropriate, 
causality tool (Table 3.1).   
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Table 3.1 Decisions made about questions within the Naranjo scale 
No. Naranjo scale questions Yes No Don’t 
know 
Outcome for Liverpool Tool 
Q1 Are there previous 
conclusive reports on this 
reaction? 
+1 0 0 Retained – knowledge of previous 
reports can be important when 
assessing if an adverse event is due to 
drug or disease. 
Q2 Did the adverse event 
appear after the suspected 
drug was administered? 
+2 -1 0 Modified – timing of event in relation 
to drug exposure is important when 
determining causality. 
Q3 Did the adverse reaction 
improve when the drug was 
discontinued or a specific 
antagonist was 
administered? 
+1 0 0 Modified – Knowledge of de-
challenge, if available, may provide 
further evidence as to causality of an 
event. However, an event may have 
long-lasting sequelae. A new question 
was added to the Liverpool tool to 
cover this possibility. 
Q4 Did the adverse reaction 
reappear after the drug was 
readministered? 
+2 -1 0 Combined – Knowledge of re-
challenge, if available, may add to the 
level of certainty regarding causality 
assessment. This question is combined 
with Naranjo Q8 regarding dose-
response relationship to increasing 
dose. This can also provide evidence to 
support or refute causality. 
Q5 Are there alternative causes 
(other than the drug) that 
could on their own have 
caused the reaction? 
-1 +2 0 Modified – This question is replaced 
within the Liverpool tool by a question 
involving likelihood of alternative 
cause, with an option to answer 
‘unsure’ (which prompts the user to 
seek further evidence of the reaction). 
Naranjo Q5 is worded such that it is 
difficult to answer No.  
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Q6 Did the reaction reappear 
when a placebo was given? 
-1 +1 0 Rejected – With the exception of 
clinical trials, placebo use is not 
common practice and this question is 
no longer relevant. 
Q7 Was the drug detected in 
the blood (or other fluids) in 
concentrations known to be 
toxic? 
+1 0 0 Modified – Objective evidence of the 
ADR occurrence will already be taken 
in to account when the user is deciding 
whether the event is likely to be drug or 
disease related. A question in the 
Liverpool tool asks for objective 
evidence of likely ADR mechanism. If 
apparent, this may provide evidence of 
causality to an assessor. 
Q8 Was the reaction more 
severe when the dose was 
increased, or less severe 
when the dose was 
decreased? 
+1 0 0 Combined – This question is 
combined with one addressing de-
challenge in the Liverpool tool. The 
answer to this question may be 
important in establishing if there is a 
dose-response relationship between 
drug and adverse event. 
Q9 Did the patient have a 
similar reaction to the same 
or similar drugs in any 
previous exposure? 
+1 0 0 Modified – this is included in the 
Liverpool algorithm, in relation to the 
same drug(s) only, and given the same 
weighting as a positive re-challenge. 
This may provide evidence of 
susceptibility, and likelihood, of the 
event being related to a drug. 
Q10 Was the adverse event 
confirmed by any objective 
evidence? 
+1 0 0 Modified – see Q7 
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The new Liverpool ADR causality tool was then used to assess 20 new suspected ADR 
case reports from our observational study. The collated causality categories for all 
seven assessors showed 1 (0.7%) unlikely, 18 (12.9%) possible, 2 (1.4%) probable and 
119 (85%) definite. The assessors achieved moderate agreement with a kappa of 0.51 
(95% CI 0.19, 0.82). The assessing team considered that there was an inappropriate 
bias towards the category of definite upon reviewing the cases and causality results. 
Accordingly, the assessment tool was reviewed. Major discrepancies between scorers 
were identified and each question within the algorithm was reviewed to assess face 
validity and likelihood of inter-rater disagreement. Questions that caused the bias 
toward ‘definite,’ and those that caused major discrepancies between scorers, were 
then modified. The new assessment tool was then tested on a further 20 case reports; 
ten from the ADRIC study and ten from an observational study of inpatient ADRs in 
an adult hospital. Collated causality categories for the ten ADRIC 1 cases showed 0 
(0%) unlikely, 24 (34%) possible, 39 (56%) probable and 7 (10%) definite with a 
kappa of 0.27 (95% CI 0.11, 0.44). Collated causality categories for the ten adult cases 
showed 0 (0%) unlikely, 13 (19%) possible, 48 (69%) probable and 9 (13%) definite 
with a kappa of 0.13 (95% CI -0.14, 0.38). The results of these assessments prompted 
another review of the appropriateness of the tool and questions. A third iteration was 
used so that the development and evaluation of tool prototypes was based on 
discussions in which 80 cases were used (Figure 3.1).  
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Figure 3.1 Flowchart of the development of the Liverpool ADR Causality 
Assessment Tool 
 
•Moderate Agreement  
•Inappropriate bias to possible and probable 
Assess 40 ADRIC Study 1 cases (Naranjo) 
•Questions within Naranjo reviewed 
•Consensus opinion to use flowchart 
Develop new tool 
•Moderate Agreement 
•Inappropriate skew to definite causality 
Assess 20 New ADRIC 1 Cases        (New Tool v1) 
•Consensus meeting to determine changes to be made 
 
Modify tool 
•Fair agreement for ADRIC cases 
•Poor agreement for adult cases 
Assess 10 new ADRIC 1 cases and       10 Adult cases 
(New tool v2) 
•Consensus meeting to determine changes to be made 
•Investigators satisfied with version 3 to re-test against Naranjo 
Modify tool 
•Moderate Kappa 
•Appropriate spread of causality categories 
Re-test tool on original 40 ADRIC 1  cases (New tool 
v3) 
•Assess 40 new ADRIC 1 cases using Liverpool and Naranjo tools 
•Assess published case reports 
Validation of Liverpool Causality Assessment Tool on 
new cases 
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After the third iteration the investigators were satisfied with the final version of the 
new tool, Figure 3.2, in terms of ease of use, lack of ambiguity, and appropriateness of 
the causality assignment. This was judged by expert opinion and consensus within the 
group. The assessment of inter-rater reliability within the study team for the Liverpool 
ADR CAT followed a step-wise procedure. All cases were presented in paper format 
using a modified ‘yellow card’ template to display the information necessary for 
assessment. All cases were completed by the investigators at the same time (for each 
stage below) and without collaboration. This was achieved by mutual agreement and 
commitment to the process. 
 The original 40 case reports (case reports of raw clinical data from an 
observational study) initially assessed with Naranjo were assessed by each of 
the seven investigators using the new assessment tool to compare the outcomes 
of the methods and to compare the inter-rater reliability between the two tools.  
 In order to examine the tool using cases other than those collected in our 
observational study, 37 cases of ADRs were randomly selected from the 
Annals of Pharmacotherapy (APPENDIX E) and independently evaluated by 
the seven assessors using only the new tool.  
 Since the original 40 cases from our observational study had been used in the 
design of the new tool, a further new set of 40 ADR case reports from our 
study were then used to assess inter-rater reliability using both the Naranjo and 
the Liverpool tools.  
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Figure 3.2 Liverpool ADR CAT 
*Unassessable refers to situations where the medicine is administered on one occasion (e.g. Vaccine), 
the patient receives intermittent therapy (e.g. Chemotherapy), or is on medication which cannot be 
stopped (e.g. Immunosuppressants).                                                                                                                                          
** Examples of objective evidence: positive laboratory investigations of the causal ADR mechanism 
(not those merely confirming the adverse reaction), supra-therapeutic drug levels, good evidence of 
dose-dependent relationship with toxicity in the patient 
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An independent panel with extensive expertise in pharmacovigilance and statistics (the 
ADRIC Steering Group) were asked to review the tool upon completion of the internal 
evaluation.  
3.3 ANALYSES 
The inter-rater agreements at each stage of the assessment process were assessed using 
a linear weighted kappa with 95% confidence intervals for ordered categories. Exact 
agreement percentages (%EA) were computed to measure the absolute concordances 
between assessor scores. Percentage of extreme disagreement (%ED), where the 
causality scores between two raters of the same case are wider than one causality 
interval apart (e.g. definite for 1 rater and possible for the other), were also computed 
to measure extreme disagreements between pair-wise rater assessments. To 
supplement the pair-wise kappa, a global kappa score measuring nominal scale 
agreement across multiple assessors was calculated with 95% confidence intervals 
(Fleiss 1971). The global kappa score provides a single statistic to quantify assessor 
agreement for each set of cases.  Kappa values were interpreted according to the 
guidance from Altman (Altman 1991): poor <0.2; fair 0.21-0.40; moderate 0.41-0.60; 
good 0.61-0.80; and very good 0.81-1.00 agreement.  
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3.4 RESULTS 
Assessment of the original 40 consecutive ADR cases by the seven investigators using 
the Naranjo scale showed collated categorisation of causality scores for all assessors 
(n= 280 assessments) of 0 (0%) unlikely, 100 (36%) possible, 172 (61%) probable and 
8 (3%) definite (Table 3.2). Exact agreement percentages for the pair-wise 
comparisons between raters ranged from 43% – 93%. Percentage of extreme 
disagreement (%ED) was 2.5% for four of the twenty-one pair-wise comparisons. 
There were no extreme disagreements in 17/21 pair-wise comparisons. Pair-wise 
kappas ranged from 0.27 to 0.86 and the assessors achieved moderate inter-rater 
reliability with a global kappa of 0.45 (95% CI 0.35-0.54) (Table 3.3). The same cases 
assessed using the new Liverpool tool showed collated causality categories of 1 (0.4%) 
unlikely, 62 (22%) possible, 92 (33%) probable and 125 (45%) definite. Exact 
agreement percentages ranged from 43-93%. All 21 pair-wise comparisons displayed 
extreme disagreement with percentages ranging from 5-20%. Pair-wise kappas ranged 
from 0.27 to 0.84 and the assessors achieved moderate inter-rater reliability with a 
global kappa score of 0.48 (95% CI 0.42-0.54) (Table 3.3). 
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Table 3.2 Causality category assignments of investigators for the original 40 
cases assessed using Naranjo and the Liverpool CAT 
  ADRIC Original (N=40) 
  Unlikely Possible Probable Definite 
  n (%) n (%) n (%) n (%) 
Assessor Tool     
RG Naranjo 0 (0.0) 18 (45.0) 22 (55.0) 0 (0.0) 
 Liverpool 0 (0.0) 7 (17.5) 23 (57.5) 10 (25.0) 
JM Naranjo 0 (0.0) 17 (42.5) 22 (55.0) 1 (2.5) 
 Liverpool 0 (0.0) 15 (37.5) 8 (20.0) 17 (42.5) 
KB Naranjo 0 (0.0) 18 (45.0) 21 (52.5) 1 (2.5) 
 Liverpool 0 (0.0) 18 (45.0) 4 (10.0) 18 (45.0) 
MT Naranjo 0 (0.0) 14 (35.0) 24 (60.0) 2 (5.0) 
 Liverpool 1 (2.5) 5 (12.5) 17 (42.5) 17 (42.5) 
TN Naranjo 0 (0.0) 10 (25.0) 29 (72.5) 1 (2.5) 
 Liverpool 0 (0.0) 3 (7.5) 15 (37.5) 22 (55.0) 
MP Naranjo 0 (0.0) 12 (30.0) 27 (67.5) 1 (2.5) 
 Liverpool 0 (0.0) 7 (17.5) 12 (30.0) 21 (52.5) 
RS Naranjo 0 (0.0) 11 (27.5) 27 (67.5) 2 (5.0) 
 Liverpool 0 (0.0) 7 (17.5) 13 (32.5) 20 (50.0) 
Totals Naranjo 0 (0.0) 100(35.7) 172 (61.4) 8 (2.9) 
 Liverpool 1 (0.36) 62 (22.1) 92 (32.9) 125(44.6) 
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Table 3.3 Naranjo and Liverpool tool assessment of 40 original ADR cases from 
an observational study 
 Assessor 2 
 RG JM KB MT TN MP RS 
A
ss
es
so
r 
1
 
RG 
%EA/ED  57.5/0% 42.5/0% 55.0/0% 52.5/0% 62.5/0% 55.5/0% 
Kappa 
(95%CI) 
 0.52 
(0.27,0.77) 
0.47 
(0.21,0.73) 
0.44 
(0.19,0.69) 
0.45 
(0.21,0.69) 
0.36 
(0.09,0.62) 
0.29 
(0.04,0.54) 
JM 
%EA/ED 57.5/5%  92.5/0% 70.0/0% 77.5/0% 72.5/0% 70.0/2.5% 
Kappa 
(95%CI) 
0.46 
(0.26,0.67) 
 0.86 
(0.71,1.00) 
0.46 
(0.22,0.69) 
0.56 
(0.34,0.78) 
0.47 
(0.19,0.75) 
0.40 
(0.15,0.65) 
KB 
%EA/ED 42.5/10% 75.0/5%  77.5/0% 70.0/0% 70.0/0% 77.5/2.5% 
Kappa 
(95%CI) 
0.28 
(0.08,0.49) 
0.69 
(0.52,0.87) 
 0.60 
(0.39,0.81) 
0.43 
(0.19,0.66) 
0.43 
(0.15,0.71) 
0.55 
(0.32,0.77) 
MT 
%EA/ED 55.0/7.5% 70.0/5% 57.5/7.5%  72.5/0% 62.5/0% 70.0/2.5% 
Kappa 
(95%CI) 
0.31 
(0.06,0.56) 
0.62 
(0.45,0.80) 
0.49 
(0.31,0.67) 
 0.45 
(0.20,0.70) 
0.37 
(0.11,0.62) 
0.48 
(0.23,0.73) 
TN 
%EA/ED 52.5/7.5% 62.5/15% 52.5/20% 70.0/7.5%  70.0/0% 72.5/2.5% 
Kappa 
(95%CI) 
0.27 
(0.07,0.46) 
0.42 
(0.21,0.62) 
0.30 
(0.10,0.50) 
0.49 
(0.26,0.72) 
 0.33 
(0.05,0.62) 
0.35 
(0.06,0.63) 
MP 
%EA/ED 62.5/5% 77.5/7.5% 67.5/12.5% 80.0/5% 80.0/7.5%  70.0/0% 
Kappa 
(95%CI) 
0.47 
(0.25,0.69) 
0.68 
(0.49,0.86) 
0.54 
(0.33,0.74) 
0.69 
(0.49,0.89) 
0.62 
(0.39,0.84) 
 0.38 
(0.11,0.65) 
 %EA/ED 55.5/10% 70.0/12.5% 62.5/15% 80.0/7.5% 75.0/10% 92.5/5%  
 RS Kappa 
(95%CI) 
0.30 
(0.05,0.55) 
0.54 
(0.32,0.76) 
0.46 
(0.24,0.67) 
0.66 
(0.44,0.87) 
0.52 
(0.27,0.76) 
0.84 
(0.66,1.00) 
 
%EA/ED and kappa scores in white boxes represent Naranjo scale analyses. 
%EA/ED and kappa scores in grey boxes represent Liverpool ADR causality tool 
analyses.   
Kappa scores outlined in bold demarcate either a good or very good level of 
agreement.   
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The 37 randomly selected ADR case reports from the Annals of Pharmacotherapy 
assessed by the seven investigators using the Liverpool tool showed collated 
categorisation of causality scores (n= 259 assessments) of 1 (0.4%) unlikely, 67 
(26%) possible, 136 (53%) probable and 55 (21%) definite (Table 3.4). Exact 
agreement percentages ranged from 57% – 97%. 18/21 pair-wise comparisons 
between raters showed some extreme disagreement, with the percentage ranging 
from 5-11%, while three showed no extreme disagreements. Pair-wise kappas ranged 
from 0.31 to 0.96 and the assessors achieved moderate inter-rater reliability with a 
global kappa of 0.43 (95% CI 0.34-0.51) (Table 3.5).  
These case reports were not assessed by the investigators using the Naranjo scale. 
The Annals of Pharmacotherapy requires authors to apply a Naranjo assessment prior 
to publication of each case report in the journal. The collated categorization of the 
case report author assessments for the 37 cases showed 0 unlikely, 5 (14%) possible, 
29 (78%) probable and 3 (8%) definite (Table 3.4). 
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Table 3.4 Causality category assignments of investigators for the 37 Annals of 
Pharmacotherapy published case reports                                                                 
(*Authors of case reports in Annals of Pharmacotherapy completed a Naranjo causality 
assessment) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Annals of Pharmacotherapy (N=37) 
  Unlikely Possible Probable Definite 
  n (%) n (%) n (%) n (%) 
Assessor Tool     
RG Naranjo NA NA NA NA 
 Liverpool 0 (0.0) 11 (29.7) 18 (48.7) 8 (21.6) 
JM Naranjo NA NA NA NA 
 Liverpool 0 (0.0) 11 (29.7) 20 (54.1) 6 (16.2) 
KB Naranjo NA NA NA NA 
 Liverpool 0 (0.0) 12 (32.4) 19 (51.4) 6 (16.2) 
MT Naranjo NA NA NA NA 
 Liverpool 0 (0.0) 10 (27.0) 18 (48.7) 9 (24.3) 
TN Naranjo NA NA NA NA 
 Liverpool 1 (2.7) 10 (27.0) 20 (54.1) 6 (16.2) 
MP Naranjo NA NA NA NA 
 Liverpool 0 (0.0) 10 (27.0) 17 (46.0) 10 (27.0) 
RS Naranjo NA NA NA NA 
 Liverpool 0 (0.0) 3 (8.1) 24 (64.9) 10 (27.0) 
Totals Naranjo 0* (0) 5* (13.5) 29* (78.4) 3* (8.1) 
 Liverpool 1 (0.39) 67 (25.9) 136 (52.5) 55 (21.2) 
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Table 3.5 Liverpool ADR Causality tool assessment of 37 randomly selected 
published ADR case reports 
 Assessor 2 
 RG JM KB MT TN MP RS 
A
ss
es
so
r 
1
 
RG 
%EA/ED  62.2/10.8% 64.9/10.8% 73.0/0% 56.8/8.1% 59.5/5.4% 67.6/5.4% 
Kappa 
(95% CI) 
 0.307 
(0.03,0.58) 
0.38 
(0.10,0.65) 
0.65 
(0.44,0.85) 
0.32 
(0.05,0.59) 
0.41 
(0.16,0.66) 
0.46 
(0.22,0.69) 
JM 
%EA/ED   97.3/0% 62.2/10.8% 64.9/8.1% 56.8/8.1% 64.9/8.1% 
Kappa 
(95% CI) 
  0.93 
(0.82,1.00) 
0.31 
(0.04,0.59) 
0.34 
(0.06,0.61) 
0.29 
(0.02,0.57) 
0.33 
(0.09,0.57) 
KB 
%EA/ED    59.5/10.8% 67.6/8.1% 59.5/8.1% 62.2/8.1% 
Kappa 
(95% CI) 
   0.31 
(0.03,0.59) 
0.41 
(0.13,0.68) 
0.36 
(0.10,0.63) 
0.34 
(0.10,0.58) 
MT 
%EA/ED     64.9/8.1% 64.9/5.4% 78.4/5.4% 
Kappa 
(95% CI) 
    0.40 
(0.13,0.66) 
0.48 
(0.23,0.72) 
0.61 
(0.38,0.84) 
TN 
%EA/ED      62.2/8.1% 67.6/5.4% 
Kappa 
(95% CI) 
     0.38 
(0.11,0.64) 
0.42 
(0.19,0.65) 
MP 
%EA/ED       70.3/0% 
Kappa 
(95% CI) 
      0.58 
(0.38,0.77) 
RS         
 
%EA/ED and kappa scores in grey boxes represent Liverpool ADR causality tool 
analyses.   
Kappa scores outlined in bold demarcate either a good or very good level of 
agreement.   
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The 40 newly selected ADR cases assessed by the seven investigators using the 
Naranjo scale showed collated categorisation of causality scores (n= 280 
assessments) of 1 (0.4%) unlikely, 90 (32%) possible, 185 (66%) probable and 4 
(1%) definite (Table 3.6). Exact agreement percentages ranged from 63% – 90%. 
Percentage of extreme disagreement was 2.5% for four pair-wise comparisons. There 
were no extreme disagreements in 17/21 comparisons. The pair-wise kappas ranged 
from 0.19 to 0.81 with moderate inter-rater reliability and global kappa of 0.44 (95% 
CI 0.33-0.55) (Table 3.7). The same cases assessed using the Liverpool tool showed 
collated causality categories of 0 (0%) unlikely, 66 (24%) possible, 81 (29%) 
probable and 133 (48%) definite. Exact agreement percentages ranged from 65% – 
88%. Percentage of extreme disagreement ranged from 2.5-7.5% for 14 pair-wise 
comparisons. There were no extreme disagreements in 7/21 comparisons. Pair-wise 
kappas ranged from 0.51 to 0.85 and the assessors achieved good inter-rater 
reliability with a global kappa of 0.60 (95% CI 0.54-0.67) (Table 3.7).  
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Table 3.6 Causality category assignments of investigators for the 40 new ADR 
cases assessed using Naranjo and the Liverpool CAT 
  ADRIC New (N=40) 
  Unlikely Possible Probable Definite 
  n (%) n (%) n (%) n (%) 
Assessor Tool     
RG Naranjo 0 (0.0) 18 (45.0) 21 (52.5) 1 (2.5) 
 Liverpool 0 (0.0) 11 (27.5) 12 (30.0) 17 (42.5) 
JM Naranjo 0 (0.0) 19 (47.5) 21 (52.5) 0 (0.0) 
 Liverpool 0 (0.0) 14 (35.0) 8 (20.0) 18 (45.0) 
KB Naranjo 0 (0.0) 15 (37.5) 25 (62.5) 0 (0.0) 
 Liverpool 0 (0.0) 13 (32.5) 10 (25.0) 17 (42.5) 
MT Naranjo 1 (2.5) 9 (22.5) 27 (67.5) 3 (7.5) 
 Liverpool 0 (0.0) 8 (20.0) 9 (22.5) 23 (57.5) 
TN Naranjo 0 (0.0) 13 (32.5) 27 (67.5) 0 (0.0) 
 Liverpool 0 (0.0) 8 (20.0) 12 (30.0) 20 (50.0) 
MP Naranjo 0 (0.0) 12 (30.0) 28 (70.0) 0 (0.0) 
 Liverpool 0 (0.0) 9 (22.5) 13 (32.5) 18 (45.0) 
RS Naranjo 0 (0.0) 4 (10.0) 36 (90.0) 0 (0.0) 
 Liverpool 0 (0.0) 3 (7.5) 17 (42.5) 20 (50.0) 
Totals Naranjo 1 (0.36) 90 (32.1) 185 (66.1) 4 (1.4) 
 Liverpool 0 (0.0) 66 (23.6) 81 (28.9) 133 (47.5) 
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Table 3.7 Naranjo and Liverpool tool assessment of 40 new ADR cases from an 
observational study 
 Assessor 2 
 RG JM KB MT TN MP RS 
A
ss
es
so
r 
1
 
RG %EA/ED  90.0/0% 80.0/0% 70.0/2.5% 75.0/0% 72.5/0% 62.5/0% 
Kappa 
(95%CI) 
 0.81 
(0.64,0.98) 
0.61 
(0.38,0.84) 
0.46 
(0.25,0.66) 
0.51 
(0.26,0.75) 
0.46 
(0.20,0.71) 
0.23 
(0.03,0.42) 
JM %EA/ED 70.0/5%  75.0/0% 67.5/0% 80.0/0% 77.5/0% 62.5/0% 
Kappa 
(95%CI) 
0.62  
(0.43,0.81) 
 0.49 
(0.23,0.76) 
0.45 
(0.25,0.64) 
0.59 
(0.35,0.83) 
0.54 
(0.29,0.79) 
0.22 
(0.02,0.41) 
KB %EA/ED 65.0/0% 77.5/2.5%  70.0/2.5% 80.0/0% 77.5/0% 67.5/0% 
Kappa 
(95%CI) 
0.62 
(0.44,0.79) 
0.73  
(0.57,0.90) 
 0.40 
(0.16,0.63) 
0.56 
(0.29,0.83) 
0.50 
(0.22,0.78) 
0.19 
(-0.06,0.44) 
MT %EA/ED 70.0/2.5% 75.0/5% 75.0/7.5%  70.0/2.5% 70.0/2.5% 72.5/0% 
Kappa 
(95%CI) 
0.63 
(0.45,0.81) 
0.70 
(0.52,0.88) 
0.64 
(0.45,0.84) 
 0.367 
(0.12,0.62) 
0.40 
(0.15,0.65) 
0.25 
(0.003,0.50) 
TN %EA/ED 82.5/2.5% 77.5/2.5% 70.0/2.5% 82.5/0%  77.5/0% 77.5/0% 
Kappa 
(95%CI) 
0.77  
(0.61,0.93) 
0.73 
(0.57,0.88) 
0.61 
(0.43,0.79) 
0.79 
(0.64,0.93) 
 0.48 
(0.18,0.77) 
0.38 
(0.09,0.66) 
MP %EA/ED 70.0/2.5% 80.0/2.5% 72.5/2.5% 80.0/0% 87.5/0%  80.0/0% 
Kappa 
(95%CI) 
0.63  
(0.44,0.81) 
0.75 
(0.59,0.91) 
0.64 
(0.46,0.82) 
0.76 
(0.61,0.91) 
0.85 
(0.73,0.97) 
 0.41 
(0.12,0.71) 
RS %EA/ED 70.0/2.5% 70.0/5% 65.0/5% 80.0/0% 82.5/0% 75.0/0%  
  Kappa 
(95%CI) 
0.60  
(0.42,0.78) 
0.57 
(0.40,0.74) 
0.50 
(0.31,0.69) 
0.73 
(0.58,0.88) 
0.77 
(0.62,0.91) 
0.67 
(0.51,0.84) 
 
%EA/ED and kappa scores in white boxes represent Naranjo scale analyses. 
%EA/ED and kappa scores in grey boxes represent Liverpool ADR causality tool 
analyses.                                                                                                                 
Kappa scores outlined in bold demarcate either a good or very good level of 
agreement.   
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3.5 DISCUSSION 
A recent systematic review of studies assessing the reliability of causality assessments 
concluded that “no causality assessment method has shown consistent and 
reproducible measure of causality.”(Agbabiaka, Savovic & Ernst 2008) As part of a 
comprehensive assessment of ADRs in children, including the study described in 
Chapter 4 of this thesis, we had initially decided to use the Naranjo scale to assess 
causality in our patients admitted with ADRs. In order to do this, we planned to have 
assessments conducted independently by seven assessors. Initial assessments revealed 
some significant issues with the Naranjo scale which led us to develop the Liverpool 
ADR CAT.  
In assessing the original 40 possible ADR cases with the Naranjo tool, several 
difficulties were found with some of the questions in the Naranjo tool. Some of the 
questions were frequently, or always, answered as ‘unknown’. There were two 
questions which caused discrepancies between raters in eight cases, when scoring with 
Naranjo. The first question that caused difficulty was question five (Table 3.1) (“Are 
there alternative causes (other than the drug) that could on their own have caused the 
reaction?”). Individual raters interpreted this question in two different ways: some 
raters took a literal approach and interpreted the question to mean any ‘alternative 
cause’, almost always answering with a ‘yes’; other raters took a more practical 
approach and interpreted the question as ‘was there an alternative plausible cause’, and 
in doing so these raters gave variable answers to the question. Question ten (“Was the 
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adverse event confirmed by any objective evidence?”) was the second that caused 
discrepancies in Naranjo scoring. This caused problems for assessors in two very 
different ways: firstly, assessors had difficulty in deciding, on an individual case basis, 
what constitutes objective evidence; and secondly, assessors had difficulty defining 
whether the objective evidence related to evidence that the ADR had occurred or 
evidence of the mechanism. For example, a patient taking an opioid for analgesia 
might develop abdominal pain secondary to constipation and need admission to 
hospital for treatment and symptom control. In this case, raters may differ in their 
interpretation regarding question five and whether there may be alternative causes to 
explain the constipation (some of this may have to with the level of detail in the case 
report). Raters may also have difficulty in answering question ten. Some raters may 
suggest that a physical exam of a palpable faecal mass constitutes objective evidence 
whereas others may suggest that it is not objective and might argue that an abdominal 
radiograph showing faecal loading is more objective. Others might use either of these 
two findings to aid in their assessment of ‘alternative causes.’ If so, these raters might 
score question 5 in a positive manner because of the available evidence and then score 
question ten positively because of the evidence, in effect scoring positively for the 
same information twice. It seems counter-intuitive to take account of positive evidence 
and score it twice when assessing a possible ADR report. Even so, there were still very 
little discrepancies between the scores overall with most assessments resulting in a 
‘possible’ or ‘probable’ causality being assigned. 
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We designed a new method, the Liverpool ADR causality tool, using an algorithm in 
the form of a flowchart (APPENDIX D). This new tool was assessed to have face 
validity by a multi-disciplinary investigating group. Seven assessors used both the 
Liverpool tool and Naranjo to initially assess 40 possible ADR cases from the large 
observational study. The Liverpool tool performed just as well as Naranjo in terms of 
inter-rater reliability but gave a broader range of causality outcomes, which was 
deemed more appropriate by the investigating group. When the seven investigators 
assessed a second different set of 40 cases the Liverpool tool outperformed Naranjo, 
showing a ‘good’ inter-rater reliability.  
We believe that the Liverpool Causality tool has several advantages over the Naranjo 
scale. First, it performed as well as the Naranjo scale with the first set of cases that 
were assessed. More importantly, the inter-rater reliability improved over time with the 
new tool, whereas the inter-rater reliability when using Naranjo remained similar, 
despite the fact that there was as much exposure to this tool within the assessing group. 
The improved inter-rater reliability with the new tool may be explained by increasing 
experience of its use. The proportion of exact agreements between assessors was 
comparable between the two tools for both sets of cases despite the improvement in the 
global kappa for the new tool. This is because it is difficult to achieve a ‘definite’ 
category using the Naranjo scale and assessors mainly scored cases as ‘possible’ or 
‘probable.’ Therefore, the chances of exact agreement between two assessors of the 
same case using the Naranjo scale are likely to be falsely elevated compared to the 
kappa scores which adjust for chance agreement. This paradox has been discussed 
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previously in the literature (Cicchetti & Feinstein 1990; Feinstein & Cicchetti 1990; 
Lantz & Nebenzahl 1996). The percentage of extreme disagreement between raters 
was higher for the Liverpool tool, when compared to Naranjo. Due to the difficulty in 
achieving a ‘definite’ score with Naranjo the chances of finding extreme disagreement, 
when comparing pair-wise assessments, is likely to be falsely low. The observed 
percentage of extreme disagreements decreased when using the Liverpool tool from 
the first set of 40 cases to the last set. This may also be explained by increasing 
experience of its use. The implication of this explanation would be that there is a 
learning curve associated with using the Liverpool Causality Tool. A learning package 
is under evaluation. 
Second, the inter-rater reliability on assessing published case reports with the new tool 
was similar to that when we assessed our observational study cases with the Naranjo 
scale. Five of the seven assessors work in paediatric practice and the published case 
reports were adult cases. This perhaps provides an indication, albeit indirectly, of the 
robustness of the tool, even when used for cases from unfamiliar clinical settings.  
Third, in the Naranjo scale, almost all cases were categorised as possible or probable. 
With the new tool, the range of categorisations was broader with some cases judged as 
being definite. A novel aspect of the tool which makes this possible is that prior 
exposure that led to the same ADR, for example during a previous course of 
chemotherapy, was judged as being equivalent to a prospective re-challenge. It is also 
important to note that the cases were extracted from an observational study of 
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suspected ADRs in children, and thus some case selection had occurred making it 
improbable to record a score of ‘unlikely’ when assessing with either tool.  
Fourth, a flowchart rather than scoring system was used in the new tool for causality 
assessment and was felt by assessors to be easy to follow and quick to complete. We 
used a classification approach based on binary decisions (taking account of “don’t 
know” responses). In this case we need to ensure that the binary decisions are robust. 
Once this has been done then the instrument should be relatively context-independent. 
A weighted scoring system, such as the Naranjo scale, will give more influence to 
some variables than others. A weighting scheme involves the validation of the items in 
the tool and the weightings. Ideally, the weightings need to be developed and validated 
in a context that is similar to the context in which it is applied. Thus a weighting 
scheme is more likely to be sensitive and specific within a defined context (as long as 
you have a gold standard) but is more likely to be context-dependent. We feel it is 
more important to develop a tool that is context-independent since we need to compare 
different settings when assessing causality of ADRs. 
Nevertheless, we were unable to achieve complete agreement about causality 
assessment for a minority of suspected ADRs. We speculate that this reflects 
underlying uncertainty arising from issues such as the perceived likelihood of 
alternative explanations. These perceptions will vary between raters depending on their 
experience. 
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This study used a multi-disciplinary team of seven assessors, with varying clinical 
experience and levels of prior exposure to formal causality assessment, to formulate 
and test a new causality tool. This has the strength that the proposed tool may be more 
likely to show reproducible results in the wider context of other healthcare settings but 
may have less sensitivity/specificity when compared to more specific causality 
methods designed for use in more specific patient groups (e.g. methods to assess 
causality specifically for hepatotoxic drugs). The size of the investigating group caused 
some difficulty in co-ordinating assessments so they were completed at approximately 
the same time and without collaboration. 
The development of the Liverpool CAT involved an iterative process conducted by a 
multidisciplinary team using raw case data and published case reports. The clinical 
team included nurses, pharmacists and physicians, including those working with adults 
and children. Previous experience with formal ADR assessment ranged from minimal 
to advanced. The assessment team comprised medical statisticians who focused 
discussion on how to classify cases and monitored progress using standard tools for 
inter-rater agreement. This approach has the strength of timeliness but the potential 
weaknesses of “group-think”, in which independent thinking and expression of 
differences may be lost in the pursuit of group cohesiveness. An independent panel 
with extensive expertise in pharmacovigilance and statistics (the ADRIC Steering 
Group) reviewed the final iteration of the tool and had input into the design of the 
internal validation. The group commented that the Liverpool CAT showed face 
validity, in their experienced opinions, and that the validation plan was comprehensive.   
106 
 
In summary, we present a new CAT, developed by a multi-disciplinary team, which 
we believe to be at least equivalent, if not better, than the Naranjo scale. We believe 
the new tool to be practicable and likely to be acceptable for use by healthcare staff in 
assessing ADRs. We have undertaken an extensive validation of the tool, with a total 
of 819 causality assessments by seven investigators, using investigators within the 
ADRIC research programme. Although this validation is equivalent, if not better, than 
that undertaken for many other tools (Danan & Benichou 1993; Koh & Li 2005; 
Naranjo, Busto & Sellers 1981), one limitation is that the increase in inter-rater 
reliability for the second set of 40 case reports using the new tool remains unexplained. 
A second limitation is that the study has been undertaken internally and not yet 
assessed independently by other investigators. This study has been published in a peer-
reviewed journal and it is hoped that the publication of the algorithm will allow other 
investigators to undertake independent assessments of the usefulness of this tool in 
other populations (e.g. using data from adult or elderly care settings), not only for 
spontaneous reports but also for adverse events occurring within trials.  
The new Liverpool CAT was used in our larger observational study of ADRs causing 
admission of children to hospital detailed in Chapter 4 of this thesis. 
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CHAPTER 4  ADVERSE DRUG REACTIONS 
CAUSING ACUTE ADMISSION TO A 
PAEDIATRIC HOSPITAL 
4.1 INTRODUCTION 
Children are vulnerable to ADRs (Clavenna & Bonati 2009; Impicciatore et al. 2001; 
Jonville-Bera et al. 2002; Le et al. 2006; McKenzie et al. 1976; Mitchell et al. 1988). A 
recent retrospective study by Hawcutt et al. identified 31,726 of 222,755 (14.2%) ADR 
reports received by the UK MHRA through the Yellow Card Scheme, from 2000-
2009, concerned children <17 years of age (Hawcutt et al. 2012). However, it is well 
recognised that spontaneous reporting systems, such as the Yellow Card scheme in the 
UK (MHRA), are subject to under reporting of ADRs, even those which are severe 
(Hazell & Shakir 2006). Thus, it is likely that the number of paediatric ADR reports 
received each year by the MHRA is a considerable underestimate of the magnitude of 
the clinical problem in the UK.  
Hospital-based ADRs can be identified by retrospective studies using case note review. 
Studies of this nature may have advantages in identifying delayed ADRs that occur a 
relatively long time after a drug was started or stopped. Retrospective studies, 
however, are likely to be less reliable than prospective studies in estimating the 
frequency with which ADRs occur due to the inadequacy of recorded information. For 
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the same reason, it may also be more difficult for investigators to establish causality in 
the potential ADR cases identified. To obtain reliable information about the incidence 
of ADRs, prospective studies are needed. Previous prospective studies of ADRs 
causing hospital admission in children are described in the introduction to this thesis.  
An aim of pharmacovigilance is to not only identify ADRs through surveillance, but 
also to prevent harm to patients. It seems logical to detail how the reactions identified 
through pharmacovigilance studies might have been avoided. This could allow 
clinicians and regulatory bodies to address these clinical problems with potential 
strategies to aid reduction in harm to patients from ADRs.  
The aim of the study detailed in this thesis chapter was to prospectively identify ADRs 
in children causing admission to hospital during a one year period in order to quantify 
and characterise the burden of ADRs. One important aspect of the study was to 
determine the avoidability of the ADRs identified and detail the reasons for 
categorising the reactions as ‘possibly’ or ‘definitely’ avoidable. This aspect of ADRs 
causing admission in children has not been fully addressed in previous studies.  
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4.2 METHODS 
The study hospital had an induction programme which was delivered to new members 
of staff to educate them about the hospital and some aspects of specific practice within 
the setting. This programme provided training to clinicians regarding medication 
prescribing and drug safety for children but did not specifically address ADRs, their 
diagnosis or how to report them. Therefore, before the start of this observational study, 
a comprehensive educational program was undertaken within the hospital amongst 
clinicians of all grades. The study team attended hospital induction for new clinicians 
(and continued to do so through the entirety of the study period) to give formal 
presentations about the study and ADRs in children. The study team gave a formal 
presentation to an audience at the main weekly educational hospital meeting (for 
clinicians and staff from all specialties) as well as presenting at individual specialty 
team meetings occurring within the hospital.  
The goal of this educational programme was to raise awareness about the aims of the 
study and to increase clinicians’ understanding of their role in information recording. 
Firstly, clinicians were made aware of the primary aim of the study, which was to 
identify prospectively ADRs causing admission to the hospital. Clinicians were 
reminded of the importance of good record-keeping with regard to descriptions of 
symptoms and signs to allow for more accurate assessment of causality by the study 
team. Secondly, the study team aimed to raise awareness of taking detailed medication 
histories in relation to identifying ADRs accurately and assigning causality. A 
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structured medication history was added to acute general paediatric medical admission 
documentation with the aim of ensuring all families were asked for details about 
medication taken in the preceding two weeks. A two-week medication history was 
chosen as the time when reactions causing admission were most likely to have 
occurred following exposure to a drug.  
A two week pilot study (described in Chapter 2 of this thesis) to develop and refine the 
methodology for this larger study was conducted prior to the commencement of this 
study (Gallagher et al. 2010). The pilot study had a sizeable impact on the 
methodology for this larger study and was useful in refining the study team’s approach 
to data collection, defining an acute admission, identifying possible ADR cases and in 
assessment of those cases. These are discussed in more detail in chapter 2. 
The study team prospectively screened all unplanned admissions to a large tertiary 
paediatric hospital for ADRs over a 1 year period, including weekends and public 
holidays, from 1
st
 July 2008 to 30
th
 June 2009. Due to the nature of paediatric illness, 
there are seasonal variations in numbers of paediatric admissions and with certain 
patterns of illness and presentation. The study duration of one year was chosen so as to 
allow data capture from a large number of patients over a time frame that would 
capture these variations. This would also allow for increased generalizability of the 
results.   Weekends were included in routine daily data collection to eliminate any bias 
that may occur in trends of possible ADR admissions.  
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Admissions were excluded if they were planned, or occurred as a result of accidental 
or intentional OD. The definition of ADR used was that of Edwards and Aronson 
(Edwards & Aronson 2000) which is "an appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medicinal product, which predicts 
hazard from future administration and warrants prevention or specific treatment, or 
alteration of the dosage regimen, or withdrawal of the product." 
Hospital information systems at the study hospital routinely recorded demographic 
data about admitted patients. These data, with assistance from the hospital information 
technology department, were automatically downloaded each morning at 06:00 hours, 
for the patients coded as having an emergency admission, from the hospital computer 
system to a password-protected Microsoft Access database, stored on a secure hospital 
hard-drive. Only the study team had access to the database and the patient information 
recorded within. As described in chapter 2, the study team had to undertake further 
case exclusions based on assessment of the admissions and whether they were truly 
unplanned. 
Members of the study team, consisting of a paediatric registrar, a research pharmacist 
and a research nurse, collected the following information from the case notes of each 
patient: presenting complaint, summary of clinical history, diagnosis (if available at the 
time of admission), and medications taken in the two weeks prior to admission. If any 
information was unclear, study team members interviewed the family, patient or carers 
as appropriate to clarify the history, i.e. medication history, symptoms, and timing of 
events.  
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The study team cross-referenced the presenting symptoms/signs against medication 
history for each patient using the ADR profile for relevant drugs from the SPC 
(Datapharm 1999) in the Medicines Compendium or, if not available, the British 
National Formulary (BNF) (British National Formulary  2008). Possible ADRs were 
identified using this information combined with the clinical history and temporal 
relationships of the medication(s) taken. All possible ADRs were reported by the study 
team to the responsible clinicians during the study. All possible ADRs were reported to 
the MHRA using the electronic Yellow Card reporting scheme at the end of the study 
period. Reporting to the MHRA occurred after internal causality assessment of the 
possible ADR cases. The origin of prescription, for drugs thought to be associated with 
ADRs, was classified using the following criteria:  
Community – drugs where prescriptions originated in community settings, for example 
general practice, or where administration took place prior to hospital admission (e.g. 
paramedic administered). 
Hospital – drugs where the prescription originated, or administration took place, in 
hospital and then may or may not have been continued, for example by repeat 
prescription, in community or outpatient settings.  
Oncology – all drugs administered, or prescribed, from the oncology ward. These 
drugs may or may not be cytotoxic in nature. 
Initially, the causality assessment algorithm of Naranjo et al was used to assess 
causality of the ADR cases. It was the most widely used method in the literature, was 
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quick to complete and would potentially allow for comparison of case assessments 
with other studies. However, after assessing the first 40 cases using the Naranjo 
algorithm, the investigators found it contained some questions that caused major 
discrepancy between scorers and some questions that were rarely answerable within 
paediatric ADR cases. There were cases that assessors thought were ‘definite’ ADRs 
(using assessor opinion) that consisted of well-described ADRs with previous ADR 
occurrence to the same drug in the same patient. The majority of these cases were rated 
with a score of ‘probable’ ADR when using the Naranjo algorithm due to 
unanswerable questions. This led to development of the Liverpool ADR CAT, which is 
described in Chapter 3.  
We performed assessment of causality for all cases using the Liverpool ADR CAT 
(Gallagher et al. 2011). Three investigators independently assessed causality for all 
possible ADR cases. Agreement on causality category between all three investigators 
was taken as accepted consensus.  In cases where the three investigators did not 
achieve consensus, a fourth investigator assessed cases to decide on causality.  
Avoidability of the ADR cases was assessed by consensus meeting between the 
investigators, using the definitions developed by Hallas et al (Hallas et al. 1990). 
Cases were assessed as definitely avoidable, possibly avoidable or unavoidable. In 
addition, the type of ADR for each case identified was determined according to the 
classification of Rawlins and Thompson (Rawlins 1977) as either Type A 
(predictable from the known pharmacology) or Type B (not predictable). Severity 
was determined using an adapted Hartwig scale (Hartwig, Siegel & Schneider 1992). 
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This adapted scale is shown below (Table 4.1). Grades 3 and 4 from the original 
schema are collated, as not all ADR admissions necessitate cessation of the causative 
drug(s).  
 
Table 4.1 Adapted Hartwig severity scale 
Severity score Description 
6 Directly or indirectly resulted in patient death 
5 Caused permanent harm or significant haemodynamic 
instability 
4 Resulted in patient transfer to higher level of care 
3 Required treatment (admission), or drug discontinued 
2 Drug dosing or frequency changed, without treatment 
1 No change in treatment with suspected drug 
 
We chose these assessment tools to describe the nature of the ADRs in our study as 
they have been used previously in ADR studies by other investigators and can be 
completed quickly. Three investigators independently assessed 217/4514 (4.8%) 
reports of admissions exposed to medication, but deemed not to have had an ADR, to 
assess for occurrence of possible ADR cases wrongly classified by the study team. The 
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study was deemed to be audit after written communication with the National Research 
Ethics Service. Therefore, individual consent from patients admitted to the hospital 
was not sought.  
4.3 STATISTICAL ANALYSIS 
Analyses of the rates of ADRs were based on the number of admissions with the rate 
expressed as ADR per 100 admissions, together with 95% confidence intervals. Other 
results are presented either as medians and interquartile ranges or percentage 
frequencies and 95 percent confidence intervals, as appropriate.  
The formal statistical analysis was based on the data obtained at the first admission for 
patients exposed to a medication (to preserve independence for this variable, as one 
patient can have multiple ADR admissions which may not be independent from each 
other). Univariate statistical analyses were performed using the Mann-Whitney U test 
except for frequency data, which were analysed using a chi-square test. Multivariate 
logistic regression analysis was undertaken to calculate odds ratios for possible risk 
factors for ADR.  A P-value <0.05 was regarded as being significant. 
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4.4 RESULTS  
Over the study period, there were 10768 patient admissions coded as ‘unplanned’ on 
hospital information systems. Upon review, 2423 of these admissions were excluded 
from further study (Figure 4.1); 1952 planned admissions, 366 admissions to OBS 
ward (and discharged without main hospital ward admission) and 105 admissions due 
to accidental or intentional OD. Of 1952 planned admissions (incorrectly coded) 917 
were from the patient’s home, 542 were transfers from another hospital and 493 were 
for planned review (subsequently admitted). The study periods for the pilot study and 
this study did not overlap. There were, therefore, no admissions included in both 
studies. 
6821 patients were admitted acutely to the study hospital, accounting for 8345 
unplanned admissions. Boys accounted for 3961/6821 (58.1%) patients and 4793/8345 
(57.4%) admissions. The median number of admissions per patient was one, with 932 
patients having more than one acute admission, up to a maximum of fifteen. 178 
patients experienced 240 admissions with an ADR. This gives an incidence of 2.9 
ADRs per 100 admissions (95% CI 2.5, 3.3). 233 of the 240 (97.1%) admissions were 
deemed to have been directly caused, or contributed to, by at least one ADR.  There 
were 249 ADRs in 240 admissions, with nine admissions having two separate ADRs. 
35/178 (19.7%) patients had more than one admission with an ADR, up to a maximum 
of seven.   
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Figure 4.1 Flowchart of patient admissions and assessments during the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
There were 4656 patients exposed to a medication in the two weeks prior to their first 
acute admission to the hospital during the study period. Of these patients, 142 (3%) 
Admissions assessed for 
eligibility (n=10768) 
Excluded 
-Planned admissions (n=1952) 
-Obs ward patients (n=366) 
-Accidental/intentional OD (n=105)  
 
Acute admissions assessed by 
study team (n=8345) 
Acute admissions with ADR 
(n=240) 
Acute admissions without 
ADR (n=8105) 
All ADR admissions assessed 
by senior investigators for type 
of reaction, causality, severity 
and avoidability 
217 non-ADR admissions 
assessed by three senior 
investigators (none found to be 
ADR) 
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had a suspected ADR on their first hospital admission. There was no significant 
difference between the proportion of boys (76/2677, 2.8%) and girls (66/1979, 3.3%) 
experiencing an ADR on their first admission, for the group as a whole or oncology 
patients studied separately (Table 1.1). For non-oncology patients, there was a 
slightly higher proportion of girls admitted with an ADR (boys 48/2627 (1.8%), girls 
53/1955 (2.7%), P=0.044), although overall more boys than girls were admitted to 
the hospital.   
Table 4.2 Univariate analyses of ADRs by gender (first admission) 
Gender All No ADR ADR Chi-
Squared 
P-
value 
All Boys 2677 2601 (97.2%) 76 (2.8%) 0.947 0.331 
All Girls 1979 1913 (96.7%) 66 (3.3%) 
 
Oncology Boys 
 
50 
 
22 (44.0%) 
 
28 (56.0%) 
 
0.022 
 
0.882 
Oncology Girls 24 11 (45.8%) 13 (54.2%) 
 
Non-Oncology Boys 
 
2627 
 
2579 (98.2%) 
 
48 (1.8%) 
 
4.062 
 
0.044 
Non-Oncology Girls 1955 1902 (97.3%) 53 (2.7%) 
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The median age of the 4656 patients who had been exposed to a drug on their first 
admission was 3 years 1 month (IQR 9m, 9y). Patients with an ADR (6y; IQR 2y 
4m, 11y) were significantly older (P<0.01) than those without (3y; IQR 9m, 9y) 
(Table 4.3). There was no age difference between the 41 oncology patients admitted 
with an ADR (6y; IQR 3y, 10y) and the 33 oncology patients admitted without an 
ADR (6y; IQR 3y 6m, 13y). There was a significant age difference (P<0.01) between 
101 non-oncology patients admitted with ADR (6y; IQR 1y 7m, 11y) and 4481 
admitted without ADR (2y 11m; IQR 9m, 9y). 
Patients admitted with an ADR had taken a greater number of drugs than those 
admitted for other reasons (Table 4.4). For patients admitted with an ADR (n=142), 
the number of medicines taken was higher (6; IQR 3, 9, P<0.001) than those for 
other reasons (n=4514) (2; IQR 1, 3). The number of medicines taken by oncology 
patients admitted with an ADR (8; IQR 5, 10) was higher than those admitted 
without an ADR (4; IQR 3, 7) and this difference was also found for non-oncology 
patients (with ADR 5; IQR 3, 9: without ADR 2; IQR 1, 3). 
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Table 4.3 Univariate analyses of ADRs by patient age (first admission) 
Age (years, 
months)  
[Median; 
Q1, Q3]  
All No ADR ADR 
 
Mann-
Whitney U 
P-value 
All [3y 1m;   
9m, 9y] 
(n=4656) 
[3y 0m;   
9m, 9y] 
(n=4514) 
[6y 0m;      
2y 4m, 11y] 
(n=142) 
244161 <0.001 
 
Oncology 
 
[6y; 3y 6m, 
12y] 
(n=74) 
 
[6y; 3y 6m, 
13y] 
(n=33) 
 
[6y; 3y 0m, 
10y] 
(n=41) 
 
580.5 
 
0.296 
 
Non-
Oncology 
 
[3y; 9m, 9y] 
(n=4582) 
 
[2y 11m; 
9m, 9y] 
(n=4481) 
 
[6y; 1y 7m, 
11y] 
(n=101) 
 
178319.5 
 
<0.001 
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Table 4.4 Univariate analyses of ADRs by number of medicines taken (first 
admission) 
Drug 
Count  
All 
[Median; 
IQR] 
No ADR ADR 
 
Mann-
Whitney 
U 
P-value 
All [2; 1, 3] 
(n=4656) 
[2; 1, 3] 
(n=4514) 
[6; 3, 9] 
(n=142) 
115391.5 <0.001 
 
Oncology 
 
[6; 4, 9] 
(n=74) 
 
[4; 3, 7] 
(n=33) 
 
[8; 5, 10] 
(n=41) 
 
380.5 
 
0.001 
 
Non-
Oncology 
 
[2; 1, 3] 
(n=4582) 
 
[2; 1, 3] 
(n=4481) 
 
[5; 3, 9] 
(n=101) 
 
100371.5 
 
<0.001 
 
 
Logistic regression analysis showed a trend towards boys being less likely to 
experience an ADR than girls, with an odds ratio (OR) of 0.77 (95% CI 0.52, 1.12, 
P=0.17) (Table 4.5).  There was an increased likelihood of ADRs with increasing 
age (OR 1.04, 95% CI 1.003, 1.08, P=0.03).  No children were admitted with an 
ADR in the first month of life. Oncology patients were much more likely to have an 
ADR causing admission (OR 29.71, 95% CI 17.35, 50.88, P<0.001). The likelihood 
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of a child being admitted with an ADR increased with the number of medicines taken 
(OR 1.24, 95% CI 1.19, 1.29, P<0.001). Therefore, for each additional medicine 
taken by a patient the risk of an ADR occurring increases by almost 25%.   
 
Table 4.5 Multivariate logistic regression analysis (first admission) 
Parameter Odds Ratio (OR) 95% CI for OR P-value 
Gender (male) 0.77 0.52, 1.12 0.17 
Age 1.04 1, 1.08 0.03 
Oncology 29.71 17.35, 50.88 <0.01 
Number of 
medicines 
1.24 1.19, 1.29 <0.01 
a. Variable(s) entered on step 1: Gender (Male), Age, Oncology, Number of medicines 
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4.4.1 Drug Classes and Drugs 
The main class of drugs contributing to ADR-related admissions (n=110; 44.2%) was 
cytotoxic drugs (Table 4.6). Corticosteroids (n=102, 41%), non-steroidal anti-
inflammatory drugs (NSAIDs) (n=31, 12.4%), vaccines (n=22, 8.8%) and 
immunosuppressants (n=18, 7.2%) were the next most commonly implicated drug 
classes causing ADR-related hospital admissions. 
A total of 551 courses of medicines contributed to the 249 ADRs causing 240 
admissions. The median number of drugs causing an ADR admission was two (n=79), 
with a maximum of six (three admissions). Seven admissions were caused by five 
drugs, 25 by four drugs and 57 by three drugs. 69 admissions were caused by one drug 
only. None of the ADRs, caused by more than one drug, occurred as a result of a 
pharmacokinetic drug-drug interaction. All of the ADRs caused by more than one drug 
were a result of pharmacodynamic interactions.
  
 
 Table 4.6 Classification of drugs associated with ADR admissions 
Drug class  
(No. of cases)  
 No. drugs Drugs  ADRs 
Cytotoxics 
(110)  
275 vincristine 51, doxorubicin 38, methotrexate 35, etoposide 30, 
mercaptopurine 27, cytarabine 24, ifosfamide 18, 
cyclophosphamide 15, carboplatin 7, vinblastine 5, peg-
asparaginase 5, dactinomycin 5, daunorubicin 4, cisplatin 3, 
irinotecan 3,  temozolomide 2, fludarabine 1, amsacrine 1, 
imatinib 1  
Neutropenia 89, Thrombocytopenia 55, Anaemia 38, Vomiting 
8, Mucositis 8, Deranged LFTs 7, Immunosuppression 7, 
Diarrhoea 5, Nausea 4, Constipation 3, Headache 2, Abdominal 
pain 1, Back pain 1,  Haematuria 1, Leukencephalopathy 1, 
Deranged renal function 1  
Corticosteroids 
(102)  
107 dexamethasone 68, prednisolone 33, hydrocortisone 2, 
betamethasone 1, mometasone 1, methylprednisolone 1, 
fluticasone 1  
Immunosuppression 71, Post-op bleeding 23, Hyperglycaemia 
3, Hypertension 1, Gastritis 1, Increased appetite 1, Impaired 
healing 1, Adrenal suppression 1  
NSAIDs (31)  43 ibuprofen 28, diclofenac 15  Post-op bleeding 27, Haematemesis 2, Constipation 1,    
Abdominal pain 1  
Vaccines (22)  37 DTP IPV HIB 11, pneumococcal conjugate 9,  meningitis C 
8, measles mumps rubella 7,  haemophilus influenza B 1, 
influenza 1  
Fever 8, Rash 5, Irritability 4, Seizure 4, Vomiting 3, Pallor 1, 
Apnoea 1, Limb swelling 1, Lethargy 1, Thrombocytopenia 1, 
Diarrhoea 1, Abdominal pain 1, Respiratory distress 1, 
Kawasaki disease 1  
  
 
Drugs 
affecting      
the immune   
response (18)  
26 tacrolimus 15, mycophenolate 7, azathioprine 2,  
methotrexate 1, infliximab 1  
Immunosuppression 18  
Anti-bacterial 
(16)  
17 co-amoxiclav 4, penicillin v 3, amoxicillin 3, flucloxacillin 2, 
cefaclor 1, cefalexin 1, cefotaxime 1, teicoplanin 1, 
erythromycin 1  
Diarrhoea 7, Rash 4, Vomiting 4, Lip swelling 1,     Deranged 
LFTs 1, Thrush 1  
Drugs used in 
diabetes (9)  
13 insulin detemir 4, insulin aspart 3, isophane insulin 2,                    
biphasic isophane 2, human insulin 2 
Hypoglycaemia 9  
Drugs used in 
status 
epilepticus (8)  
12 lorazepam 5, diazepam 5, midazolam 2  Respiratory depression 8 
Opioid 
analgesia (6)  
7 dihydrocodeine 3, codeine phosphate 3, fentanyl 1  Constipation 4, Ileus 1, Decreased conscious level 1  
Drugs used in  
nausea (4)  
4 ondansetron 4  Constipation 4  
Anti-epileptic   
drugs (2)  
2 carbamazepine 1, nitrazepam 1  Constipation 1, Respiratory depression 1  
  
 
Drugs that 
suppress 
rheumatic 
disease (2)  
2 methotrexate 1, anakinra 1 Immunosuppression 2 
Other (16)  4 
 
calcium carbonate 1, amlodipine 1 
oxybutynin 1, baclofen 1 
Constipation 3 
 2 dimeticone 1, carbocysteine 1 Rash 2 
 2 desmopressin acetate 1, alimemazine 1 Seizure 2  
 10 glucose and dextrose 1, propanolol 1, acetazolomide 1, 
spironolactone 1, loperamide 1, macrogols 1, captopril 1, 
alfacalcidol 1, ethinylestradiol 1 
Hyperglycaemia 1, Wheeze/DIB 1, Headache 1, 
Hyperkalaemia 1, Intestinal obstruction 1, Diarrhoea 1, Renal 
dysfunction 1, Hypercalcaemia 1,  Inter-menstrual bleed 1 
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4.4.2 Nature of the adverse drug reactions 
The most common ADRs were oncology related including neutropenia (89), 
thrombocytopenia (55) and anaemia (38). The next most common ADR was 
immunosuppression (74), occurring in both oncology and non-oncology patients. Post-
operative bleeding, linked to peri-operative corticosteroid administration and/or 
NSAIDs, caused 28 admissions (26 post-tonsillectomy). Vomiting (15), diarrhoea (14), 
rash (11) and constipation (9) were all common ADRs causing admission. 
Hypoglycaemia in insulin-dependent diabetic patients caused nine admissions. 
Respiratory depression following treatment for status epilepticus caused eight 
admissions to the hospital’s PICU.  
Previously unrecognised ADRs included post-operative bleeding in children exposed 
to corticosteroids and one case of Kawasaki disease, commencing three days after 
measles/mumps/rubella vaccination of a one year old child, which was deemed to have 
‘possible’ causality by the investigators. 
4.4.3 Study team identification of adverse drug reactions 
The ADRs in this study were identified in a prospective manner by each member of 
the study team which consisted of a paediatric registrar, a pharmacist and a paediatric 
nurse. All three had taken part in a two week pilot study to refine the methodology for 
this study (Chapter 2) and had attended ADR reporting training at a MHRA regional 
Yellow Card pharmacovigilance centre. The patient data for all acute admissions were 
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collected each day by one study member. This allowed for follow-up on the other days. 
Working patterns altered throughout the year but each investigator completed 
approximately equal numbers of data collection days.  There were 240 admissions 
associated with an ADR. The pharmacist identified the highest number of ADR 
admissions (n=96, 40%) in the study period. The paediatrician identified 85 (35.4%) 
admissions and the nurse identified 59 (24.6%).  
Of the 8345 acute admissions in the study period, the pharmacist assessed 2969 
(35.6%), the paediatrician assessed 2634 (31.6%) and the nurse assessed 2742 
(32.9%). Therefore, the pharmacist judged 96/2969 (3.2%) admissions to be due to 
ADR. The paediatrician assessed 85/ 2634 (3.2%) to be due to ADR and the nurse 
59/2742 (2.2%). There was no difference between the proportion of admissions judged 
to be due to ADR between the paediatrician and the pharmacist. However, there was a 
difference between the proportions of ADR cases identified by the nurse compared to 
both the pharmacist (p=0.01) and the paediatrician (p=0.02), with the nurse having 
identified ADRs less frequently than the other two investigators. Of the ADRs 
identified by the pharmacist, 46/96 (47.9%) were oncology patient admissions. The 
paediatrician identified 29/85 (34.1%), and the nurse 39/59 (66.1%) oncology patient 
admissions.  
Independent assessment of a sample of non-ADR cases (n=217) was undertaken by 
three senior investigators. Each investigator assessed 75 cases independently (eight 
cases were duplicated in the randomisation process; six of these were distributed to 
two different investigators and one investigator received two copies of two reports). 
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The investigators highlighted five cases that required further information from the case 
notes. At a consensus meeting with the investigators, four of the reports, with the extra 
case information, were deemed not to be ADRs. This was mainly due to 
investigations/information confirming a disease process, such as a culture-positive 
stool confirming infectious gastroenteritis. One case was deemed to have insufficient 
information to assess the symptoms in relation to the drug history, but overall was 
thought unlikely to be due to an ADR.  The analysis of these cases confirmed that none 
of these admissions were due to ADRs. 
4.4.4 Origin of ADR Drug Prescriptions 
Prescriptions originating from community settings accounted for 44/249 (17.7%) of 
the ADRs. 85/249 (34.1%) ADRs arose from prescriptions originating in hospital for 
the treatment of conditions other than oncology. Prescriptions originating from 
oncology accounted for 120/249 (48.2%) of ADRs. Of the patients with one ADR 
(n=140) in the study period, 39 (27.9%) occurred with community originated 
prescriptions, 71 (50.7%) with hospital originated prescriptions and 30 (21.4%) with 
oncology originated prescriptions. Of patients with two ADRs (n=22) in the study 
period, two (9.1%) occurred with community prescriptions, six (27.3%) with hospital 
prescriptions and 14 (63.6%) with oncology prescriptions. Prescriptions originating 
from oncology accounted for 15/16 patients with three or more ADRs. One patient, 
with three ADRs in the study period, had two ADRs to hospital originated 
prescriptions and one ADR to a community prescription. 
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4.4.5 ADR Assessments (Reaction Type, Causality, Severity, Avoidability) 
238/249 (95.6%) ADRs were classified as type A (predictable from the known 
pharmacology) with 11/249 (4.4%) being type B (not predictable). Assessment of 
causality using the Liverpool ADR CAT showed the highest proportion of cases 
(94/249, 37.8%) to be in the ‘definite’ category. Oncology cases accounted for 80 of 
these 94 definite causality cases (Table 4). 41/55 (74.5%) of possibly or definitely 
avoidable cases were classified as ‘definite’ or ‘probable’. 92/238 (39.1%) type A 
reactions were assessed to be of definite causality. 8/11 (72.7%) type B reactions were 
assessed to be ‘possible.’ The majority (16/17, 94.1%) of the more severe reactions (≥ 
Grade 4 adapted Hartwig severity score) were assessed to have definite or probable 
causality (Table 4.7). ADR assessments by age groupings (not standardised) are 
reported in Table 4.8. 
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Table 4.7 Origin of prescription of ADR drugs by type of reaction, severity 
score, avoidability and causality assessment 
  Oncology 
(n=120) 
Hospital 
(n=85) 
Community 
(n=44) 
Type of 
reaction 
A 119 (99%) 85 (100%) 34 (77%) 
B 1 (1%) 0 (0%) 10 (23%) 
Severity Score 1 5 (4%) 1 (1%) 1 (2%) 
2 0 (0%) 2 (2%) 0 (0%) 
3 111 (92%) 74 (87%) 38 (86%) 
4 2 (2%) 8 (9%) 4 (9%) 
5 2 (2%) 0 (0%)  1 (2%) 
Avoidability Unavoidable 112 (93%) 57 (67%) 25 (57%) 
Possibly 6 (5%) 25 (29%) 14 (32%) 
Definitely 2 (2%) 3 (4%) 5 (11%) 
Causality Possible 9 (7%) 51 (60%) 23 (52%) 
Probable 31 (26%) 24 (28%) 17 (39%) 
Definite 80 (67%) 10 (12%) 4 (9%) 
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Table 4.8 ADR assessments (type, causality, severity and avoidability) by age 
  Age 
  0-11 mths  
(n=27) 
1-3 yrs  
(n=51) 
4-6 yrs  
(n=51) 
7-11 yrs  
(n=50) 
12-16 yrs  
(n=70) 
Gender Male 
Female 
14 
13 
25 
26 
29 
22 
32 
18 
35 
35 
Type of 
reaction 
Type A 
Type B 
27 
0 
45 
6 
50 
1 
48 
2 
68 
2 
Causality Possible  
Probable  
Definite 
13 
12 
2 
17 
12 
22 
12 
16 
23 
22 
12 
16 
19 
20 
31 
Origin of 
Prescription 
Hospital 
(Oncology) 
 
Community 
11           
(5) 
 
16 
35           
(26) 
 
16 
49           
(31) 
 
2 
45           
(21) 
 
5 
65           
(37) 
 
5 
Severity scale < 3 
3 
>3 
2 
24 
1 
2 
45 
4 
1 
46 
4 
2 
45 
3 
2 
63 
5 
Avoidability Unavoidable 
Possibly  
Definitely 
20 
5 
2 
40 
9 
2 
38 
10 
3 
41 
8 
1 
55 
13 
2 
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223/249 (89.6%) of the ADRs were classified as grade 3 (‘required treatment or drug 
administration discontinued’) according to the Hartwig severity scale, as we defined 
anyone requiring admission to hospital as ‘needing treatment.’ 14 (5.6%) were 
classified as grade 4 (‘resulted in patient transfer to higher level of care’) including 
respiratory depression (8), immunosuppression (4), neutropenia (1), fever/seizure (1) 
and leukencephalopathy (1). Three ADRs were classified as grade 5 (‘caused 
permanent harm or significant haemodynamic instability’). Two of these most severe 
ADRs occurred in oncology patients with febrile neutropenia and septicaemia and the 
remaining case was a child who required bowel resection for ileus, with impacted 
faecal matter, following treatment with loperamide. No ADRs contributed to death.  
Two ADRs were classified as grade 2 (‘drug dosing or frequency changed, without 
treatment’) and seven were classified as grade 1 with (‘no change in treatment with the 
suspected drug’). 
We determined the avoidability of ADRs by the method of Hallas et al.  194/249 
(78%) of the ADRs were assessed as ‘unavoidable,’ while 45 (18%) were classified 
as ‘possibly avoidable,’ and 10 (4%) as ‘definitely avoidable.’  Five of the cases 
deemed to be definitely avoidable were associated with hospital prescribed drugs and 
five with community prescribed (Table 4.9). 31 possibly avoidable cases were 
associated with hospital prescribed drugs and 14 with community prescribed. 114 
(47.5%) of the ADR admissions occurred in oncology patients accounting for 120 
ADRs.  Of the ADRs due to oncology drugs, 112/120 (93.3%) were unavoidable, 
with a further six being possibly avoidable and two definitely avoidable. These 
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‘definitely avoidable’ cases were oncology patients with constipation following 
treatment with vincristine and ondansetron (with one also having dihydrocodeine) 
without laxative prophylaxis.  
 
Table 4.9 Assessments of potentially avoidable ADRs 
  Possibly 
avoidable 
Definitely 
avoidable 
Type of reaction A 45 8 
B 0 2 
Severity Score 1 0 1 
2 1 0 
3 35 8 
4 9 0 
5 0 1 
Causality Possible 13 1 
Probable 20 7 
Definite 12 2 
Origin of 
prescription 
Hospital 31 5 
Community 14 5 
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Of the ADR admissions not associated with oncology patients (n=126 admissions and 
129 ADRs), 82/129 ADRs (63.6%) were classified as unavoidable, 39 (30.2%) as 
possibly avoidable and eight (7.6%) as definitely avoidable. The eight ‘definitely 
avoidable’ cases comprised four patients prescribed antibiotics where the antibiotic 
choice or indication was deemed to be inconsistent with good practice, one patient 
with intestinal obstruction being treated with loperamide who had not passed stool for 
two days prior to admission, one patient who had a seizure after alimemazine having 
had two previous occurrences of seizure following the anti-histamine, one patient with 
deranged renal function which improved after cessation of captopril where improved 
renal function monitoring may have avoided the ADR, and one patient who presented 
with adrenal suppression following two years of continuous treatment with intranasal 
corticosteroids. The possibly and definitely avoidable cases and the reasons for their 
allocation are summarised in Table 4.10.   
 Table 4.10 Possibly and definitely avoidable cases and explanation of assessment result 
?Avoidable Frequency ADR(s) Drug Classes Reason for potential avoidability 
Definitely 3 Diarrhoea and/or 
vomiting 
Anti-bacterial Inappropriate indication, signs/symptoms of viral 
illness 
Definitely 2 Constipation Cytotoxics, Drugs used in nausea, Opioid 
analgesia 
Appropriate Prophylaxis not used 
Definitely 1 Lip swelling, rash Anti-bacterial Same ADR previously to same  medication 
Definitely 1 Seizure Antihistamine Same ADR previously to similar medication 
Definitely 1 Adrenal suppression Corticosteroids Avoidable with more rational prescribing 
(prolonged use of drugs) and improved monitoring 
Definitely 1 Intestinal obstruction Anti-motility drugs Could be prevented by improved parent/patient 
education 
Definitely 1 Deranged renal function Drugs affecting the renin-angiotensin system Avoidable with improved monitoring 
Possibly 9 Hypoglycaemia Drugs used in diabetes Avoidable with improved patient education (e.g. 
appropriate insulin use when unwell) and more 
rational prescribing 
Possibly 8 Respiratory depression Drugs used in status epilepticus, Hypnotics Alternative medicine available, Multiple doses 
given - avoidable with more rational prescribing 
 Possibly 6 Diarrhoea/vomiting Anti-bacterial Inappropriate indication, symptoms suggested viral 
infection 
Possibly 5 Constipation Antiepileptic drugs, Opioid analgesia, Drugs used 
in nausea, NSAIDs, Cytotoxics,  Calcium-
channel blockers,  Calcium supplements 
Prophylaxis not used 
Possibly 4 Immunosuppression Drugs affecting the immune response, 
Corticosteroids 
Possibly Avoidable with improved monitoring of 
drug levels,  Avoidable with more rational 
prescribing 
Possibly 2 Haematemesis NSAIDs Avoidable with more rational prescribing (less 
NSAID use)/improved patient education 
Possibly 1 Neutropenia Cytotoxics Same ADR previously at same dose of medication 
Possibly 1 Neutropenia, 
thrombocytopenia, 
anaemia 
Cytotoxics Superficial infection after recent admission with 
febrile neutropenia. Possibly avoidable by 
prolonging antibiotic use or commencing GCSF 
Possibly 1 Hyperglycaemia Corticosteroids Avoidable with more rational prescribing 
(prolonged course steroids used) 
Possibly 1 Hyperglycaemia Parenteral preparations Avoidable with more rational prescribing (more 
judicial use) or improved monitoring 
Possibly 1 Seizure Posterior pituitary hormones Possibly inappropriate medication used for a patient 
with seizures 
 Possibly 1 Diarrhoea Laxatives Avoidable with improved patient education 
Possibly 1 Ileus Opioid analgesia Avoidable with more rational prescribing (possibly 
use alternative analgesia) 
Possibly 1 CNS depression Opioid analgesia Avoidable with improved patient education 
Possibly 1 Vomiting Cytotoxics Possibly avoidable with more appropriate anti-
emetic prophylaxis 
Possibly 1 Gastritis Corticosteroids Previous gastritis. Possibly avoidable with improved 
prophylaxis 
Possibly 1 Hypercalcaemia Vitamins Avoidable with improved monitoring 
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4.4.6 Drug exposure prior to acute admission 
Of 8345 admissions, 6020 (72.1%) were exposed to medication in the two weeks prior 
to admission. 3417 (56.8%) of these were male and 2603 were female (43.2%). The 
median number of drugs taken was 2 (IQR 1, 4), with one child exposed to 34 courses 
of medication, due to an admission for cardiothoracic surgery, in the two weeks prior 
to re-admission. Figure 4.2 shows the distribution of drugs per admission.  
Figure 4.2 Number of drugs per admission 
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Children under 1 year of age accounted for the most number of admissions. 1737/2539 
(68.4%) of under one year olds had been exposed to medication prior to admission 
(Figure 4.3). Of the other children admitted, the age group most frequently exposed to 
medication was the 16 year old group (95/99 admissions, 96%). Children aged seven 
were the least exposed to medication (163/245, 66.5%) prior to admission. 
Figure 4.3 Age (one year intervals) and number of children exposed to 
medication prior to admission 
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Of 6020 children exposed to at least one medicine prior to admission, those aged 16 
years were exposed to the most number of drugs per admission with a mean of 5.93 
(95%CI 4.92, 6.93) drugs. Children aged less than one were the least exposed to 
medication with a mean of 2.82 (95%CI 2.71, 2.93) drugs per admission (Figure 4.4 
and Figure 4.5).  
 
Figure 4.4 Mean number of drugs taken by age (one year intervals) 
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Figure 4.5 Box and whisker plot of number of medicines taken by age group  
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4.4.7 Cost of ADRs and Length of Stay 
The mean cost of 238/240 ADR admissions to the study hospital, using information 
provided by the finance department, was calculated to be £4753 per admission (95% 
CI £3439, £6066). Cost data were missing for two ADR admissions: one oncology and 
one non-oncology patient admission. The mean cost of 113 oncology ADR admissions 
to the study hospital was £5428.91 (95%CI 4041.24, 6816.58). The mean cost of 125 
non-oncology admissions was £4141.4 (95%CI 1963.84, 6318.95). The mean length of 
stay of all 240 ADR admissions was 5.67 (95%CI 3.28, 8.06) days. The mean length of 
stay for the oncology admissions was 5.45 (95%CI 4.35, 6.55) days, and 5.87 (95%CI 
1.4, 10.34) days for the non-oncology admissions.   
Data from the Health and Social Care Information Centre (NHS) 
(HospitalEpisodeStatistics) showed, in one year between 2009/2010, the total number 
of paediatric emergency admissions in England was approximately 597,800 (includes 
paediatrics and paediatric surgery, cardiology and neurology). We estimate the annual 
mean cost of paediatric ADR admissions to the NHS in England to be £82.4M using 
the mean cost of all ADR admissions to the study hospital. Using the upper and lower 
confidence intervals for both our estimate of ADR incidence, and study hospital costs, 
we estimate the cost to the NHS in England of paediatric ADR admissions to be 
between £51.4-119.7M. 
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4.5 DISCUSSION 
This prospective observational study is the largest of its kind in children and the only 
one to comprehensively assess causality, type of reaction (predictable or not), severity, 
origin of drug prescription and avoidability. This is the first large study in children to 
investigate risk factors for the occurrence of an ADR-related admission. The majority 
of admissions associated with ADRs in children occurred as a result of prescriptions 
originating in hospital. Potential preventative strategies for ADRs causing admission in 
children should therefore be targeted at hospital prescribing. Analysis of the ‘definitely 
avoidable’ ADRs in this study suggests that more careful attention to practical aspects 
of care, such as improved monitoring, following prescribing guidelines, improved 
patient education, and heightened suspicion about potential adverse reactions could 
lead to a reduction in the frequency of ADRs causing admission. The avoidability 
assessment method used in this study was not subject to validation in other studies. A 
more accurate and validated avoidability assessment method might allow for more 
accurate estimates of avoidable ADRs and allow for a more targeted approach to 
consideration of prevention.  
The incidence of ADRs causing admission in this study (2.9% (95% CI 2.5, 3.3)) was 
similar to the incidence in two systematic reviews, 2.09% (95%CI, 1.02, 3.77) and 
1.8% (95% CI 0.4, 3.2), but was significantly less than that of a large US study 
published in 1988 (Mitchell et al. 1988). In that study, the top three drugs causing 
ADRs were phenobarbital, aspirin and phenytoin, all of which are used in children 
much less now than in 1988. Since these medicines were hardly used in our 
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population, it is possible that the discrepancy in incidence rates relates in part to the 
reduction in use of these medicines.  
This study of ADRs causing admission of children to hospital was included in a more 
recent systematic review of studies of ADRs in children by Smyth et al published in 
2012 (Smyth et al. 2012). Of 102 studies included in the review, 72 had assessed 
causality, 34 had assessed severity and only 19 studies reported avoidability 
assessments. A pooled estimate of 42 studies investigating ADRs causing admission 
showed an incidence rate of 2.9% (95% CI 2.6, 3.1). Of 19 studies reporting 
avoidability, only three had reported the case-specific rationale for potentially 
avoidable ADRs. The study detailed in this chapter provides the rationale for assessing 
55 ADR admissions as ‘possibly’ or ‘definitely’ avoidable, out of the 62 avoidable 
ADR cases detailed in the systematic review by Smyth et al.  This study should 
therefore encourage health professionals to aim for prevention, rather than treatment, 
of ADRs causing admission in children. 
This prospective observational study is the first to attempt the identification of possible 
risk factors for ADRs causing hospital admission in children. Older children, those 
exposed to more medicines in the two weeks prior to admission and oncology patients 
were shown to have an increased risk of ADR in this study. Girls showed a trend 
towards being more likely to experience an ADR than boys but this result was not 
statistically significant. An increased risk of ADRs occurring in female gender has 
been described in studies in adult populations (Davies et al. 2009; Zopf et al. 2008).  
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The data used for the risk factor analysis was extracted from patients exposed to 
medication prior to their first admission, due to the occurrence of some patients having 
multiple admissions (some with multiple ADR admissions). Therefore, the univariate 
and multivariate analyses were of this data. This sample was representative of the 
larger sample of all admissions. All other data described in this study included all 
admissions to enable a more complete description of the frequency and nature of the 
burden of ADRs to paediatric patients.  This allows for readers to compare the data 
more readily to their own settings. 
The only measure of drug exposure used to assess risk factors for ADR occurrence in 
admissions was the count of drugs patients were exposed to. This was because of 
limitations in the dataset, as discussed in Chapter 2. There have been studies, including 
two studies from the ADRIC research program, assessing off-label and unlicensed 
drug use in children (a well-known theoretical problem and risk in terms of paediatric 
drug safety) in relation to the risk of ADR occurrence, without consensus as to the 
overall effect. The limitation of the dataset in this study was mainly from parental 
history of drug exposure. In part, this may be overcome with linked electronic patient 
records between community and hospital settings with electronic prescribing which 
would remove some of the reliance on clinical history. However, there would still be 
problems with reliance about adherence to both prescribed and over-the-counter 
medications. Electronic counters for medication dispensers and drug-levels are among 
some suggested solutions to these problems but are likely too impractical and costly 
for a study of this size. 
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Causality was determined, of the ADR cases, using a novel causality tool, the 
Liverpool ADR CAT, which was developed during the process of undertaking our 
study (Chapter 3). The majority of ADRs were classified as ’definite,’ and most of 
these occurred in oncology patients. In order for a case report to achieve a score of 
‘definite’ it would have to include a positive re-challenge or a previous history of the 
ADR to the same medication, a condition which these oncology-related ADRs 
satisfied. Type A reactions were more likely to be assigned a definite or possible 
causality and type B reactions were more likely to be deemed possible. This may be 
due assessors being less confident with type B ADRs, which are unpredictable and less 
frequent. The more severe reactions in our study were more often assessed to have 
definite or probable causality. This may reflect a confidence in assessing severe ADRs, 
which are more likely to be described in the drug safety literature.  
The majority of the ADRs seen during the study were oncology related. These were 
mainly children with a febrile illness who developed neutropenia 1-2 weeks after 
intravenous chemotherapy. Clearly, patients with malignancy are often exposed to 
medications that cause ADRs (Lau, Stewart & Dooley 2004), such as neutropenia 
(with fever), nausea, vomiting, diarrhoea, anaemia and bleeding secondary to 
thrombocytopenia, all of which may require hospital admission. ADRs to cytotoxic 
chemotherapy drugs are expected and, for the most part, may be unavoidable given the 
nature of the underlying illness and the treatment options currently available. Although 
several studies have evaluated a potential preventative strategy for neutropenia (Sung 
et al. 2004), no definitive evidence exists regarding the routine prophylactic use of 
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granulocyte-colony stimulating factor (GCSF) to prevent ADRs due to 
myelosuppression (Sasse et al.).  
Steroids, along with other immunosuppressants, increase the risk of infection (Kelly et 
al. 2010). Immunosuppressants featured frequently in our study as causative agents for 
ADRs. The nature of ADRs associated with immunosuppressive therapy included 
proven bacterial infections and viral infections (e.g. shingles).  Although we recognise 
that infections may also occur in healthy children, the role of immunosuppressive 
therapy in predisposing patients to infections is well recognised (Glück et al. 2005; 
Shepherd et al. 2008; Toruner et al. 2008).  
Another frequently recorded ADR in our study was post-operative bleeding, in 
particular secondary haemorrhage following elective tonsillectomy.  The majority 
(23/28 admissions) of these occurred in patients exposed to intravenous 
Dexamethasone as prophylaxis for post-operative nausea and vomiting (PONV), and 
NSAIDs, with Ibuprofen being used commonly in the post-operative period.  A few 
patients received either Dexamethasone or NSAIDs. Dexamethasone has been linked 
to post-tonsillectomy bleeding (Czarnetzki et al. 2008) but its role, and the role of 
NSAIDs, in causing secondary haemorrhage in these children needs further study 
(Cardwell, Siviter & Smith 2005; Steward, Welge & Myer 2003).  However, intra-
operative steroid has played a major role in improving outcomes for PONV in children 
undergoing operations (Goldman, Govindaraj & Rosenfeld 2000; Steward, Welge & 
Myer 2003) and has enabled daycase surgery for many conditions, thereby reducing 
the length of stay in hospital. 
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Respiratory depression following treatment of seizures with benzodiazepines, a well-
recognised and potentially serious event (Stewart, Harrison & Dooley 2002), was the 
cause of eight admissions to PICU for ventilation until recovery.  Some of these cases 
were transfers from other regional district general hospitals to the study hospital 
tertiary PICU. Some, in fact, occurred as a result of rectal diazepam being used by 
paramedics in out-of-hospital care of seizures. Drugs used to treat status epilepticus 
have been widely studied and their efficacy and adverse reactions compared (McIntyre 
et al. 2005; McMullan et al. 2010). There may be drugs other than diazepam which 
have an improved benefit-risk ratio when used to treat seizures in paediatric patients 
(Appleton, Macleod & Martland). Further research is therefore warranted to optimize 
strategies for treating seizures, for both in and out-of-hospital care.  
Data collection was undertaken by a multi-disciplinary team consisting of a paediatric 
registrar, a pharmacist and a nurse. In this study, the nurse identified ADR cases less 
frequently than either the pharmacist or paediatric registrar, who identified possible 
ADRs at the same frequency. Despite the difference in ADR identification between the 
three investigators, there were no ADRs identified in a senior investigator review of 
217 cases deemed not to be ADRs by the data collection team. The differences in ADR 
identification between the members of the data collection team is unexplained but may 
have occurred because of daily variation in numbers and types of admission to the 
study hospital: the research nurse assessed fewer patient admissions to oncology 
despite approximately equal numbers of data collection days between the three 
investigators. 
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The ADRs reported in this study highlight some of the adverse consequences of drugs 
in children.  A limitation of this study is that we have not taken into account the 
benefits of these medications.  Furthermore, we cannot be certain of the aetiological 
fraction (the risk of an event occurring in the presence of a risk factor) for some of the 
drugs in our study, for example immunosuppressants, in their contribution to the stated 
reactions. For these drugs, more research is needed to accurately assess their 
contribution to ADRs and the ill-health of children, to allow for more detailed risk-
benefit evaluation.   
In this study, we have not considered ADRs caused by medications during inpatient 
stay in hospital.  This aspect of drug reactions is likely to add greatly to the burden of 
ill-health to children and requires investigation of paediatric inpatient ADRs using a 
similar prospective study design to accurately identify the epidemiology of the 
problem. The first systematic review of ADRs in children by Impicciatore estimated 
the incidence of ADRs among paediatric hospital inpatients to be 9.53% (95% CI 
6.81,12.26), with 12.3% of the total reported as severe reactions. The more recent 
comprehensive systematic review by Smyth et al did not provide a pooled estimate 
from the 51 inpatient ADR studies included (due to the varying sample size and 
incidence rates) but almost half of the studies had an incidence of more than 10%. 
Both these reviews provide evidence that ADRs among paediatric inpatients is a 
significant problem. A proportion of these ADRs are likely to be serious due to the 
types of medicine prescribed in inpatients vs those in outpatients and some of them 
may lead to an increase in length of stay. The associated financial costs are likely to be 
substantial.  
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The cost of ADRs causing paediatric admission to the NHS in England was calculated 
using knowledge of the cost of admissions to the study hospital, our estimate of the 
incidence of ADRs causing admission and an estimate of total paediatric admissions 
annually to hospitals in England. Information regarding total UK annual paediatric 
admissions, obtained using Hospital Episode Statistics, does not include emergency 
paediatric admissions from other specialties, thereby underestimating the total number 
of emergency paediatric admissions to hospitals in England. Although the ADR 
admission incidence from this study includes oncology cases, which is not included in 
the total annual admissions number used for our cost calculation, our estimate of costs 
of paediatric ADR admissions may be an underestimation. 
The cost estimates provided in this study are rudimentary and are reported only to 
highlight that there is likely to be a significant cost to healthcare from ADRs causing 
admission in children. Our estimate takes no account of indirect costs associated with 
ADRs and does not consider ADRs occurring in other settings.  There is likely to be a 
greater burden to healthcare from inpatient ADRs amongst hospitalised children and, 
therefore, our crude cost reporting is likely to reflect the tip of the iceberg 
economically in relation to ADRs in children. Future work in this area would need 
specific evaluation by investigators with specialist expertise in the field assessing both 
direct and indirect costs. This work could also allow us to more fully understand any 
economic impact from interventions aimed at reduction in harm from ADRs in 
children.  
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Clarification of the ethical aspects to this study was sought by written communication 
and occurred simultaneously to the funding application. After consideration, the 
National Research Ethics Service considered this study should be described as audit, 
due to the study collecting information routinely captured during clinical care 
(demographics, clinical presentation, medication history, etc.). The obvious advantage 
of this is the negation of need for individual patient/guardian consent, a task which 
would likely be almost impossible for a study of this magnitude without a significant 
increase in resources. A significant disadvantage was encountered when considering 
publication of results and the depth with which data about ADR cases could be 
described, due to patient confidentiality and the necessity to guard patient identifiable 
information. Another potential disadvantage may have occurred when seeking 
approval from the host hospital research governance processes, as a perceived lack of 
weight from the study being deemed audit by a national body may have led to 
increased scrutiny and an increase in workload for the study team from those 
processes.  
Several sources of bias are likely to occur in this large study despite the prior 
undertaking of a pilot study. Some of these sources of bias are likely to represent the 
inexact science of identifying and attributing causality of ADRs. There is likely to have 
been some recall difficulties in parent/carer histories of both symptoms in the children 
and drugs taken. An illness in a child and subsequent admission to hospital can be a 
stressful event for any family and this may add to recall difficulties.  
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In a study of this nature, when investigators are collecting data and assigning outcome 
(ADR occurrence vs non-occurrence), there is likely to be some element of interviewer 
bias. This occurs because there is no gold standard for identification of an ADR and no 
standardisation for causality assessment.  This may represent the apparent difference in 
numbers of identified ADRs for one of the investigators compared to the other two. 
Also, there is a risk of misclassification due to lack of standardisation of some 
assessments, e.g. causality, and unreliable assessment methods, e.g. avoidability. This 
might lead to over-estimation of the severity and burden of the problem of ADRs.  
Although the findings from this large study are likely to resonate with many paediatric 
settings caution should be exercised in assessing the generalizability of the results and 
conclusions. The children’s hospital within which the study took place provides 
secondary and tertiary level paediatric care, a feature which is not replicated across all 
child healthcare settings in the UK. The hospital provides tertiary specialty care for 
most, but not all, specialties and, therefore, alternative tertiary care settings will have 
specific differences in their patient case mix and medication use. The hospital is host to 
the busiest children’s AED in the UK and the increased volume of patients exposed to 
healthcare and medicines may play a part in risk of occurrence of ADRs. The local 
population is known to suffer from higher than average (UK) levels of deprivation, and 
worse health outcomes in many conditions, and, whilst not investigated in this study, 
this may be a risk factor for occurrence of ADR. Internationally, patterns of 
populations, disease and drug use are different than in the UK and this is likely to add 
to variability in ADR occurrence, nature and impact. Nonetheless, our study highlights 
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the problem posed by ADRs associated with hospital admissions and this is a problem 
both in the UK and internationally.  
The results of this study will be used to inform paediatric pharmacovigilance practice.  
We have demonstrated that ADRs cause admissions to a paediatric hospital and some 
of these are serious and potentially avoidable.  Strategies to reduce the burden of ill-
health from these ADRs are needed. Prevention will depend on whether an ADR is 
avoidable or not. ADRs that are avoidable by applying existing knowledge require 
efforts to implement good prescribing practice. The vast majority of ADRs identified 
were Type A (predictable or dose related). Some dose-related ADRs may reflect a lack 
of knowledge about pharmacokinetics and pharmacodynamics in children and may be 
amenable to prevention through personalised dosage regimens (for example by 
developing better pharmacokinetic models). Other ADRs that are currently 
unavoidable may be ameliorated by co-medication, for example concomitant use of 
laxatives to prevent constipation. Since many ADRs are unavoidable in the light of 
current knowledge, there is likely to be a continuing burden of ADRs in paediatric 
hospitals and further research is needed. Consideration should also be given to how 
suspected ADRs are handled in hospitals to improve identification of, and 
communication about, ADRs.  
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CHAPTER 5  SUMMARY, DISCUSSION AND 
FURTHER WORK 
ADRs causing hospital admission are a considerable burden to the paediatric 
population, the extent of which has not been studied in detail in the UK (Smyth et al. 
2012). Chapter 2 of this thesis describes a pilot study, which aimed to inform a much 
larger prospective study providing more detailed evidence of the burden of ADRs in 
children. The information obtained from analysis of the methodological difficulties 
encountered, such as defining what constitutes an admission, identifying admissions, 
data collection and the assessment of patient information and ADRs, all contributed 
toward the design of a larger study.  
Given the problems of assessing ADRs in children in the observation area, where 
children stayed within the hospital for less than 4 hours, these patients were not 
included in our larger study. Short-stay paediatric assessment wards/units, used for 
assessment, investigation, observation and treatment of children with acute (or acute 
on chronic) conditions, are now very commonplace in the UK. In our pilot study, a 
small but significant number of patients in the observation ward had experienced 
ADRs as a probable cause for their attendance and their investigation and treatment 
may be a significant burden to the AED department. Undoubtedly, as these patients 
were not admitted to a hospital ward, some of these reactions could have been assessed 
and treated (or reassurance given) in a primary care setting. This aspect of ADRs in 
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children warrants further investigation as to the frequency, nature, cost and 
avoidability of these reactions.  
Assessing the causality of ADRs using the Naranjo ADR probability scale during the 
pilot study, and early phase of data collection and assessment in our larger study of 
ADRs causing paediatric hospital admissions, proved to be unreliable according to 
expert group consensus opinion. Our group included experts in pharmacology, 
paediatrics, neonatology, pharmacy and statistics. Many ADRs that were thought to be 
clear-cut ‘definite ADRs’, such as those with a positive re-challenge with oncological 
cytotoxic chemotherapy, were assigned a category of ‘probable’, when using the 
Naranjo scale. This was due to some questions in the scale being redundant in the 
context of current medical practice (e.g. use of a placebo), or being rarely answered 
positively, thereby lowering the total achievable score and sensitivity of the tool.  
Chapter 3 of this thesis details these difficulties and describes the development and 
evaluation of a new algorithmic causality tool, to more accurately describe the 
causality of the ADRs within our research programme. This new method, the 
Liverpool ADR CAT, was shown to have moderate to good inter-rater reliability. It 
performed as well as the Naranjo tool with the first set of study cases that were 
assessed, and better with a second set. When used in a large prospective study of 
paediatric ADRs, the new Liverpool ADR tool assigned a broader range of causality 
categories than the Naranjo tool. This was thought to be advantageous and more 
appropriate for the assessed case mix by the consensus group.   
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The study described in Chapter 4 of this thesis, which assessed the incidence and 
nature of ADRs causing admission to a UK paediatric hospital, showed that 2.9% of 
acute admissions over the course of one year were associated with an ADR. The drug 
classes most commonly associated with ADR admissions were cytotoxics (110 
admissions), corticosteroids (102), NSAIDs (31), vaccines (22), immunosuppressants 
(18) and anti-bacterials (16). The most common ADRs were immunosuppression (98) 
and cytotoxic chemotherapy related reactions, in the form of neutropenia (89) and 
thrombocytopenia (55).  
Almost half of the acute ADR admissions occurred in children receiving cytotoxic 
chemotherapy for malignancy. The children affected had received intravenous 
chemotherapy as inpatients, before being discharged from hospital, only to be re-
admitted subsequently for treatment of the adverse reactions caused by their 
oncological therapy. The adverse reaction most commonly requiring treatment was 
febrile neutropenia. This is in keeping with other paediatric admission studies in 
tertiary children’s hospitals from other countries, and suggests that this group of 
patients still suffer from troublesome ADRs, despite many years of evidence of the 
problem (McKenzie et al. 1976; Mitchell et al. 1988).  The treatment of febrile 
neutropenia causes a significant burden to children undergoing cytotoxic therapy (Lau, 
Stewart & Dooley 2004).  
Although paediatric oncology patients are known to be at significant risk of serious 
ADRs, this study also highlighted some of the ADRs that occur commonly in other 
children. Of note, NSAIDs and vaccines were commonly implicated drug classes, 
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causing ADR-related admissions during this study. These are both classes of drugs 
used frequently in children (DoH 2012; Neubert et al. 2010). Of the non-oncology 
patients, about two thirds of the causative drug prescriptions had a hospital origin. This 
is likely due to the severity of illness of children being treated by secondary care, as 
opposed to primary care, and the drugs necessary in treating severe acute or chronic 
childhood conditions.  
The studies in this thesis investigated ADRs causing admission of children to a tertiary 
paediatric hospital. We have shown that a small, but significant, percentage of acute 
paediatric admissions are associated with ADRs. This is an important finding but is 
only one piece of a pharmacovigilance jigsaw. Children who are admitted to hospital 
invariably receive more medicines and are, therefore, at further risk of ADRs. The 
systematic reviews published by Impicciatore, Clavenna and Smyth highlight the 
increased incidence of ADRs occurring in children within the hospital setting after 
admission (Clavenna & Bonati 2009; Impicciatore et al. 2001). The incidence of ADRs 
among inpatients is likely to be of a magnitude of three to four times that of ADRs 
causing admission. However, there is little detailed research evidence of the burden of 
this problem within the UK paediatric population.  
ADRs causing admission can be assessed at one point in time and cases need a limited 
amount of follow-up to collect data to aid in causality assessment. However, patients 
can stay many days, weeks or months when admitted to hospital and may have many 
ADRs, occurring at different times during the admission. This poses a different set of 
problems for data collection, case assessment and data analysis for an inpatient study 
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and needs an alternative methodology. A large inpatient study of ADRs has been 
undertaken by the ADRIC research group.  
There are other settings where ADRs are likely to cause a significant burden to 
patients. Clinicians caring for neonatal patients use medicines, often off-label, in a very 
vulnerable patient group in whom signs and symptoms are often vague (e.g. vomiting, 
crying, unsettled, irritable, etc.) and difficult to identify. A similar picture may be 
viewed in both surgical theatres and paediatric intensive care where patients are likely 
to be sedated and have an altered conscious level. In addition, patients may be very 
unwell with life-threatening illness, requiring intensive support with vast amounts of 
medication use, which may pre-dispose them to an increased risk of ADRs. The 
methodology to assess the frequency and nature of ADRs among these inpatients 
would need to take account of these difficulties and assessment tools would need to 
address the uncertainty of clinical signs in some patients.  
There are likely to also be a large number of patients being seen for relatively less 
severe ADRs in outpatient settings, daycare wards and in primary care settings (both in 
and out-of daytime working hours). Whilst these patients may not have such serious 
reactions they are likely to pose a significant burden to healthcare settings. Also, even 
the most minor ADR can cause concern amongst patients and carers and there may be 
indirect costs to the economy from the time needed to seek medical attention for these 
problems. 
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5.1 IDENTIFYING ADRS 
The methodology used in the large prospective study in this thesis was labour intensive 
and comprehensive; three full-time multidisciplinary research fellows (a paediatric 
registrar, a pharmacist and a paediatric nurse) assessed all acute admissions each day 
for one year for occurrence of ADRs causing admission in children. There is a need for 
ongoing pharmacovigilance within healthcare settings to monitor drug-related harms 
but this methodology is unlikely to be acceptable for individual settings, due to the 
time needed and cost. Also, our study methodology did not investigate ADRs 
occurring in inpatients, or adverse drug events in admissions or inpatients, both of 
which are likely to cause significant harm to patients and burden to the setting. A study 
of inpatient ADRs would no doubt require an alternative methodology in comparison 
to an admission study e.g. patients can be subject to multiple admissions with 
potentially more than one ADR occurring during each admission.   
Others have used alternative methodology such as nurse assessment of randomly 
selected cases (Mitchell et al. 1979) or information technology systems (Dormann et 
al. 2004), combined with laboratory results, to identify cases, or signals for occurrence, 
of possible ADRs. Dormann et al showed their computerised ADR signal detection 
method, using lab parameters in adult patients, was better than clinician spontaneous 
reporting but did not compare computerised signal detection against systematic case 
analysis (Dormann et al. 2000). These methods still need clinical input from 
experienced physicians, with an interest in ADRs, to assess the cases identified. 
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In the study in Chapter 4, the doctor (85/ 2634, 3.2%) and pharmacist (96/2969, 3.2%) 
identified a similar number of ADRs and both identified significantly more than a 
nurse investigator (59/2742, 2.2%). Although no false negative cases were identified 
from a senior investigator review of a random selection of cases, this difference in 
detection rates remains unexplained. It is possible that the nurse investigator had a 
lower sensitivity for identifying ADR cases. This difference may be an individual 
clinical difference but may need further investigation in other settings to optimise data 
collection methodology, should future investigators wish to replicate this study.   
5.2 ASSESSMENT OF ADRS 
Assessments of type of reaction, severity, causality and avoidability were undertaken 
for the ADRs investigated in the studies contained within this thesis. There is ongoing 
debate as to the best methods for assessing and describing ADRs, with no universally 
accepted methods for any of the assessments (Smyth et al. 2012). Type of reaction and 
severity assessments can be classified succinctly using structured guidance. However, 
assessment of causality and avoidability is not so straightforward. There are many 
causality tools used by different research groups and regulatory authorities with no 
consensus as to which is best.  
5.2.1 Causality assessment 
In this thesis, we present an alternative quick and reliable causality assessment 
algorithm (the Liverpool ADR CAT). This tool underwent an extensive internal 
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validation using spontaneous ADR reports and published case reports. The assessment 
tool has been published in an open access journal in the hope that other investigators 
use it to undertake external validation studies (Gallagher et al. 2011). This could 
happen in the following ways: 
 Researchers could assess using the tool for spontaneous reports from their own 
studies or settings, evaluating cases in different populations (paediatric vs. 
adult), to assess inter-rater reliability among the investigating group. 
 The tool could be used to assess published ADR case reports from the 
literature, instead of spontaneous reports, in the same manner as above. 
 The tool could be compared to other methods for assessing causality, with 
investigators assessing which tool may be more suitable for assessing causality 
of ADR cases in certain populations or in particular clinical settings (i.e. 
general medical vs. specialty vs. clinical scenario). Evaluation of the tool in 
specific clinical scenarios should be approached with caution (for example 
teratogenicity or hepatotoxicity) as there may be well validated tools more 
suited for use in those areas.  
 The tool could be used to evaluate ADR cases rated by a specific investigator 
types. For example, the tool was internally evaluated by a multi-disciplinary 
group. However, it could also be used by a group of pharmacists, doctors (GP 
or hospital generalists/specialists) or nurses and tested for its reliability within 
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that group using the methodology outlined in Chapter 3 to assess inter-rater 
reliability.  
 Investigators could also investigate the reliability of the tool between different 
types of investigator (e.g. nurse vs. pharmacist) or between different grades of 
investigator of one type (e.g. medical student vs. junior doctor vs. consultant). 
This type of validation study would likely need an investigator-defined ‘gold 
standard’ set of results to define the causality of the cases, as the results of the 
participants in such a study may show positive inter-rater reliability and agree 
with each other but not be consistent with an experienced rater, or group of 
raters. 
In evaluating the tool, it was noted that the inter-rater reliability of the Liverpool tool 
increased upon its use in a second set of cases when assessed by the same 
investigators, in comparison to Naranjo where there was no increase in inter-rater 
reliability. One possible explanation for this increase in inter-rater reliability may be 
due to a learning effect within the group. It is possible that assessors learned to use the 
tool more effectively and answer questions more appropriately. This effect may be 
better understood if it were to be repeated in external validation studies of the tool. 
Another way to investigate this effect would be to use a RCT methodology; 
investigators could compare users who have had training in use of the Liverpool 
causality tool, but were previously naive to ADR assessment methods, against users 
who are naive to formal ADR structured causality assessment methods and have not 
had training. Investigators could use similar methodology and analyses to those 
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described in Chapter 3. This trial is planned as part of the end-stages of the ADRIC 
programme.  
Two groups of clinicians, naive to using causality assessment methods, could rate a 
number of ADR case reports for causality using the Liverpool assessment tool. The 
number of cases can not be too high, due to the time required to complete assessments, 
but should probably number more than 20 to provide a reliable indicator of inter-rater 
reliability. Clinicians could be randomised to either receiving training in use of the 
tool, or not, at the beginning of the study. After a short break, perhaps a month or so, 
training in use of the tool could then be provided to the appropriate group of clinicians 
and the process could be repeated with a second different set of ADR cases.  
Inter-rater reliability could be assessed between the groups before and after the training 
intervention. The participants’ results, before and after training (or not), could also be 
assessed against a ‘gold standard’ set of results as defined by the investigating group. 
The training might be best delivered in an electronic format as it may be difficult to get 
all the participants in the ‘training’ arm of the study together at the same time to 
deliver face-to-face training. Also, if the training has a positive effect on clinician’s 
ability to perform ADR causality assessment effectively, it could easily be 
disseminated through a variety of electronic media and targeted at many groups (e.g. 
student and post-graduate doctors, pharmacists and nurses).   
Such a trial would require expert statistical input into the design of the study. Several 
variables are unknown, namely; the number of cases to be assessed by each participant, 
the number of participants needed to provide a reliable indicator of inter-rater 
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reliability and the definition of a significant increase in inter-rater reliability. The 
above suggested number of cases ‘should probably number more than 20 to provide a 
reliable indicator of inter-rater reliability’ is derived from personal discussion with 
statistical expertise. An increase in inter-rater reliability of ‘good’ to ‘very good’ may 
only need a difference of 0.01 in score, whereas an increase from 0.41 to 0.59 would 
still remain a ‘moderate’ inter-rater reliability. These are questions which would need 
answering with a well-thought out methodology and study protocol.  
5.2.2 Avoidability assessment 
Assessment of avoidability of the ADR cases in our large prospective study was 
undertaken, using the definitions of Hallas, with a non-structured group consensus 
approach. The methodology used in assessing avoidability in this study may be 
improved in several ways. Firstly, a more structured approach to gaining consensus, 
such as Nominal Group Technique, rather than open discussion, could be used. This 
would be, with little doubt, a more lengthy process but might yield more valid results 
regarding consensus avoidability assessments. Secondly, more expert opinion could be 
added to the investigating group for the assessment of certain cases e.g. a paediatric 
oncologist presence may have aided in the assessment of the large number of 
childhood oncology ADRs.  
Evaluation of structured ADR avoidability assessment methods suffer from the same 
difficulty as when evaluating assessment of causality tools; namely, the lack of a gold-
standard for comparison. Several methods for assessing avoidability exist. Ferner and 
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Aronson reviewed these and came to the conclusion that there is no universally 
accepted method for assessing avoidability and none of the previously published 
methods were adequate (Ferner & Aronson 2010b). Concurrently, the authors 
published a new algorithmic method for assessing preventability based on their own 
mechanistic ADR classifications (Aronson & Ferner 2010). This method looks 
comprehensive but there is no evidence base, as yet, compelling investigators to use 
this new tool in place of another.  
 
Indeed, there is scarcely any evidence-base comparing any of these methods using 
measurable outcomes such as inter-rater reliability, or comparison of appropriateness 
of results. There is a need for an evidence base in this area, assessing the reliability of 
avoidability assessment tools. Future investigators, wishing to produce an avoidability 
assessment method for use in research studies or every-day clinical use, would do well 
to not only systematically create a user-friendly method but also provide evidence-
based justification for the use and dissemination of their method. Investigators in the 
ADRIC programme are assessing this issue in the context of the difficulties with 
avoidability assessments during the observational studies. A more reliable avoidability 
tool is being formulated and evaluated.   
5.3 PREVENTION OF ADRS 
The avoidability of the ADR cases in our study of paediatric admissions is detailed in 
Chapter 4. Although case information is provided to highlight the reasons for our 
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assessment of some cases as possibly and definitely avoidable, there is, unfortunately, 
a limit to the data that can be published regarding these cases, due to concern regarding 
the safeguarding of patient identifiable information. However, this study is the first to 
publish such data in some detail, providing insight into possible areas for intervention 
for reduction in harm to children from ADRs. We concluded “that more careful 
attention to practical aspects of care, such as improved monitoring, following 
prescribing guidelines, improved patient education, and heightened suspicion about 
potential adverse reactions could lead to a reduction in the frequency of ADRs causing 
admission.”  
 
Evidence of specific interventions in adult populations cannot be extrapolated and 
applied directly to the paediatric population due to differences in the developing 
physiology of children, the pharmacokinetics/dynamics of drugs in children, the 
formulation of paediatric medicines, and differences in disease and ADR presentation. 
There is a need for systematic evaluation of interventions aimed at reducing the 
incidence of ADRs in the paediatric population.  
 
We assessed 55 of the ADRs in our larger study to have been possibly or definitely 
avoidable. It is obvious to state that we think these ADR admissions may have been 
potentially avoidable. However, it is probably untrue to comment that the remainder of 
the ADRs are therefore unavoidable by definition. It is probably more accurate to 
comment that the remainder of the ADR cases were deemed to be unavoidable, in the 
context of present day knowledge of good medical practice. This definition of 
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‘unavoidable’ ADRs allows us to think forward. Some of the ADRs in our study that 
were deemed unavoidable may be amenable to prevention in the future. This may 
occur because of change in knowledge of improved therapy regimes with improved 
risk-benefit profiles, improvements in patient-tailored therapy (personalised medicine) 
or improved ability to ameliorate adverse reactions and prevent morbidity. Some ADR 
admissions may be preventable with improved ADR identification. There are several 
examples of these potential scenarios in our study: 
 
 Oncology patients are at high risk of recurrent ADRs and warrant further 
evaluation into tailored therapy, and targeted symptom prevention, to prevent 
ADRs.  
 
 The risk of post-tonsillectomy bleeding in relation to steroids and NSAIDs has 
not yet been defined and needs further evaluation with either a RCT or well-
designed case-control study. There may be safer anaesthetic or treatment 
regimens with equal, or greater, effectiveness at preventing PONV.  
 
 Many infants are admitted to hospital after routine immunisation with fever.  
Investigations for infection are undertaken and patients are treated empirically 
with intravenous antibiotics until the investigations, usually two days later, reveal 
no evidence of infection having been present. This is a common scenario. 
Research aimed at improving the identification of bacterial sepsis may have an 
impact on the assessment and treatment of these infants.  
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The majority of ADRs in our study were assessed as ‘unavoidable’. If the major 
burden of ADRs causing admission in children is to be addressed, it is with the current 
‘unavoidable’ ADRs that research must now be focussed.  
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5.4 THESIS CONCLUSION 
ADRs causing admission of children to hospital are an important public health 
problem. Thankfully, no children died as a result of ADRs in our study. However, 
some of the ADRs were serious and needed intensive care. ADRs cause a significant 
level of morbidity in children and pose a significant cost burden to the NHS. Almost a 
quarter of the ADRs were assessed as possibly or definitely avoidable. Interventions 
are needed to reduce the burden of these ADRs urgently. ADRs that are currently 
‘unavoidable’ may be amenable to prevention with increasing advancements in 
medical knowledge. Future research should be targeted at increasing knowledge of 
how to prevent ADRs.  
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